var title_f13_26_13728="Small bowel obstruction on plain abdominal radiograph";
var content_f13_26_13728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel obstruction on plain abdominal radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain upright abdominal&nbsp;film shows a distended stomach and slightly dilated loops of small bowel with air fluid levels and a paucity of colonic gas, consistent with small bowel obstruction",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Deborah Levine, MD. Copyright &copy; Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13728=[""].join("\n");
var outline_f13_26_13728=null;
var title_f13_26_13729="Haemophilus influenzae type b conjugate and hepatitis B vaccine: Patient drug information";
var content_f13_26_13729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Haemophilus influenzae type b conjugate and hepatitis B vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16949?source=see_link\">",
"     see \"Haemophilus influenzae type b conjugate and hepatitis B vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24340?source=see_link\">",
"     see \"Haemophilus influenzae type b conjugate and hepatitis B vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Comvax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10028704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_multi_vaccine_infants.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11747 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13729=[""].join("\n");
var outline_f13_26_13729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178299\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028704\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16949?source=related_link\">",
"      Haemophilus influenzae type b conjugate and hepatitis B vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24340?source=related_link\">",
"      Haemophilus influenzae type b conjugate and hepatitis B vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_26_13730="Neutrophilic dermatosis hands";
var content_f13_26_13730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neutrophilic dermatosis of the dorsal hands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Painful plaques that have progressed to ulceration. These developed in a 60-year-old female with seropositive rheumatoid arthritis. The histologic appearance was epithelial hyperplasia with intraepithelial sterile abscesses and dense dermal infiltrate of neutrophils with an absence of leucocytoclastic vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel L Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13730=[""].join("\n");
var outline_f13_26_13730=null;
var title_f13_26_13731="Cyclopentolate and phenylephrine: Pediatric drug information";
var content_f13_26_13731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclopentolate and phenylephrine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/51/25394?source=see_link\">",
"    see \"Cyclopentolate and phenylephrine: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclomydril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Mydriatic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Instill 1 drop into the eye every 5-10 minutes, for up to 3 doses, ~45 minutes before the examination",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/51/25394?source=see_link\">",
"      see \"Cyclopentolate and phenylephrine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Infants, Children, and Adults: Instill 1 drop into the eye every 5-10 minutes, for up to 3 doses, ~40-50 minutes before the examination",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclomydril&reg;: Cyclopentolate hydrochloride 0.2% and phenylephrine hydrochloride 1% (2 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Instill drops into conjunctival sac of affected eye(s); avoid contact of bottle tip with skin or eye; to avoid excessive systemic absorption, finger pressure should be applied on the lacrimal sac during and for 1-2 minutes following application; preservative absorbed by soft contact lenses; wait at least 10 minutes before reinserting",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic procedures requiring mydriasis and cycloplegia; preferred agent for use in neonates and infants",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F13897369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclopentolate, phenylephrine, or any component; narrow-angle glaucoma or untreated anatomically narrow angles",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patient's with Down's syndrome, cardiovascular disease, hypertension, and hyperthyroidism; feeding intolerance may follow ophthalmic use of this product in neonates and infants; withhold feedings for 4 hours after examination",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients; increased susceptibility to these effects has been reported in young infants, young children, and in children with spastic paralysis or brain damage, particularly with concentrations &gt;1%; observe neonates and infants closely for at least 30 minutes after administration; may cause transient elevation of intraocular pressure. The preservative, benzalkonium chloride, may be absorbed by soft contact lenses. Wait at least 10 minutes after instillation before reinserting lenses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action and duration of effect are partially dependent upon eye pigment; dark eyes have a prolonged onset of action and shorter duration than blue eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 15-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause blurred vision and increased sensitivity to light; preservative is absorbed by soft contact lenses",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1057558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cyclomydril&reg; is the preferred agent for use in neonates and infants because lower concentrations of both cyclopentolate and phenylephrine provide optimal dilation while minimizing the systemic side effects noted with a higher concentration of each agent used alone",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chew C, Rahman RA, Shafie SM, et al, \"Comparison of Mydriatic Regimens Used in Screening for Retinopathy of Prematurity in Preterm Infants With Dark Irides,\"",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 2005, 42(3):166-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/26/13731/abstract-text/15977870/pubmed\" id=\"15977870\" target=\"_blank\">",
"        15977870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13190 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-E4F9E9D48D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13731=[""].join("\n");
var outline_f13_26_13731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155396\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057551\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442275\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057544\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155390\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155380\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057554\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057547\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057553\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13897369\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057557\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057543\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057542\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299108\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155385\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155387\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287215\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057541\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057556\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057549\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057558\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13190|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/51/25394?source=related_link\">",
"      Cyclopentolate and phenylephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_26_13732="Fungal OE";
var content_f13_26_13732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F83226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F83226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fungal otitis externa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel G Deschler, MD, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13732=[""].join("\n");
var outline_f13_26_13732=null;
var title_f13_26_13733="Nabiximols: Patient drug information";
var content_f13_26_13733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nabiximols: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/44/15046?source=see_link\">",
"     see \"Nabiximols: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F596136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sativex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming; avoid long-term use. Use this drug as ordered by your doctor. Tell your doctor if you have a history of drug or alcohol abuse. Misuse of this drug may cause unsafe heart-related side effects. Tell your doctor if you have any heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause a fast heartbeat, blood pressure changes, dizziness, mood changes, or a change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor if you have seizures or have ever had seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pain in patients with MS (multiple sclerosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pain in patients with cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tetrahydrocannabinol, cannabidiol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Heart disease or schizophrenia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with a sex partner who plans on getting pregnant at any time while you are being treated.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694746",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not spray near an open flame.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4067422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not spray into nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use spray if your mouth is sore.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695547",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prime pump by squeezing it 2 to 3 times.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695660",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray into mouth below the tongue or on the inside of the cheeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694747",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not spray the back of the throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site in your mouth with each spray.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened 5.5 mL vials at room temperature. Throw away any part not used after 28 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3761597",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened 10 mL vials at room temperature. Throw away any part not used after 42 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11457 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13733=[""].join("\n");
var outline_f13_26_13733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F596136\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020225\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020227\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020226\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020231\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020232\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020234\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020229\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020230\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020235\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020236\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/44/15046?source=related_link\">",
"      Nabiximols: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_26_13734="Granulation bed on a chronically open abdomen";
var content_f13_26_13734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Granulation bed on a chronically open abdomen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 392px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGIAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwbcSMk0biB6Uh9KRhzVFi55POaQsAcDmjaRQw78ZoAC2e3PQ0wk5ODig4HTpmmM3PTj0oACx7mmMT+FIT1qNm+XrxTEwJ55NMLDmms3BqFnyO+aCSWRueCKhaTims1Rk5ouArNk01jmkJoxmjcBCT6UYJp6pntU6QsT04oAgRCfrUyRf3uKsLHtPSkfr0oAYBjimNzwKeTzUTH5jQA09KjINPJ9q2fCfhu98SakltaJiPcPMlbog/x9qTYLUi8L+Hr3xHqSWllGzD+OTHCD3r6U8FeF7DwpYDenzDksQdzHuSam8M6BYeD9KTCLGVHXux96xfE/if7YwS33bQegBrCUuZ2R0Rhyq7LfinXllYiElIx2rz/UZFuHZjkH2NXRdmbIkGAakt9ClvFLwsuz0PH5U4qw27nNtEiElm469OlSQW0lxJiCMsW6DGSa6638JT3DiMJlvfgV2nhPwjDYSefqARpFPCoSVX9KrmsSo33PCfAEU2n/EJEniYSRF9645AAz0r32w1CAp50bho85z6e1cX420mPRvido+twbRbXUwjk8sYAJ4PA+tdNrdr5Mvk6VErXN0+xIwMfMe/0HWs6ktOZl049Clq+nz+OdT/ALJs8m3jIknKj5UHYH3PpW0nwN0mSJA806HHzYI5r0DwF4aj8OaMEk2tcyfPPKOSzVu3EpfhchfavKqVm2dUVbRHkcnwM8PBvlvp0+pBrB1/4K2kRUabqLOCedyg4r2u5MaLljtz+dZ1zIHbC78HoCMVl7eXc1jC54gnwcCf628OR2VcVrWfwj0tBmZ5pD6bq9SaNYyCxIJ/WnoRuI6CoeIl3NFTRwFt8LvD6DP2be3uxqw/w00E9bNenQE8V3QXsuBU6IcdBz7Vn7aTK5Ujzl/hXoUq5+zlT7E1m3Hwd0p2JgaaIn0bNeuqgA5IxS7ODg4oVea2ZLijwe9+D00ZY2t1E+DwssYP61izfD6e3Ypf+HHmTvLaPnI9cZzX0ksQxzSGJQOVB9M1vDG1I9TOVGnLofL934H8LTnykv7zS7o8D7TEQM++RWNf/CjWwjS6RLZ6pDnrBKM/ka+sNQ0PT9Tt2gvLaGVH6qwyK4i++Gk9hM1z4W1CSxmPWN2LRt7Yrsp4+/xHPLDR6Hy7q3hPXNJGdQ0u6gX1ZMj8xWGVIyCMYr63l1fXNKhMfifRftduQR51n8/4kYz+lc9eeFvBfjJi9kUhuT1CjymB+nSu2FdT2OadBxPmjb/+um4r2nXPgfqMUjHSrqGVDyEmO1vz6VwGseBPEOlSul3p8mF/iT5ga1U0zF02jlaKnlgkiYrIjKw4IIxioiMHiruTYQg+lJinduaCc0AJ0opaQEdxQAUUDAFA6UAAOKkRqjoouBMG568U/PoeKrA08PigCwDk4p4b1qsHzUgOaBpkwOR15opnRfSigaZqeuMZpM4z+lJnj17/AFprEj+dAx5bGTTGYddwFMYkdxzTGbAxmmArHrUbN196Y7gdTUDy8EdKZNyR3wM5qFpBgj0qMuaYSe9AiQuTUbH3pO/Wk70AByaAvrTutSRxk9KAIwmenWpEiJxyKsJCfrU6R7elFwIkhwAT0qTAAxUhGKjbrRYBpPPXmo3p7kAVVkclsDFAA5AznrUROeRTthJ5rqvCHg+51yQSOTDa/wB/HLew/wAaL2GlcpeFPC974iugkA8u3BAeVhx7gepr6N8IeH7Tw/p2beJQka7uByx9T61D4e0K3sYYLW2RVRBwAOfxrqtQh8ixaMlAjDjDDP8A9asJzvojeELanB+ILu9u3bzDuUtwMYx+BrGXT5Z32qgHrtxXd2VjDPtU/vD6AZx+Vb2n6Pbx8BQAeScf/rqb2Ktc81tPB1xdy8yCM57LyPxNdrovhRdMgIR/Mk/ikcf0rrLa0QZIbgd8VPtQNkEtilzDsZ+naaYrYysFDgEdK5DVfEceib2usshfbsBGWNdNrni3SdGjYXt1GCo/1akFvx54r548b+Ml1zUHGn25WAOSrue59MUXtuHK3seg+JvGXh66057Od7h5iQyoiAmNgcgg5611Hwvtp9e1w67cK8drDGY4Ec857sa8c8C+Cr7Xr2OQqyW+7Lyt3+lfUPhyxTR9NitYR8iqBg/zrz8RXT91HVClyq73NuaTegXoo7jiqlxMEHyqT9TS3D7FAbqei1QmcscyEYA7VwtmsIkbsZXLEjPqaj3/ADfIu4j+IniopZGl+VMKnbjrT4jtAHp+lZOXY3UbDShLfOakRG6cGrCxhhz0qaJF3fLxUhexFDGSPTHpVgKAOOKeqAdOtIwOcc0O5F7jCoOTTlXjODT1T2OfaneWc9wKSiS2NI4GBxTChJ6nHSrAjyM5IFOWJV5HWrsTzWGxQ4Xj86lj27sNnPvSg5BxUdxIEQM7qo9ziruokayFuII5V2vtY9gRXFeLfANhrkyzW7Gx1FeBcwgDd7OO/wBa6WbVrNRiS5iUqccNzWZeeLLC2yEDSMPQYz+dCrKOzNFSm1scPdyeKfBkRg1G0OsWKDJliGJFHuOf61paH4o0PxDGfKkCS9GhmIBHtUXib4qPbQrHDYRSbRw8rZJHpjFfPfjjxDd6trcl+tvBZO2MC2TYOO/ufevSoYjndjOeHkldqx9E654H0HVYT9o09EdwTvUAE1w+qfA3TrmJm0+7eOU8AN0zXE+GPjDrujxJb30Ud/bqAAXJVgPr0r2Dwb8StG18qiz/AGS5PHlSdCfrXbd9Dkce545rfwY1yxiaW1kiuVB+6AQa4HU/Dupac225tZF59K+2klWVVOQR6g5GKzNY0zT7hMXMMcg3d1HpVKpIzdOLPiRonU8gg03ac9MCvqS9+Guh6pO0n2dkX1XpTv8AhUvhkRKnlSeYR94GrdREeyfQ+WSvejHOK+i9b+CmmzRM+nXciSYzt2gj6GvIfEPgXVtGlffAzxjneo7VSmmJ02jkthIppWrn2WUDGxgfQimi0mOcRsapNGdmVccUZNWXtZlA3IwH0qFkIJBougsNBI6U8Pzz6U3HFJigCYOD1NFQ9qKLgb7HA4HSoDISeKJH65NVmf3oKuSO46kkVA789aZK/pn3qFiSeM0yR0j5PFQk04AZ6Um3jNMBKT+L1p+32p6x5PNAEWKkSMntU8UI9B+NTxxjtRcCvHB61ZSML2qUJjtT1Xj/ABpDsMUenSkOaeeBngUzPvTAaTzUbsOc05jwT3xUDtmgQ1/mHJJpgA9KkVSxx39K7/wP4PW4X7bqkRKdY4m7j1NLYaVyl4J8HNqyC7vg4tQflVR8z/4D3r2fSdNt7OyjiiQJHGoCqOn51Lo1lCkSxxIqIg2gLwB+VdBb2Sj7qhAvbrn/AArGczeMEjNsZcToFAC8cEYNdRPBDdRAuCzEcbjx+XeqgsIlUuzBUBzz0Fcr4j8c6VoEbE3cTOOiKfmz7CsnqaLQ7yysIYzhBjA5I4qbUr6002Hzb24jt4R/E7Y/nzXzX4j+MusXSNFpLvbLnhzjI+lef6l4i1nVZd+pajcXB9JGyPy6VSi+pLkuh9K678VrQXP2PwxZT61d46RKSBXkXir4p+Mprua0mX+ygODAIdrge+a5vwz4judHZ5Ld/LlbGSBwQPWvTNK8SaP4jjii8SWNtcSdFkkQbgPZhyKtRi9EZ80lq9jyMXFzqcu68lkllJ5LHqa9s+Hnw5s5LO2u9Vj8xp1Dou4jA96zdb+HoglTU/DCpPbhvM8kn5kHt/eFeueF9ZtdWsYGtSqvGvzxEYZD349K87FznB8p6GHUZR5lqdFplhBaxRx28SxqmAABWhLMsRIjzu9T/SqpuBGoKHGRyfSqdxcDcSG/EV5/mb2LHml2YsT9TUUjmQ4/hrPS6864KK3yL973q/CodcjAX3qJMtKwqJux0x2q3FCByR25p8ScDC4561KATx+oqBOQ3YAMLUija3SgAg9/yqZMFcsOlBDYwZLjjrUqR4Pz9aktozK3yDJqnq+t6bo+4XL+bMP+WcZz+dNqyuyLuT5YrUupGScKpP4VYW1c5JGPc1w8vijWNQYjR4BaxdC20E/marT2mpXaBtU1O5fB5jRsVKqxW2pp9Wm/iaR1up63o+mgi4uxJIOqRDP69K5i58d+YxTTLBevDSksfyFZ0lrpsWCkRY994JJ+uaVEUoAsfHPCkGplVb20OiGGpx+K7IrvxNr14CuSi5xhUCgf1rNMWq3JLTTpj1ySfyq+wbf5aA/Vqq3d0LWMjfk+oqHdnTGMY6RRVe0kGTJcMGHXpiqktrCXBmmdh1Dbx/hWXf648eQXJ578VkXGrblz5mDjNVGkzRm/JBYRvhoEmPXc5DGuS8Y6fZX1swWNVmHKlewrI1PxDHCSfNG6uW1PxYZCyx8jpxXZQoTvdGFWpTStIw5Y9sjKexpsZaNw8bFWHII4NUp72aV2bO0nmq7TSluZGP417MYStqeLOpBPRHp3hP4l69oMgVpVvLUjBhn/AKHtXqHhz4naPrcqRagGspiMZd8qT6Zr5i89x0Zhj3pUu5VPJDD3q+VmTnBn29p+qWE6slpLHJs5JU9vWrm0SuxOMeueK+PvDnjPVdHdGsruQKDnymOQa91+HvxPsdbC22qtFY3Y44PytSaHbqenRvhCHXjPUVlJFDdGVZo0aJsgq3f61dsporgzBZY3BzjB68cUnklNuEw/ckcfWpEcxqPgXQ7qPetrtY8/KetYsfgrTonJ8hWXOBz0+tejyIBFgrH14GepqERRtneoGO445ou7BZHFweDdEuowJrTy274OR+FUdS+EeiXCho22HqADya737J97bhlz3HIpNiwoXbfjp8pouwsmeE+J/hZBp65t5H3HlQWrzDUNHubOeRDG5Cnrivpi8lk1K8kLLgD5QX7ipo/DenXjf6Tbg5HYYz681qptGcoJ7Hyh5T+h/GivpW+8C6OJcLbxk56jnHNFUpkezPnOWTIIzUDMAMZpjMSKaeSMCtkjIC3YCmjpShSakVM47UARgcjFPVc/Wp0j4xipo48DkUrjSIViOBwPxqZIx6VIFzUiLgjjFJsaQ1YxxUwQCnKOMd6XPTt70kMaVBPOMUhwOlPJyO5qJ2xVCEc8VCxFDvzxz9ahkJagQ1uTyRT7eCS4mWOFGdjwAoyTVnTtOub+dIoIi7HjjoK9X8I+HYNIhMsmHu3GNw7ewpN2HGNzM8E+Efsg+1X8atOwGxCAdv5969FsrYRghVXJHTqapXN9a6bbma+nSCIDq5xmuE8VfEtEzb6EN4xzJyF/+vWbdzZJI9Xe/sNNhL311DAqj+JwP51wPij4wRWsrwaDH5u3jzM/Kfxrxm/vLrUrkz3kzSyH16D6DtUITipt3Dm7G1q/i7XtVdmutRudjfwJIQv86xGy5LMSSepJqREqWOFmIwCTRohWbZXEefSrEFuXYBVJz7V0vhnwlqmuXCpZWrsvdyMKPqa968AfDK10Qi4vQlxdFRyRwv0rmq4mMDop0G9WfPljotwhV57aVEPOShGa9k8FXvhpNJWw1DToBu+87IGz788ivX30iBk2GNSO/Fcp4l+H1lcRy3ForwyKu5vKTdk+m0da4J4h1H2OyEIxWp5X48u7/wAHSCXwpfyTafKd3yIZPs4P8LHBA9s81f8AAGkrqGnHU49ZuU16TMu3zcJk9iO+fWks4tZ0G5ayltZhPJkvGBuLZ7ED2rN0zwF4gt7qWeznW0iL74o2BLY6hcjgV008RGUeWqYVMO4PnpM7uw8fiNjZa5C9nepwwK8N7j/61XG8a6SoL/acj7qggrz+NZ17pGoeMhbaZqukw2VxCpIupJCHnI6IoxtBPrnmuH1PQ5INQl02Kwms50PyiTknHv3rjqUlHVbHfQcajs9Ge1eHkjvXN1DMsiSDJCHIP411trEFHygV414CvdW8Lb49Qt2kspMZKDOw+teu6VqEGo2q3FrKsiH09fSuTS9kVWpyj6GmRgDhcU3bk80qg7d7EKg6luAKzb7xPpemnZHKLm4/uR525+v+FN26nKlJu0VdmoU2KHZgEHc9qx9X8T6fYqY7ZxdXJ4Aj5XP171zd1LquuzGS7dre1Y/cHTHsK17DS7eyiSSOLKsfmYn5vrzWXO38J0ewjDWo9exSQ6xrUv7yV7W39Cdpx9B1ra0rRdP08s8vlzyf3pRu/wDrVJJKy8wg7RwSODVY3MwVyqsPTknmhWQ3zSVo6It3WoQxn5kCAHChBgYrIvrl5F3AnH1Bx+FQXMm3LOUYnBLZbI/A8Vg3+pCIlnlAPucY/IUtzSFNLYuyIMkseeuc5J/Oq73YiBOe2SMjH865vUfEEIGDIOOlclqfiWFFYiUfnWkablsjSz6nYatryxRMfMAOOvSuM1jxHuiZhdgew5rjtX8QRXCssQMknQBfWqthoGsatKjSwSxW5PLMpAFddPDKKvMfNf3Yol1HXJXbEUzu+eicVHZ6drmrE+XDMqd3YEYFd9onhW003zBGizzAH94/Rh7dhXV6PD5CeYoXAOB26inKvCnpFG8MK5K8meNS+B9RMZeV1MndWJqFfAeqso2QKfqwr2e7hIkBDY3HHHamHCBg4KEqSB/nsahY6p0Lll1J6nget+HrvS3kWePIU43qDtJxnvg/pXPlT0xX0TfoJLeSO4RZFZcDJzivH/EPh+S0nd4I2MXX1xXfhsXz6SPLxuW+z96ByuOKbtx9asyRkHnrUZHtXemeNKnbcjHHrV21kMibM4Yd6pnFOVijhh2oauEHys6vRfFur6M6eRdzGNeNpc17b4K+KtnqscFnqjJHPwFlY4yc96+f4ojOqsi7i3YCklsJ4xuMbrjkHGMVlzx2Zu6TeqPta1lWSFJOsZ7mnJ5Zk3AhkPbP8q+YfCnxS1rQ4ktbw/a7ZRtXePmUfWvS/C3xi0m7vRBqRW1RhkSHIAPp0o3Iaa3PVBKIwHZVCjg9xisTUbxZPlT7vqp5zVpL+11WFmsbhZoXA/eI2R9Misy+thGoVXXPUjPOaEhXKb3DHdgnjjmtG3JCKNgZSMgdx9T7VkQwTtOSWYIvOQvWujsoB9iKsGVjySapiOduv3cj7XXGcgse9FXtQsj5xJj4PTv/ACoouKx8f4OeBj9aesfPQVZWIcetPEeK6mzlsQLFz0qVI8DtUyoM09VB46VLY0iMR8dKeq8dqmAx1pRnsaLjsRiOnqv1p2M/SlHBFACe2KNvX0pxJ796jkftyKpAxkhxxmq7v2pztz3NNSNpDx1PagkiwX4XNa2j6Jc38wWFMj+JjwBWnoPhuW8IZiEj9TXc/wCgaJYZlkWOFBuOPvH3qXIuMLj9E0SLTISsYUYGXkI61R17xtYaSrw2jm5uwMBU+6Pqa4/xJ41n1SJrbT0a3t24LZwxFcosJJ5PJ5rNs0sXNa1i/wBcuPM1CZnUH5UH3V/CqKR47flVqO3JHAzV6z0u4unCQRO7E4wqkmolNRKVNyMpYzjjipEjOOma9F0H4Wa7qW12hS2Ru8xx+gr0Hw98GrW3dW1W5M567IwVFc88VCJtHDt7niGj+HtQ1WdYrO2eVmI6CvYPBnwheOeK41x42VefJQ5z9a9e0rRLDTIEjs7eKJAB90f1rSJVQCfwxXFUxUp6LY6YUlEq6TpltYQrFaxJEidAoAFXV5bgdT6dajkkWJA8rEDoFXrTGvJHXZax+ShHJByx/GuR67mmvQvqY7dt145U4zsTlv8A61VrrUS8Rj09SgJ5fq34VWW3ZsbuF7j1qVNqYEY49aTmugcnczlsd9y084VpW6nHJ/Gr0Nou4YUA+wqyEjRC88yQxjksx4rLfxL5xMGkWjN2M8hwPwFQ5Lqy0pS0ii5qqWVvbN9ufaGGMKfm/DHOa4Wz0bbqElwZJ7hWPyzXLlpAPTJNb407MqzXchnnznJ6D8KubcKQRkHqCOtYutJ+6noddKCp67sowwxyZVsOAOeKpILrQbh7jTofNtpB+9hHr6gVrlYo1LRIV9T2qs17Hu8vDFu3GazTZpfm3V0UJrzVNbYbpGt7bHClSP0/xrQ0/TILKMOIw8p5Ltg1YjlaZSuG/LaT+FE5Vdoy554GP0qvNk3t7qVi1E4AyuN2KGlkG7aAqntzUbTqkQJJDemagmuHKZnfYvpjBq07GVixPeARkO5DEYLEBf8A9YrHnuEck7lCqeSgAFU9V1GG3hLZBbP3jxXF6p4utkBR36dlqlByNIwVjptW1KKIYM20+hGK8/8AEniOKKU7mLHtjmua1/xQ00hMBIX1NcXd3txfXG2MkknGe9dlHC31YSkoGzq/iJ5HYRnGeg71mWGm6lrMn7oFgfVsD8zXR+HvBEl0I5dQk2K+cKASSR2J7V38WkppOyONRlBxt4BHrj1radaFH3Y7mlHDSrO89jmvC/hSPS7iOe6w10jZU7vlX0I969IhuI2hA3EL6HoPrXPB/PlZlcsGwcngn6j1q3K4DoEDeWAN3zZOfr/+uuGtOVR6s9Snh4wVka08arboCOOSjg9v/wBeKiVmKnBy/wDEoOOvH/16yBeTpIVZ2kReAQcZHrSw3rNJnIGGIPOM/wCf61kolOLtYuXRkmZyNqtjoAeCBWPI888u11Z5F42jPYZ/xNdDZmCYsXCgghiGyCee3qeeORWTqGJJH2DBjbb09KuMTOE2naxnZ+1gbBhujZ7mnxaWxhnN0isWR9r7sAfL+p5FXtPt4QH3PhmwccfKa2UubcWjRyEqSm0/KMEVSfKzCrKTdrHiPjDQTA5ntowsfdF5x71xcsZU4PUV71qS2pZkjVXDcdK4TW/B8l1cPNY7FTbuKnjBr08NidLSPJxmFfxJHnTJg03Bz9K0b+wmtJNkyMrehFZxBUmvRjJS2PGnDlep6R8IVt7m9eOcKXTpuHavdk0DTryLbNDCykYOVr5x+F919m8RICP9YpAr6P0xZGjDh8g/7NeHmF4VND2cElOkmczrnwl0/UEc2LfZnIOAOVz9K8x8UfC/W9FjeYRJcQA/ehbdj6jrX0nZFomwxLVdnKSAecm5T3xWFHG1IdS6tCMnZnyf4X8U6p4XmZNz+URjB6rz6V7B4P8AHVnrkDCZv36HBJGM12Gt+BtB8QqGubZVK5y6DaR+VeVa78Kb/TNTa48L3fneWQdj/K30B6H9K9OljoT+LQ4KmF/lPY9OjSTY685wRnr+VbQQIV3HHHJJrwTSfibqfh2Q6Z4j0+RJkODIw+Yfj6e9elad4tg1jTkntnyCOdrgkA/zrsupao5HFx0Z0U0CPKWIO4nBH8OKKda3sdzGM9dvIByaKBHxrggY6Uqgk4z+dA68VIqnggV0s5dxEUknB61KFHXOTShQAOOKeE44HXvSKsNCYGfSlA/HtTz0OKCvPJ+vNCARRkY/WgjuKeRgYA/Go3NWkTca7ADI61WbLE4qwFLnABNaWmaTJczAKhJPPFFxWuZtvZPMRtGT6Cuw0PwwPLWS5DA9dvtWzpmj22nQedclRt5JJ4H0rn9d8V3FxObXRVCRjgygZJPtWcp2NYQuzW1nxFZ+H1NvCokuEGBGvavPdTvrzWJt90x2ZyEHQGu18M/DLV9cIurlfJjlO8ySnlvwr1fRPhJodokbXazXMox95sD9K46mKhE6o0G9z590vw9eahOsVpbySOTgBBn/APVXomg/CDUbkqdRkW1Q9sbm/Kve7HRrHT41S0t44UHQIuKvhU2jaM1xVMZJ7HRGjFHl+kfCHR7R83c010R2OFWu50rw7pmlpssrSKMdcgVskHb7U0nA5bn2rmlUlLdmqSQbYkXG0YHpTDL12AAe4pWcZ+YnI7d6YodwSiY77jzUDGO7Nw7YXvmkBYZPIHvUywg8jk1IIhkEnp+VLmsOxXWAyOTIS3uasoqoOcECnbS5Yj7o7np+dZuoapb22Qjq56Z/h/8Ar1m5dyox5nZF6ZlJJ3YUe+KrzXSQrvYhFx3/AMKxku7vUZP9HVSi/wATL8v4VfXSo2/eXkjXEo9RwPwrNz7Gvs1H4jJn8/VJCcEQZ++RyfpWjBEltGiBQoAxVvKRLhcBensKozh3zu2gdsEVk1fU2Tvoti3y+3HP0odCDuPA+lZ6u0LLukGDxycVcSZJE5BJ9jmhIGrDJQduFyUPBG7GapvbQEFigfB4BAcD8c1eLAr+7VwD68VSkTggysq5yQHPH1GKqKBMagKsQI8j/ZYkVK0+1W5DY5K5Py/Xiud1nXrexUok7M69TjIHtXE6x42EDuI5evdTkH8K2jTlLYq1z0HUdbihfeGwwHQ4Irh9a8btEGEci4HbaAf0rz7VvFN1dbhv2qfQc1zj3m8kliT6V2U8L1ZLlGO51uq+Lry7VlzhT3z1rlLvUQWOWyx96htobzU7lLa1RpJJDhUQcmu78KeGodPvEkkKSzugKsyBgpPGNpzyDxz1zXVyQpq7M1NzdonLaZ4c1jXVBtbcJETjfKwUfhXbaJ4C/sqNJbmRJ7gkDaoyPoPWunsoHgmXdiMoMnJC7ecHA+v86Vp904GDIc8Zzj6AZrlqYiT92OiO2hh483M9WSW1raRMNqMrqOdxz39ePpTHEr3DZ+ZWGVJGM464watsjvKhYqFxjYz8DIzxk96RhsG4Quqx45RdwBPQtzxn8q5JJ3uz0abSK1rDtdhgDPJ6HFLc7dpjxl+ByDn6+/5UXEmCpVmKseSo5+uMCsO/vJre7wqyLD2YY5YehA/Sko9zb49jQE8MEm2bIUcZUfe/CoI/lcDyhl/ugN2/A/zqlBOZAJJkVwDwCcbf8a1lsC3kCCRHlYbysbZIGePx9hVpMicox3eoiyzG5JRQwK47DsDjipkgcSchkyBjK88VYS0LKQEJZDlh3B/P/Oasuy7ULwMvcupzkdwaDG5Uit40B2vu5ycgg9fy9KhnHmkIEIAGOOtXA6FN6qCCed3H5H1qMygRME6MRnIH86QWM4WKLcqiEnKglj05PXsf8mo57d1JBIUj05FaDFmfEgbaM8dcd+lZ16+CR8wIbByc8VVxOHRlCXw/Fq07Ncosi7doJPIrh/FXgWW0uC2nhpI/7p6ivVLCKaVQLVCQfvHjn6DNO8QReTaAM53cA7Tgtn+ldFOvOD0Z5WJw0Ju1jx/wfpdxZeJ7Dz0KlmIx1wMGvpTTNkcC54OAelebWOitLqtneMhCR5ByMYb0xnPAPcda9Jht5fKTjOOnOKyxlX2jTFRoqlHlRrRO2N4K4FSbyzZz+FZ9sXSTPQf3cdKtK6eaBv8AmPPIxXFY0a1LkbBAdjY5yR6ipopQE8sbcSHGSMHNNjRSR5g3L37cVeWGJlbcgIAzgnj8/wAq0gc1SSRzXjDwjpfiGNYtRhDn/nouA6cdQa8W8Q/D7V/C940/hq7luYV+cQsMOB9B1/CvoaWPzJEDA7CSoJ6A4zjNUruJnkkKhjOjZUsB/OuiniJ0no9COSNRWkfO2jfFG4s5RHf24Rl+VnyetFek+LPhxouveZdGA2l1J/y0hOAT7jpRXpwx1KS945J4KSfunzug9PyqdEJzjrUMXYd6vQoSBmvUZ5SQKgycnmlxxj/JqQKMnimnjjilYZGAfYU4DH/6qRz6UbScY5zVLQhjWYnoTT4bdpXAHNaFnYPLtwvB9a6zTtJgtU8652oo5+ahsajcxdI0MSyqXTCd+K3b66s9DgCxxBrg8LGoySfetC0sr/XJ/s2kRvbWx+/dlCAB3C+teheFPBun6Mu9U+0XTDLTzcufx7Vx1sVGGiOqlh29WeaaJ4N13xcRcazJJZ2P8EOMFh9K9S8OeBdE0eNRBZRPIvJkkXcx/HtXUQxhU9BVoYQYBxmvLqYiU+p3QpqK0FhgSJMbQoHSnlhj+IimA/Lu70u7HVsisHqWPYnqePSmFuh3HnsOKjaTcT3NN6kDH5UmhkjMA2VOT9c0zJY9adHEDnPP6Yq5FCoQ9KV7AyqsJIHf3qeOIgfOeKsKqqOBnFUrzUba2Q73Dv8A3R0FRKQK7dkWFA52LwO/asfUdZtrUN5Z81x3B+Uf41n3N1qGqybYSwh6ZxtXH071ctNIggXJAkm67mGcVjKbexvGmo6zMoXOp6sSqM0cBOckYH5d6vQaBEED3DNcP6v0H4VqCFAOo3e3FW7YkZQ8H3NTHXcqdTlXulGKMQL8i8DoAcUqeY5LHIzx1rQlgLAEg+mVHWoZIAoBfbt74yCPrV8jMvap7me6MZT82R2GDn86e8CKmWkAPUZOM0+5vYlAVSVUDswwf5ViX2uxQRHLxJzy24Ej8M0KJouaQmqSmJSyhjH65AFZT6iLfYzyBEboQVOPrjpXOeJfGFlBG2HWVsEFS3X34rzLVPEsty5EbFUB45P8q3p4dzNb2Wp7RfeIorSMSF1b1O/g/hwa4HxV4+nfMVrKyLg5wTivOLzVLifhpWAHqarWdpc6jc+VbqHYcszMAB711QwaWsiHWitEaN9rl3dOzNMwzx1rIlndvvMWPqTmu607wFaT2yS3eqrHIMh4yMAn0BHP44rpbHwpo9pLus0WaRVDHcNy89QAw5xW/tKcNEFqkzhvC/gbVPEkaTWpjigaQRmSYkBeM56dK7jRvhLBDNc/2xclxEDtEJ27j26gnH4V02kvJHayWyNhsF1QNgLj09OnSqzXb2cp/fPLHgFjnGD3Hp9K5p4mT0RvDBN3uypaaDaaT5hs7MYYYdo/vYHXn8j+FQ3BVHV1Q5A3EKQpPr24yMH8K04NdS6DKBgH5sbOp9x/nmmXFtFLvJCJGOV6DAPuD1H171jeT1Z1QpqGjiQC2MoWWFw0oXBbueP8KggllX5ASzfewOCoz37fjU7wrEE+zs4OME7s/U/yNQygTQBXCCcZJccbh6YqG3c6qdrExg80M0LEKTypPAB9cGph9peBzLNsUAEq27Mi/Qdhx6VlI0tudsQzIFIYHkYHcevrWhFcQ5jmYyfMwYAseR649KcV3FV02GtEJELRlNijO0jsT39Kx9dgRJyqKjrkEMjlvyPHr6V18hN4X8hQJFw4XaoZgBz8oABxjPfjt3qbU9Kjbw006Nbm5ilNvOn2raFXhhtXPzHODx+INbRpNo5frqjJJnC/P5UaT7mwuBuPQVq215L5Yt5ZZPs2PlRmJRT9Pr7Vd+xIblY550spHCgsY34G05yoyeuB2B3DjFSz+HtUtUiN7aTRROqsjy/IoB4GSSAOvQ9KzcZWujd1qTdpaEMFyhcuykZPVew9Ke10EypxIn8O7P0+n6VRIaMlcjI75/zmr1xbG2njR5o5RIqspiYHOR0PUAjoR61FmzT3E1cjD8qhDbGPGRx/9apJY9j8YyvBBOQcU9Ysq28MCOoA5NIFkzKPKIdOTn5dvGf5fyo5WQ5ruQTo4fbINo6KFbHORzzz0+n6VWFoHVjl41B+UMTyRwenFX0nJb7qIRn5mHTpxnuD1+maI7uCPdFKyBWwSQCTn0HP1GaqxDnJFSFrq2VsgICQwIbGfTmpbdRdiVbv94ykscscDjO4AA59Pxps85VmigDFTnY20bse5HTvmrah4NPaJdjySMFZxglPoR+VNGMtdWXdD8uV2kVCxdiSDycds11+MIirgACsvRrRYrWPsdufStaMqg3Bc9utcs3dmEnroTQxKqk4yeoq7DaxSBJZVVSDhlx09/pUMQYbWOcd6lUnzByUX+8f89KEjmm29mWYYsS5RgVxwQP8ahk1A28qhkOGHOBuA/KmyyMJgkT8Dhsd6sRLHJI7q6hP7o5bp+oq0uiMnprIS2aGYbZCH3nPXhvT6Yp88Xkx5TIXkEE5pBGANoKocjKjvUNxH823zCcDHtTewlq9DLu4wy/uyOeoFFPlaMlhKgAAySRxRUxhKWx1qfLofH1sv7wZzxWgox0qC1QFh71ebAUdsV9a9T5ZbEDDAGeKjxjOOpqwEaRsAcdq0tP0uS4xtXPrTQWuZlvbNI/3STW9pujySAMY+Oua29P0ZIn3S/Kq4JJ5xV6K5e+uHs9Ci894+HduI0Pue/0pSmoq7KjC7sQx28VoyRojPcuPliUZY/hXR6B4UnmuUu9abO07o7UNlV9Nx7n2/nWv4e0GHTo93+suX5kmbqx/oPauqt4OmRXl18W5e7E76VBR1Y60gVAoC4IH6VfjAXHoO1Ii7FAIwaHYgcck1wttnSkTlxjIGT29qQMecn6+9Q7gqkE5Pc0kZLjofSpGSk8/Lzj34pwBY46ihUGecFsVYWI+mP60m7AMjjXsMGrEcWTwp+tSRQksODUl3cW9jGGuH2Z6KOSaly6ib1sgWIKeQWPpUd3e2VmhNxMAy9I15JP9K5/UdcN4/k2cbknoFPP4+lVbfRpZyZL5vl7Roev1NYup2NVR0vN2H3ep3WoOwtY28nOBjhR9T3pbbSAjLJdN5jnkr0ArViiSCNVRMR9lAGKjm3sNyqdnOADyMVFn1Nk0tIkiyKMAdB09qeJVH3hkk+vWsZrpC+A/zJ6/4GnR6kiPudgFB60WDkubduBv3FCVHp1qa6uYF+6/IHRufw4/rXL6h4otYosbgp7nJFcdrHjOJ8hZmZhx0x/KtIxeyRCouTvLQ9Kl8RWsX7rKg+5BH5VzOt+Ko0ZgZ8D0RuPyryfVvFSl9iSMPXccn9K5jUPEADscmViOrcYrphQlLc0VOENT0HWfFvUqzP8AnXDar4ie4djLLhT1VeazLaw1rXAHhTETcqWcKK6TTPhvJNb+be3qrKvzMgU7cfXFdEadOnux3k1dI452uNQYi0t3ZR/Fgn9aWTw/rW0k2E4XucZr2HRtLtbSWOKyEu8t+7UriNsDn3z6YrudE0CZJJ71YAk6JvwPk+YfQ5/Wr+scvwoyqU7fE9T5dbRr6Jfnt5MN6qea1dKS801ObcqH5OV619HHSLa4sCL+FRciQsxHIIPbOeT7dapGDSbWKWK7trW4jfAMc8WSR7MOVx7EVLxF3ZmUYW1jqzxKK5fzN7AMnB9x9a6aw1BXUeU5yAB0x+vrVnXfATfaGutMuY442O4QhjgD0Gea5CbztNu3hmIRweGXjNZTSnrE9TC1bO0j0uG6eELs8yQKmQC+cjuD2HPTFZCNPBcIrxSIVbed4IP1HI9azLHUftQC7gAeBkjIOPWtvSri8mhlt7wK7Ku5N7A/L147c1jZ79jrlKNN90wjJCxgytKiqQElLME+YkAemee5qW2jV8bnBCn7jc9B6GpbZxEkpjHMi4OAMYzzhe4Ix+VNZIwEDoZAo2FSBwOv1/z1pXvqzRaaJaD7VI5JGEkyxRoC27G4bh0GB3PSq10iTDNqCkpzkdM8+n51G0BtLjEbkIvbd8x78c8Y4qKWe4uGZyUeR85LD8+fxprUnltK6ZWufORD8u3HJVRnj39KWCJUuHkSN2gZSSCwADHvj2P41oRwyrBF5sGUKZHzcgHpkn19Kfb6VcwiIyxtFG4yu7oAePyNPYlz8zV8P3rQXUXk7SHfnID9+cKVP54z7VW1Qljc6lG0K3E9yyzASLmReoYxADGCOW46ill02OzDyyKySBRnaNrbc9fxFY9xLHc3bPG0jZJO5xhmHbPXmq9o4x5WYRoxqVPaRLkl/HIU8xSkAAVVjYkqO/3v5cda0LPw7qerxFtJt5LyJVDFkYNj8T0Jx92sGS5jaWBZowkQ2o7QrzjucZ+9+Veh+BfEWgaDaXdxcXV9NqExZT5amNdo+6T2549cVVKMZu0noRiZToxvTjd/ecXZWlptkju7w21yjhRC8JOfUkjoBzngn2rdl028sbe2mhmRrIOXM8Ep6hgNo6MCeMAjPeuQ1S6eW7aWbB+Y/U5Ocse55raeOaKG3lm0yVUaESyCIceWRhWPUDJGTn3pRtqkh1VPRt79DYtJIFeKOEiOPzlQyswIUZG5w2AVwRn+ZqnrVteNrDGS3KmN1h3KpAJIwmRyTnGfeobKV5eIGEfzGViRkLk8HHrngHp0pbwz3CxSSNEw2eSWZipGDkHHY44zjFLmTViFFwncplVRpDKJl2qWG2Pdkbhn8iTyfUVWnhe7aL7NlnK9OSyAdiO3elMEdxfBtvkqiBdsIPzAdyeuT1NdDDBbvanaMgnGO4Hv69uaiTR0RbWpirbm0tiSzBlwxJIGQeh+lXdCt5Z5hJNHhE+bJ6nNaK2IJV9xj8o5wvKg+v8AKtJQZ5WkUR+WzDHlrhQAOABUSkrGU5vY0LVRGu7HXtiriSo/7uMYx1OKgg2vEEK4C9mHXFWoId54BwO3WsDmk+48SpKuIjv2jAwOlOKMQu/GCeeeM0JbuZl2BRGM5HTmp1LBkjKqIejHPOe30pmLlbYimtFZNzv93kFTgj8aLQSQnzDIZOhGRx+NTSFRkITj6VVD7xhDnsR0FGwknJaiXMjGdnVsng464qeJ/lLyqSTzgGooQsI8xMl859qaLpPLk3YwxyD6UNlNXVkY/im5UwxwxMWllIHTkL3oqhEPt2uuynKr8igeg6mivewtFQprm3PKxNZudo7I+c7WPy4w2M5q7a2clzJx0HNTWlkSiDPetM6jpmi27SXlwu/HCAZYn0r0Dg9SSw0Zy+B1xk/StK51fSPDdvi+kDTPyI05J/CuB1b4g3kyvFpVutqh43t8zkfyH61R8KeG9X8XasUhLSycGSaQnbGPc9vpSlJJXY46u0TtraTVfHdzMmiobGwjGZXY4J/Lv7V6b4Z0qDR9MhtYB8qLy3dj3JNW/Afg/wD4RvTxZpcmYlyzvs2gkjp1Jq9DB++KqflB4rysRW53ZbHoUqaijRsoT6jp6VrQqODkgenrVe3jCKCeB7VM74Xnr25rjbudCHOwA5/DNVmkzn24zTZH3Ly1JGN3vz1FIZNEhY9KvwoQMLyKjgQlV+Yc1bUBOBggdzUNpDHJHgZwBxU7COCEy3EyxRjrvPX6etZlzqixOUt4/NIOC7H5Qf61gXEd5qc24MSh4MjHgfQVi5lxpuXkbOo+KIoo2itYmDNwHY8/gPWsi1sr3UZDLNvjRjnLt8x+lXdK0uC2JkO6WccfvCOPpWqJ9gOFwRyQe9Q05bmiUafwIh07T4bNPkU5PVicsamuLpI/9XMoPTaDzWTqmsRwAhFUqRzk7Stcbq3i1EJEmc4yCWJz+dVGLeiGqcpu7O9nnLxsNm0E7svHyfxFY19cQx58xUAx1yqnH/fXP5V5xefEWe0fAEbZ6HJDD8q5nWvH13eoyHb5eTu3Hg/1Nbww8pPVF8nLqelaj4psrdm+YMVGDtY4J9a4rW/HQO5YQwz715lda7NcOecrnrntULTxlcu+G79zXVHB2+IXto/ZOivPEFxcsSrnA7lqyJtSlmPzMWP6VRXzLqQQ2qMxPTjrXWeH9DNhKk2qoMSLmPuB9a3cYU1qZupKTsjFsdO1PUEmktrKaWOIBpGRCQgPTP1rpfD3gma4lSTVWMCE524+au98ORKYgsahcvkRxr1I96372a0u4mt7iFYpXIHnglTEf5fXiuWeKvpEORp+8V9P02zW1itLDClCC8jKCfYiunhgtLe6VHfYzcgoNuOMHj3rk4rO4s5MpIZFUkKw/iFXWjmUF7ZixkHJ5BI7j3rmu2dqpxmtGbsvhiG23XVvKZYo38zb1U+2M1bFyos5IhHFMzYKkryv8xj2qPRkkuLbY7SxEDgDOKz7hhaXf3hkeuQKXMzmcOZuLd7GnJDIlpGbd7bdJkAR8yH6j0Fc3eW8qMPL3OwY/O+GwD2/+vS6lc3d9PD5TOkajG1OFJPqev5VGJJI1CyZWQc8NwfwNO9tUXRi72ZNeYMELFIYYim3EbFm47sM5BP4VyOq6Ra6jJ8pjZm6fKflNdbaBru3k/ckRA8sOg+p7Vj6latZ3siKQdnJYEYH41abvdHVCnH4WzktP0x01GS0Fu1zKU2qEB4bPBrUs7l7V/s9zZuhClQ3YHtwfQ/pXQ6bcJEYyfKKSjdLjlgPTj+R/lUsGqBrSWygsrRIGYHfKu6QjIOM/hTtf4jOcp3stUVNOKXLgorKRnJLbfmA9T0OeePWrTwSJbsoTy5mAGCMM2emP69/r1qVzBHK01tDHHIeGVfunsTg8DPb0p11dB1hZ9kKLkBkOFxj6/jUBGpJsxLmzBXA3sFGeeCDmiW2XeTcqwlIwpT5c/TA6555rQeZ5nXyFJYKWL4wCuKhfYsQKSKWHzNz90+v+fSkpHUqjtZldIVMfzscheC3f244560ye7u1vA8jtJGSrOPl2sD6g44I4/WrNykRs0mkBQSbspGPmBHRs9O/5VT062k1DU1tIo9zyfu9iDecegB5yKuNwXLJNkmv6g99c5WzWCwwpt4ncyCJSP4WxyDz16GtHwXoel6ibhNU1JbBNpMcjD5XPfk4/KpvGHhFvDE1oWk+028y5QlShGDkqV6j/wCvWRcpCXd4oDBG2MRhywH0J5rSd4T/AHi26EU3GdL9xKyfX/hx8+maTKpMeoTQtGrM8k8JMbEEYC7QSM+pHpTL7QJdP2tLqNk0TRrKrQzGQuD1XAHUd8/hmpraS5u7MaXC0CW0kgl3S4QKwBBJc8DIIz9BW3pvgzUZYp57JrW5WAK4a3bexHJDLnAbkEEHrQo+0XuxJnVdJ/vJ2OWtxPbq81oFkERXEpXayMWIG1c5JOOnPGciun0G31k6PK9sUt1mhKbN6RCbqCm1ed3XAIH15qW28R6VDYC2n0mBHWQGRygfzhgjDbtxHXjAP1FYNnLbPckxObbHSQIQqnPTcoy2PlOTz7VouWCumc9Sc6l1ONvPc0bZfOjlzabFXDSBVCbB3IHYYOP/AK9XLe1iulkxtjkVfn2qMDseP59KpWd4tu0cm3dg4fcCwk5wy46duuRWrpupQujbglvPbNjPO2UjHAHQsOCcfeHNY2v6hV5lqtjlZFl0mcymTzESTGc4yDV24z9gNxZh2jKksU/h9f8A9VWPEixahcySSTRx+YSxXdgDJ56nNZlnf/ZIHtbPy5uxBY4z2P169ajc0pSlZOw7S3nusjziRKcMSSMrjoO35129hb4hRVOAB26CuU8LQOsk0lwdpJARR0ArurIBgFVgorGpvYmtNtk0NuCFJJzV2K3IT5nVQSQfqKdFEoHzPlem2rALqDhVVWbn1z6/pSjHucE6jexGyqpODnkHp7VVmkSJsNks3Y1amkYyEH5cDHFZ9zGVZ2V2bI6sMYNUwpq+5G2SzF8hVbhVP6U5JV3+WkeQR0HrUIEjruGS4+9g8fjRCsqhizYJOcVBvYkeMqxVXCHuBzWXqcqW9rKZOQOmDjmrssgH3n2N34rlfEN2XnjtQSRyzsRjPoK1oUvaTSFUn7ODbNfwlagos0pxgZBair2nBLLRwSCS42jI6f560V9FY8FnyDf+K76fd5SxW27qY15/XpWHia6my7M7nqzHJqzpmmzX93HDAhd3IAUDmvaPA/w7t7eeCS/WOa5YjCt91e/TvTq1o09yKdKVQ534b/C+bWmW81ZZYLDAKdml+meg96978M+H7DQrL7Lp9ssEWcnHUn1JPJrVt4BDGFwNqjC4FW4oM4HRutebUrSqPU7oU1BaIba2+Sqr8uDngVnw2wjZiV53HGa6G3TZggEkVlXZ2zyAKQAx7VzSZtEhY4HI6c1DJKSOtLJISCfXpUUMRkcdqksWJWduxz1rQtYAOuPbmnW1uIyPlBPWrLskEbySfKqjPNTKQ0GRHGTuVVXqTxWJqGpO4coWjg6Z6ZqpqN7NeyZjUmEHCRr39zVm00dpU3zyb5s8Kxwo9vrXO3zaI3hBRV5EemwecRLKQsZ5A9q1GhRZcRPyVyFPG76VSneO1JEe5ZgcZXIKnvkVQvLxowzPcqEK5JX7o+hIoUGW7yd0XNSvPLX5lXaoxtAw351h6h4gtbaJwZwFxjGc8fWuF8UeMJCkqwzthhtJ7kfWvONR1uecHfM2Ce7V008O5ltKC1O98TeMEEbJZ4cseAT+prhtT1q7vZA11PnaOM9qwJ7sqCVYu5/Sqey4umCkO5PRQCfyFehSwyiYVMRbSKLt3qSBjtJkb1qg0sk/L8+3pXR+H/A+saxLthtWVVOGZ+AuDg5rr5vh3baSIvts7TMRyIxwD6dea0dWlT0MVTrVnZ6Hm9nZy3Egjgid3IzhRk10Wj+F2nmAuxJhum04A/Tn9K7nSdFsbecLHEBt68g8fWuzstHijgby4ct71zVMZ/KdUcIqfxlX4c+G9DtdRiEtk06MDG2SSzA9xjpitjxJ4cs4dR/0S2eO2B+UP82V9c//AFu9GnC4s5fM8yWJxkBlODjpVieWSUAGR2GOpOcCuCVVyXmN0ffvHYri2jTyFswFcD7p46VLrM0f2UvKhacPkKzYGO+AB1/EVZtxFboTkPJjq3NY2pySSb1wpY9xgVEWbezUnZE89208apDg4Hr0qa3VpElcwS7Y1LsQT8vvjPSseyQhONy575yc1r21y+DHM6+QxAdegJ7cVSsi5QcVoTaHqi2l+gbcYDGWZiSx6HA9jn1FLJqUl8VngiTDvtVZPvj6471qwW1v5ZKqM9v/ANVZ+pWbLG8lsFBxyPf1P/1qFNPRmKUXO9h11eC1t4ZLiaRXJI2DOR+FZ91eC5hwSdiEsBtz9etYz3Ejvid2PPJb/GrbmJrdAZMt0yXp6dDqVBQ33JZbp3RTKqhGBwdoHHr0qoJW3uYSw3AqdvcUmz5MbMoTwwOcfTH+FMRp0AYx7EJwpIPPuPWmbRikJIjZLLu3nnJ9aTy4i4Yqyvt5+fgn8avqyO6pIFG7g44x7jt+tRXtp5EYCPv3DLD+Jfw7/wCFFnuHMr2e5FE8UX+tMjWxxuCgbj9MnGaS3m+1MYriNlRWyMnDYP5CoFSZVCSsMHoepz+H+eantonEmxQqjjJb+WAKWthVIRvc1bmC1GmDbGz4PzOM459Tz6Djis6Dy0m3ldzMDlTgf54571be5jMUm9Qi5H7tW5Az271m6idqB0RQrYGAOMjuP8mlcyhTvoX4RC6lxcGDy0IR+pJwQBz2I9OlO8NtcpqqvDZw3BQB8TRFRxwpDKOCx4B6E9c1kxxrIQA+FxypPtzir41Rre3cQtcQHcJYtgxhwRkN0BHGRxW1NpO7Y61KSi4xV7mxPrB1zVrV9WeT7Gu1DGqBfLHcJgYGD+PrXQeOtLgm02yhs7m2by/uxBFDqpHVmXg9PauGhupXn+0T3fnXExxJIxLHBGOfwrfa6sorby0hhaZz8sqIxzz6nt+H1qlUTUr9Tiq0nSlBx0t06GQLO4gsDEssWWVgMbVJAxld2cjNWNPGpsk2mPK9lJJsjkgz8z45GQMtkL2GTxzW3q97cw2waQxQniJk2bV55+bsCD9OnTrWVdm3k024ublo3vS6gvE3zKw6ljyST69M5z7uK5dhe2lPdblm4sNAs71LHyJL6WQgOSzxSwt3UqAQ3rxz1zVi3htdMiOp2ti6afLIwRo5ZEeIgAfxZ3BiMHggcd6xdJ0y9ubWeRZZZfMkGxjMAnmf3mBznjPNaN9A9vZy2yNLEsiASKCCrjPIHfAIPOecD0q1VVtFYmrF35XJv5mZBHPLeyDFu1m0hk8tiX8sN1K556dfXFactpCkYeFIoiQM5xk46AkemePyrnZrPyZzJscIhOOSpAxkE46Z+tW9L1AXV5HDKjJZsu0jOQV5yef5ZzWD5nobdpLYzNU0i6kuXmdjJblTIWxjA6dcHH8q57UkltGKDJXqrr90r2Ix/KvUbeWXzp4baZ7e3aLOH+Tf22/Tn8a5nXfDMbwNLBviywHlqqqCCOcdRwccY79qSSWhv9aa0exZ8I2ks2lpKJcuwBy3TFdlpa7UO9sMD17VR8M6f9h01dh2hVA24zuOOK2o4FeBfMI3Nx/k1g0pM5ak9zfsLVHgRjt8w8HBrPcyiRi7/IGJUtgfTFR2EstupZskfwqeML61cun+0ISpRiQCq9eKqyscVnGWuqKbTqcl2JJ4+X/GoZGDYypJA6k54qpcRs0T+Wdr9AD0JNJBO6ARyHAA/CobOlQ6otSOWUYOD6VTkMm7AbrVmPByrHn2ptxbtu6cjt60ilZaGZcD5izE8DkVwkt19p1kliCTIQv07V2+sBzaTLFJ5cjKV3dlOK4ew0gBo769MjIDlY04Jx3P/wBavVy6lvNnFjquigdf4jvzb2qW8TBSqgYxjtRXJ6/dy7d7lvmxg56n1or2Yw0PJciHw54cstHtlEECiUfxFcsffNdzotl5R86Q4cjCj0qxb6QluVkc+Ywxj0FaMEOCMEjjPPrXhOTk7s9TRKyHJG7jg/MOprRs4sE8A4pLeMMVDfwjPFWk/dj5gD05IqWIRjtj9Mc1gaoxN2x+hwfpW8SCxJHB6Vh6sC18dvPyj8KgqO5RRS7AY46VsWdttJ4GPUimWVuMgngn3q/czRWlozyso9AepPpUNljLlo4I/MmZQiiuevb2O5JmnU/ZlOI4+8jfTvUOpXUkkwl1HEdsOY4RyzN2G2lsbOaW5ju7wAgqRHAOPLX1HvWEnc3hBLVlrT9Oe6ZZmKqScHaAAntT78Ro3lI+4c5RPlGfdj/KpLi68iJlkRiMdUbBHv8ASsTXfEEdrY7IGAl53MvIPb8D9KcUNKUmZt/ex2jMZpFwMnZuIZfQZ5yK8r8U+IjdtIv2qV85ACtxUHizXxK8sUUuefnYdSfTNcBd3+ciJtzZ/AV3UMO5as2qTjT3LV9cAKWZiT2Gap6fZXWoXACIzZPYZwK2/DPhq51bfcXDBIUwTuIyxJ6Adfxr0nQ9OTSYHESBAVw3v9a6J140Vyrczp0JYh8z2M7TvDWmnREBtI0uovnLu3Mo6FfqOv4V2XhLwtDLhUjCWytvb5fvHHTNUoIpruc+VEzyHoFHX3xXdeH7ldP0tY5dokA+Yv2P+NebOtKb3O+tRjRheO425h+w7RHCEQN0HAx6n1rkfELidlZASVPzLjNdPqOt2hUqzF368ciuWutUdrg+WqhPTGKleZFBSbvYh0+HYu9Gw/Xlcite11aa3BMrxvjtGCCay3laYlYGYsRnC9aqzKdmC7Bz0LE0NXOv2al8RtXXiAyKf9GZW9zk1EmotcQnCt9B1/Ksi3MhXyzkv3q/a71JUGNHb+9/SkkEqcYq0USRXsshKBSBk/h6VajuFC48kF8cZqjDtjZm+Y/MeSOT9e1LIWaXIKrkdutPYnlu9Bl1O4BzkSZyAB29KrxiRzl+DnIOc/rWrBkjaAx49DT2iikR5MqNgB2DPP8AQfjQirqPQs6VqLxKclmOOnrWnPqkdzbpHEfJcj5yT1rmI5MgCFSJDx97Of0qS1gLTLI3OMkkmk1bUiVCD1YaihyAArY61XjClMSDaM8MCTg+45zWpc7HAP8AAuR9M1nzmMIylBuA4cccevHX8qpDTurFxPs0cTksScfKoPOe3Q0sMMMt0GKOEK9Au7H0wPWqNuqxgFJgy5OUJCnA75OP6Vfs7iVxmJAAh3F2ORg+p+lVYzkrXsx2Itx34MyjON2Cef0x0preZcMSiqgjIYqzfNt7d8n0x1qlNLtu0+SKQgnJ3nHHBOT7c960rBGnUrc3BSFFLiMg4/2h7evTmnoTJNJNhNI91ECLYRGP5mYkk5yeRn2Pr2qrbxuTM8l6Syj7rAndj7v6E+vQ1oubWQbUPkhujEHbj35z1qGK4jBjadIyFypVPlYkfdyB1Gf0oTb3J6e6isI7hoY4/KgLMQwaVxg+nPbjuahgeARyRyRBkbOE53K2euemO30qeTULlxMhOATgxjOxRntis8rLuEipuU4JPrzx+f60n5GqhK2pDdRb3lCQgZyQd/K+oyMZqwsStF5c4HY9gx/qfpQsskYLvBg+3QkevpUaSOAnmblUfMjfTtz1/pRsaxm7WZWeIJPIId6hTkAn9K6Sxkaa5hxvEOMqJmzswOm7AHr6VhyxSy3gZVVpZjysYAwT22jpV+zju7LUXs7uCdHb5TC4wST2OemfWnExrJTj5m5qNlBqLq9psdLj53itiBsIGMEE+2OeKseFtD07Q2hOtpJ5bHNsqhZRtHUSqvJPI+tZMtk0EzJb2+4NkZ83B9cjnHt17d+lbun313PcWkq3EEMsS+X5itsAHZ8e4PbBPpW1O6d7XPJrQ5V7r0LGra/HDeziOAQ2zBTsC7ATgdB6Ht6VRn1iO/hTkiIDbuKcgjnI71heJLCe51WY3DzLcqwY9CpDcnJ98gj6mqRs9S04yfYpllVE3MFOMEjkEdjgnn9azldts6qNKlyR11OhaO3uw3yAl1wu18Y55BHfPvV620VIUWWUlVVh/qeAF9Se5H0rnbSS1+1wMYnB/wBa5PBznsOB+Va154igazZIXKszYyeA3fHPGKz1TLqRla0TRXUpBNi4cSFPkEhVcleRjgDIwe5qO+eK6vra1g2MoTzG2fdHOAD6H2rn116HEh2bXdTlmYAZ9s9Olbvg+De891uldpwuWlUAjHXoT+dEm2rsylT9nq0dJBb+XHGgHXLfhVu1tAzJz8o5IPan2oG+QuP9XjlSfrTjOACIhJuJ3ZH9ahI45Tk9EPlSO4URuqF/UL19hWO1v9nuhGjyuhGMkng+9anmZO2Y8nkYHSmMwD+WGGSDlv71Nq4QbjoYsrokjb1BwcKwxmqoVpXPzZPX1ArUugPLKodyA8+5rMu1VV3IwDY9etZ21OyDVh6TiFyckjPXtmppr5Fj3sQCB0z1rg/Gmr6rod1ar5SR2Uw3I6sCS2OhHbrWUmv3F6DuOCenevTo5c5LmmzgrY2KbUUdddXKzzbUbAOeBVhFQQ7nQgDn/I/pXP6Q5Kgvtbvv963rqRo7Uux5xnJ/zmvThTVNcsTzp1HN80jgfFMo3ybCAo4680VS1hzPclBz8worrjojB6s93cB+MdqlS3+XHXjOadCmMHAIPJNWAhIyCBx0xXzZ6oxV2gbSCcdcUTyxqB5rKv1OMmq93eCNNsXMpH4CsiTdIcuxagdi9LqaBQsa78cBjx+NVbdWkcSOSSTkn1piqGYZGBmo7zUobANGvzzDqB0Ws5ysaxjfY1rm/ttPQNO/zY4jAyTXHXOr3N7eCS3RpbgZEaYHlqfUmmWdte6xM05DCFm5kcH5h7CunitoLC1SK3hVY279ST61g3fVnRGCh5sx9N09kmF5qDF71xgAcLGf9kGrtxcJDKfM3q6ZwvPfvipLsYHmSNhOjY+mKz5Z47WNbqR1kEJIO9slk449KErlDJ5brG+R1RANxZnA3p7Z715F498RSahfPbWh8u3h4J+7z3NO+IPjcTz/AGSy3JGgIzuyBk9q4G0sNR1tjHaIywbvnmYHHvyK7aNHS7NYvlXdmbfXZum8izRmycFzyW+ldDoHge7leKW6UInBCZ5b/Cut8N+GLbR0SQoskpGGdjg59geld3C32ex/0owJDtGMn5s+pFaVMUkuWmL6s789Xco6VpRit0X7OiEDIBboPwraTTvITFxDHubkc8H61nQaoAq+QWkccA7QuB7etN1bV5pQiQbgiDbg9z71xSu9zVKcnZaIlSdLWVnRIEYZ4jbOPzqpPcyTthnO09BWdFbuC8srbiT6U2fczAZwPQUkjqVJXuy+Vgt4xJJMozn5cZOaS3e0uRiNvmH94YLf0rOZNzbCN2BxTYSBx9189MVdirPuaCI0W4bQMHqaj8qSXcwAwT97NLIx2r3YD5s1IHWKFj0P90CoZpG4kcQSVmz5jDpnkj6+tXV3PKN685BwO30qhb+Y0hMgwx9RVvcq568cGkN7lpWbq/zRFcbQevPFQyj5CUTgDB9T79ajWUTSx87Vbv0z+VTzKI3KcBTjHTNFyOWzCGQFCuGPrtJFNY8MAGy3HXoPQ1BCJYZDJGeTwV7mpZpTCgYrnP5GncpK7Hy/OwYRxxscA7CcH3+tWIpUgjcMWZMdcD+fasqLUYd+3axHUk803V2VoPMgkxJ3APIp/EyJQ5dGRx295PcSSWZym7JBPFbMCSLa7njjMgIPzR5wfbNc3ZatcW4ZIcrKDlsHINdDZajO8O6RFKn7xXkCm7oVSMmhksD3AdmhOFbfJtyFVfXaOKdBEss2bfhEXCkOT0+vI+lMuLnbJ5mMr2qzbXojO9VyrjlAelJybViGpLUrtb2sbOJHXJHyrj7pB6478cVKlw0/muSzxxIFHAAAPH+cVJdxwXwRlQb1GMMM4HfHNSxxbVQQ4EwGwRrHktk5yPXnB574px7GcpK13uVftFvHAAyOpHBJGd/tn09apoUn81SXi3Y2qVGAeMc/nz9K2prGO+hL2e7zI1XzI2YkMxIBYA4ABJFVkt2S4hW8dbaRR5W11wSRx/CD+dVyWCFWOvcz54QgUEEPnjbkqf8AGrcKvEqi5UpHj5Y1OR659e/0qa5jF1aDy0VTbsFdAFjJGTyRnJx0zgdqsmzM0kKy7rGEfKRtyADk8+ppOLQ/bJrUyJIt1zzs+Uj5AuCR16f41JHawB+QHwflVOmfetdNPt/OaOJ9ylmjXZ0cenP9RSXunskZk8xVKtkqGHyDvkAZHPSlYPap6GNFbqZpCjOiA4LY6fy9KvatMs+qrcXgWKO4CnashdkAAG7196lhSNiQ8oMnBwTnI69z09qfC/k3kMj2weRHDYK9T1wR3+lUnZWIk7u63L7S20ywvLMJFxh9ny7scceh75qZbUyacHtdxjQ5cbSe4PDduneszWJA9618tt9ltZ2yI4+iH0x2JwTitzQNSjaGWOKRYwX2ny8+YvHBXkkd+/14q4aSaOKqnyc0R9pbtJdm8AdZljyzxgcRHPBQk7x175FQ3enpIEa3kG7goyHlQecA9xz0NWJlaRrkXDPJKE3gf6sknB3ZHUcmqt7cNYwy27AOFO1mBJB/DqPrUVXdGVJS5tDkdZvLa4dRsXzEkxIqqRk+oI6fjWfHePNCUibaiv8AvdzYBBGclRk8Y6j2PFYtzNK2oXIhVVKMXyWwWGenX5h9Oab9oQBVu5wIG+QjJBwwwW3KDuQdCOvPSimtdT2J0moe6bEd/bz6zpkOmop8/qyAEBQQxjIJYcFfY88jHFew6LZOtkGKkBju5/WvJ/BlnHf6tDqhEYlQMipBDsjCj0BJJI6ZPbFe22ciw28aHcQi9qKzTlZbHmYmTikluQ+WyhgxbcxH5D3ppIRCrH95xjvTt7BzwxJG4DdTPKkG5iAXPqelYbHN6iiUxKWVN0jYypHAoIPmebKDgrhSCKrTwFGMm9t+duB0pkz7YxlmJbsOO1Fy1G+wlwP3oEZDIR0IrKvJ4IkaafASLDMeueegqzOoCjazbz8oXPU9K4XxhqbSMmjWUgaSR/nfP513YHD+0lzvZGWKrezjyrdnN+NtTk1ZmuHZSiyfKfSsnSZT8ozyD2ra1q0jiskto1xGgyMHJJxzXPWIMMhUZBOK92x5F9T0DQT5nOR15HTt0rX16byoepwOgNY3hcgYZev51L4ruwMx+g5yKjqV0OSi2zXjZB25waKtaHb+apYgctkmitmzNI9pTUScbIvl7EtTbq6dowu7GPTjNVlzGvA4HtSfM55xXzbPXsC/NySaTABK96eOvy9RVTUL5LJAUCtKeRk8AepqZS5dS4rm0K+p6gtiNqEGX1PaqGm6S+qyCW9Z0hkOQo6uPU0um2Z1WY3VwSyZ+Vem73+ldXYfKHO0+WiZ4XJH9K5r8zOn+GtNyKUx28awwsAAPlVDn9Kns4xcx4EYdgMjt/8AqrF8Q3DlEnBXYHAOQVbv1xweKgj1cWoL7T5W75WLZx/n3FNoXK3HzLWqsYE33BiCAHKvyMV478Q/GYtrPyoI+p2rk98dc16B4v1m1h0mS7vZkdFH3MFSPT2r5x1jU7jxVrrO7YgQnbx0X/OK6sLR9o7y2RUp8kbdWWfC2ntrWoGW8OIc5Yk9a9OWS3sbWO3t1CiM5AC1xlsRaWsccRRMAHI5zWlZTXcy7I5ZGf720N1H0qq8nJ+R6eDpJRvLc6V7nfEsXHnMc8imXNw8iKsrbsDBrOi3GUqRlxje3YZ9fStIKtsdzunzL3G7GRyc9B/OsbWNZpOQ+BcZ+aroJdeXBIPasU3ERukigLuoI3EYHGefpxWnJOoUiEFFHbOSfT9KTHyWJX+ZQoySO1RLEASHPy9zmgCRY1kY4c+/aoXughG0bie/vSsPyQoJe5KRndGDgEjGamEQQ+ZuAJOPU1S+3YkAjGDu+bipJpyw+U4A6cUXYuVosbyA3Uj6VMxBjWSP5wF3fKMhfrWVDeqpPmEqvTjv+NQy6pGZPJjwE6kh+M1XKK7+ya0lzGGBjdgODuYYz6/rUVxfqIdjDJ7DuOe9Rx2xuoCYmwByfT61mvZyidYxkuPUY+mPWpsXBqRr2svnud0gz1BIrVVgyKoLZ6Ev0HvmqGmWSTq3ngDa2cg4/L6/0q/HIkcvlbCVAwSeq59aT0FUknsV5fMti7LIHLDOCeKg/tQTEpconHRSTj8KtzRRqC2NyqenXH41lX8YWTdbf6w5B29Px9aEkTHXc07eK3uEUIqqzdCH3EfUU2XRN8uCGPBOM4zXOWn2m3uI5Y2IIORgdT+ddfp+qHULfZdKIn6ZBwCfam7omqpx1voZ2i2FrcXsqGRAV6r/APX4rT1G5is41RAh4+YN29+Oaz2tjpt4ZE5Rz1JyfzxVmDTYdUR3WV0yeVdBk+/PUUX6szqatO+hTFzFJLIWkCSZAK8nd75zXS6fpMFzZecR8g+8VbjP0rBk0YQ2pWPe+wkhMYUHv369MdaZBfyWw2DauOCSSGHtnNKpG60FdzVoHVw6aiFgBIGxxu5qrJCzOYzzx/FVmy1tGgCzoPPHGd3Uevf8v5VM91DKI5SCAw5yDz9DXNecHdmV5LcxS8trG6FTtZSo5I9+3XnnBqW0ZbpCjW7+c4AXyoy+4jp0yeme3arDLFenbukVc4+Y5AqVLR7Kfcty4/iDLwc+xFdVOrrqRPlkn0Zo3jWemhBPYr5c1sJBLs2mNiOeM8kg8qeCao2ssN9KlvbWtxduFzFItscsvboeMNxu7VctLqez04wQW1neRSE8XiM+0nrjJwD9KzrK3lN67QWWnwTY/dxyzHA6ZwshII79jXYpRnY44xcU77+pcN7dWchtzbxwMHKvJMQ3zg4Pzen0xz2qGG6t7iJgIW3MSjgE8Nxk8EjHPU/nUdxaXMd81k0McxVziW3jyg4yVQAAD3xjvxVyxDWSzPC8ysz+accbh3Ddsfjj2rO0eaxbdo3W462sYpI4oXdROTuR1Ycntk/UYPGaa9jPcviKWVyG2+W+WIOM4U9O3/6+Kv6bPb3UjzXMsiXEpIHAUryRx13DnnkcVVW5/fbbyD/WZjDNEGjRe2WBzjPB4PsaOVE+0le/YLGbz2m8ywS6BZVaGVd4k7ZBONrDPf1681yzQql0TBKLdZPniIO4bcnjPXjkfWuva2NhbiSSJYUQDou44yckbSPwJrjdbminmE9vAS5wW/dhDu9doODxjJ7+lTU2t2N8MuaTstztrCAyCPz4rd4mAB4LAnB6gk+v+GKpeKLa2Fm77DE0X3ChK59BnrXD3PiTUobtysqQswBaOJAIwfUdQM4zxxzSzanc3+x7qUvjkhvlC/XA/wAawlzPRs6aWEkpKTOals2EzsY1w3sfl9x7/jV7+yjBZ28uZPMckgluEPH3ff3P5VLOzDbgY2nBLNwT7VpaNFNeXUcXOxOSAOpz6/XFCk0elUklG51XgzTGhCGTZuIAIUBRnHtx2rtDvJj3ZGzj3+vvWdo9m1vjzADgA9K1c7pSQpxjI5qG29T56tPmkWVAgQ42s57mpRK3l/IyAdziqQaRnxsCKO7Hr9KY6kDaJFCY5UDk/jQmc7hcjmy0xQyHaWzT2TYrNkewpEjG0s7naOAe4qjfOV3gE8KXbJ6L3NVTg5y5UXKSir3MfxPqgsNPkuQUEjArGp6gdM/zrh/CuhXWty3GrzF0gXMcLD+Ju5H06fnUWupP4i1NEMzJHLIIYkA5PNeu2WmQ6ToFvp1uNqwRgAnnJ/xNfSU4KjBRR49SbqSuzyHU4yjyxs+dh4OOa5soUky2ev4kZruPEdvGLmQoBubk4PWuWuYCWG489cetbLYyZ0/hFQwQgDrxg9TVDxfc5uZUPY4I7VpeGVWG2YneeSPSud1fbc6oqgHaWO6piveG9jc8P22YQcgbVHUdaK1tGs0jhQN8+BnryM0U2xpHXZLdCcAdKXOFUqaSIZPTHaqeo6gmnWx3L+9J4U/z+lfNydj14q7shdUvRYQbmwZT0B/nWDp3/E4uTPcFmtkODkHDn/AVX0+CTWb8yTb3t1bktxvPp9K7GCNYodsaquBwMdK55S5jrjBQXmSxRJCypAgHy8ADt9KIJn3NAFPmOeCD3pMhirNuVQMZA6H6VTLzPK7Z8yIZye6Z7gChENXK2sFCnmB1MbADoA6+x9q4LVNSTTp5nSSURxj/AFcnOQe2RXT6rvxJMZd4PVQeR714r8RNXSHMMMgZ24GOp+tdFGnzysaO0I3Zk+OPEVxrV0tnAx2M2GUcZqxpuhtpFvumUeY+MnofwpPAnhqa4lOo3Eb7VGVLDGfeur1/rFbqylYsk/T8K7ak1BeyiZ0YucvaSMIbCF808bhx0yO/OMA1Naxs24QNg5J5IBx6ehqs7CQ/KQoA4B5z681YtWa0kUnYMEcZ5HrgisXY9KMmb1rOliFa8dWl47c/5+hptxcNd7gvG48d/esebfcXHmMGKE5AI/L61o2xCBGkyrMcKSePcfrWTVzojaOpo6U/kLLBsGxznOMHrmtHY1mXuNhAY5h3DJIz3qitvtiiljk/eHseMfSpL+UeRGFmZ9gyPb1FTYU53ehcMk13guwLBQCcDAHtWXcsIhtfG3OevFTadMvlu8rhE7A96ZeyLdhUQAqOpH9aRcHbVkduiPKJF5XHbqTVm9k8i3ZuF4zVCUPC6KF+QDoO9TO6ywKjkds7v89KAfvanNyysxLyMXz79DTdJEs1/EqIrndwM8Gr96kDXh8lNsR9e/r9cU+2hW3nSWILkMCB06f41dzVrTQ7iKGKOwBPDYGccAetZ8MLPcMADvAzgDn8P55+tJb6ktwPlVgOApJ/nV+wjD3EYH7tMHO4dPb169KzZyRi6d7jr3NtboMKHdQSFPBPrWUsm0lug7g9QT3rT1IebIQjlCBglxlc+g61QQpt3IrSEDOCef5f40rNmlNqw5gGkQsOcZ9d30+lJ5JMbMxTIbkZwx9sf/Wp4ngZfOZp93OUGDj369u9S2SJcRSMpUOOShOcj0/+tTtYUpWKZe2ICtsVmGFC8En1/Gqb53gxsrqBgYXBJ9/eo7+N4ZS+B5G75SY2AAx97j9efwp1pd2ts/mZLjH+q3ZJ9R049Rmq5dDWL07lnzDKgBB2gcqwolu4IoiY5pI2xj5Tg/hVe4zJdgxExxOMqJD1Pof8adFHHKrmQDemPkO3BPocng0uXoPliFprmsJby7b5JI8geSwy7j2IHb61aM4nCySIPMbt0xVRbkQAKhiRzkhSRluen/1v51PC2+RVCShzkmL7vPfpjp6Gm1oRyRTuiWKRsbmZtq9SDjHp/wDWro9LluZlgaViYIwFKjcQg9Tk9++BWObPMAdkRs43AgfyPP5VseH7OS0m+aTIlAEYXGGOeQf7v4ipcbqxhWklG5tNGg/1DAb/AExknt/nvTbxpPscjOd8aHOQfmP4enr/AJNV/EkyxIFjUbweWBGPpnoR/k1z9vq1y13sddoAyGOSF989R9e1Y06bucqg5x5kdLozXFzbMjoMA/wnBH1ya2tSghmsjb/ulnZRhz95T7ZOD+Oa4hb1rQxgLIHJO4klTjsR/wDWrUuL6eSyeWKUGReR8uCce4/nW/Uxq0ZXuZ1jr9xo98LHWpEiuDnypWXYkgGR2B69iMV1SatDdRmC4iWCRANymL588csCeDjuK4t501G0njvUHmNw2XAbp25yR+nrWXqEet29lJcWomNpE2ZJfMZtoI4Qoc5XjGccE1tGKnotDlnGUNWegJ5E5ktYRGC+G+YnK4PHfgVpWdrGrK8ksMKYKvEGZmTHfBOSPxx2615Z8PFa31OW7vBceaq7ASrbyDz0PSvUhcRSOkbbhJ5e4MDt4x344PtWTfI7FtuS3MLxLdsgijSV44iN2Y+UY444JBx2IzxWCJ2mdWEjS3AUEjIO5vbv07jPOK6jXLWY+U8kAKScZHQ+5965K8t1RwIdyyNwqlwoD84OfT8vqKlO7senh3HkRkX8LNOZXjJJGWGNtPtreTAZEdlcehOB74q5CVf91KVjcj70keQjdgWxx07cd6cLho1WKN40WVRvkILYHGeOuPcelNxOl1LKyKiRyoW3hjDIMkY+Vh7gcdRXdeE9NXEZC7M/MxHU+lc3pdgLi7jwpWNTk5JO49vrXo2m2xgTapHPLcc/Ssubuc+Kq2jZblkwTQrkMSnH1q5a79uCCpPtSR3TJIFmGVHOQOlOvL+KSFUQbmJOeM5o06HkScnpYWeLO3dM2euPaqMqGJ8oznPOPUVV3Tmb5kdR0yKl/fGQu7YTpsPJqWaqDj1J3nRYx5h6DpXnXjHxJOs81nYxSADiWVgRnnoPau5uC32g42SBFMmD19vpXHXM7Xs6208ILSNgAjJFexl1Kyc2edjJ/YRU+HUEmoap9uuYtsNnkpu6bzXorOZxJ+8O0dicA/lWZaQw2dqllahSoI3Fed3FW3DW9q7jIHQbl5H+Fd8ndnGjgfEYkWVxjDBiTjORXNyq6uM5APPT+ddV4gYySMzEFhx+FYESlnBbcTnFap6EPc09OeWDS3IGCfUZrE063a61KV2ACr3xW/cOsemKvA9e1U9BVljLouSzEkgZ70R6sGdTpcXChDk4xmirulKVc52Eccf/AF6Khlol1HUI9Otd7OPO2kKh7n1/CuY02OXWLsSybmgByznox9BWfEZtc1DYcsgP7w9MD0rsrGKOOIRRhU2AAACvmJO59DCCgvMvQgW6+XGgT2qeMiMvvABPqM5NQrK4jQNghuCTxj0NSsC2Swyp7r/hUJAwllBQhsNjo2fmH19vaqVxMqAZQHAILBdpOecn15pLqTMn7zMioOnQ4/xqhczEIwZySp4J7E+tUhRiZWt6lFb2M8kyBBGu4S5PQDpjOK8W8JaE3iDWJtW1EDyWcskfc/l0rY+JuukzLpEDuWlYKwxjAJ5A5q14XCWBfygWt48FX28j8uld9NOnTb6smdpSS7FzVriOwj8gFdqrjg/kPpXN/aDKWycbug6/pW74gEVxmSJs4GSep/OuQd3hDbuec4xSguY7IcqReLMZD5ZQjdyEbrx2XrV+FRK6SOuQvRy3zCudgkPnKRkjPGeq11cAYWCFm3uR1zkt+HenNWLjcZ5x+2BZASi4I4OD+FaN2IJ4VaNV83oc45Pbp3rNO0oN3yEHPtmpSi4LZ+6OSe9Zmlx0t75rgZxgDJ9aitcyTMR90ep61j318qSYAIZuBWnosjMVyDn371XLpcTqWZpTSAxiMZGD+VLbyLCwAHX71Q6i5jywHtiqsF5u3BwM9M56VFiue+ho3O1n37uexz27VV1KQJEuHAB4ZR1qZd7EsEBUflVS/ieaLdHjpzzzn1x6UrFU5WZBAYy5MueQO/5H6dKtwKrQsQoA3ZD4JbvlfT3/AAqvDvJRgdgzyAOx6j8/atBSEyQhZxght+3DZ4bpzQdDq32NDS4y0qMAqykjPG4HH8X9CK23MEEJjRtzlgDkfMB9O+Ko6JbtPFduEjB6oGPzrnsF6nJOBxjJFOWOWGcSMBmNh80sYOT6FTx7YqXHqc7mpSa7Et4FM8i20/nWu3cpZdh9xjPUVWeFJQ7yhnLRkIFIC54xkY6Vr28strM91poiljTdlZ40bA44KkngdvY1SuoTCDNJGEWQ5Cq3ygkZx9MdKbVtSYz6GSZBYJEt1dTrhsqrhQI2HQjkkYPHTmrt1qQF2xO/fOoMhdNp3EZI256eh4zTJ7eS4RlZbczM4KXBzvB9OuMHvx+VOtrRgu25Dx3JcvvE3UL049B+dW2mrDur3Y3VrHzbH7wYIckbjxntzyayrWK2tZ4Zpd0jxqSyNGGHHThs8Ed8cVt7mivQ74NsB91zyCRx8w4P1wKzbuUSybkfBRyyuQG59CKmOjCMm48pY+3zNDFDI4aDbjykJAhGc/d6D6rgfSsq/u7yxR44pAUuF2srAZ68DnofQ01o43mRlfAY5ZiM885xwOParNzEszYaYbgrKdwLrsOOFBHrnmqck9WXTjy6LYi8i7U+ZcpLauh8plkTbgkZ5yO47d627dHe2iWaV22gZkd+GIGF+pxgZNYUkT+TDuLNsXCs5yxH9fp2rWsLx5bURA8IPmYr1H161DlbRFyu1zPc3ILlEjxuUELjcc7R9PenWlxi58yBE3ZLLgb1AAzgrnkd6wpbxotpjDbNpViwGBx3461Ct95Lr9nLCQ4Iwx5989qlGUqd7nTi5LJ5crJ5nUbkA46AAcjHes26SW18mSOcgMx24OSMeoPH86z4tTJkAljZVJIGOgPer5k+02wkRkDISWYdh/n0pKNnchLl0IMt9piztyH/AHigkbs9+nH0rrLqQT7Y42ZmdR5RMh2qQcHpgHpjn05Ga49gHiBjeJyMsHGdxB4w2fp0461oaFfSuHWQO6qp3Ln5cevPTk1quxlVg5aroP1GO4s5B50MUkX94DFbdrrFneLbR3cUcTQoArLH6d2HO7/PFYupXr3EUcc67E3Eh9pzn0I/+tmodPTzGUIw47k//XrKUnF6Gywsa0Lz3O9sbi1RI8RSy2zKPKeQiIg5yShGcgZq7pc0I1JbeRgoHVXG4r7EDr+FYFvu2AWbFXVg5RwCQfUH+eOveodUdYVhe4DidMqIxyi9/k545zxRKSep5v1f3uXudT4kkFyyGFwfLPylW+79DXn+tmK3vI5I45ZpCMuszAgMACCevUg5U9sZ60p8SzW6SPlGLAqIzGGVefQ//WIrBmu45XaWRRM+c43ktn0Gefzz9KI92ddHDyho9iFpJZnOWBaU/LsXqegUc5H9cVctdKuH1JomhdZY/ldXyCuOxzUCxJqKmKJWV2YHYg6+zHgZ+lek+FtEaO1jAQdBuI7n1NEnobVaipq7LOh6UY1QhCxUcKB19z711UaLbwgFCWPUE5202OMwAJG21sckUHceQSPXJzms2eLVqOo7jJpoUGWAJbjpziqVzKrKot4mGPQdatXMiEjpkdCxqNpSQAONvXipY4aGUtxKJx5iBc8DtUl0spTcrAL1GKkuRkOdpPHesa4vZFk8hdx3dDRBczSOjpzLoXrRAtlNNKeW+Tdjk1l6PH52rCXG5UGAcd609XxBpcEeDuK9fTIqHQkNvZmdwRvHy19LSjyQSPCqvmk2bCyeW3z4G3p7USzLcxyAjcqg9R3rKluvmJAOR0FXdKLSIzsCARwKtrQg4bXEAlUNgncelYcJ8y4VSBg8c9q6jxtalXLg7VzjHTFcvZoPPUL03Y3MKuOxL3J9dlMVksY4x936mrejxhLeIegG4etZ+vKJb+1gUAHOcew612Hhy1QxxiSPIAHIGcntTvZBbU3dJsgArMu0/eAA7+porZcCFFPyuQOR70Vi9S0eXeG7UWNoqs4Mv3mOOp9a6iAuGjJK7CCMH1rKv9O+xahtDFoyMo3Tj3q/Yjdw2Ru744+tfO1IOMrM+gjJTjzI1IU3BggwQDkA/nVaZ1RMq/XnGOB/nipoWUHZJkgccdap3Ra3LIV3pk7WOeB/dzUCW5TurtFUCSGQvyA4yCO4rL1i9t1tHkBw4XJz0I/xq7exwzW7PEWQ44XPp/LmvHvH2uXEAFsp27sqx9q1pQ53ZFuyVzjLdm1TxXLdyk7ElL5PbngZ7V113qUQnUL95uTgdPriuQ0iYQwzMGKtPyR04q3Zvm43o2cdOK9KpG7t2Oejq22dVfzj7NDLkcHDDPXI71jTmKSVXYgxMcDBpDfKxIceWoIJAGQT7ipdOgUykjv0JGBWKjbU7Fa5Yt7MC4WXBAUAj1/LvWnFPl9w2g9B2/Sq2XYbUYNn5v8A61QuZMhguCazlqbRaRauEBJdwyR/w4Gc8/8A660NEuY7HzNwZ/MQxlAcZB6g8cggmsuKa4VyUdow6FCFJGQRgj6VBHL+8JPJHGKXoXZSdmQeJrS2UB7ISqgUbhMwJ398EAce1Z+i6o0U4R+la+o3MNzAUC7X6Ek54rlbyH7Pdfuzu5IyK3p+8uVmFWPs1c7q4kFzCMHAXk1Uii8py0gyP51QsLrbbiNyd2OnrV+OYMAsnT1Pf0rJq2hcXdXNBZN0QKgAk9cd/wD9VNj5YgccYK+oqk8yGTYpO3HapGkKAY6nn0waztc0SaLaGIzLnC8jd8vU+v0q+0aygfZwiIwJIVsFfUGs+wT7S6RgIZW4XJxn264zWkZYYZCPtDABhh1Tbkf3uT1z1H1pWKtqW7DzICWE7ZEYwydxnpnrkcV0UqPJbwpOkjs3XafvE+hxnkH9Kw9B8+4YCNPkU7iuMKCenJHQjOK3mkWSVop4pUiPyq5UM3o2PcfhUu7Mp6MZaRSTOmQVBxHETg4wOAeMdKlu4o5pEjZF+QbCFXhQO4xznOfWpry3mhKPfSYiUBWJG1mTHy4XAP1IrOuLnYkqxRkouHG1lAQ9M59fxpvTciL5tiHU4lDsA6SZJ2kDg/gelVRlbfeIW6lWkkGQT9cdfxqpJccq0qoRyAW5FZ91qjq5BPA4OB1/+vQka2toye4vDgiJcqP4M9B3/Csq0tytwXyyoTyp5+mB61LHc/vBIo4z35FSTMtzIvmKAyjGB27847U0XdDL688mNY9p2Fs/IQce+D0NWGvdKCwG3edwFBcSKIyG7gEE5HvUUcf2r5Z/3YBxkHJyOnr+dVprKTfsiTczc4xgj3p9CudXLGp3ZnMZjyoAwoAAPHT0/MdfeprIma2Ds+Mc+hqjFp7ywiR5NqA/MoPbs2KfYP8AZmUTOquckoGBO3oOnX6Gly3LckloasgWUh1QmMAZAPQ/57+9U3jQ3KtCVVSAUcA4HvUdxcuRsiIEZGCAefxFJbylJl2jzFUFm9gBk1NiVKy1DbOu2Qsj7CUOByO/Pr61LJcSZ2iQbDx7YpxDecQyMj916ED8ahml2gEjKc4xinuI0LKUGMsTiQDj3H9au2k8Fqj3AEYnjYMBszwfUHhh+tc6tyQgwDwePWppXViHLgdM/Q96aTWpm7Sdjor/AFQEpPIwWOXJZFxHj0yB9QQfTipNNuIjdwxuP3YbgjPHrXOPb3EX+kQKpTaOp6j6dxWhpryCQ/aTIBs3BiQcnHB6dPeomlI1g+SOmx6mJ7WOyYoWEb/xH5iD1FcZq159qndFmjGw5BycN7fp6UlvrPkyMt0pkRl5C8jP0HQ9OlQ6tDAY0vA7K0vKlVAyvfp3zx0qLNbnPSShJ3KrwKkBV4mEp5J29PXr+FVxp6m4A2ySMwAjGwLz/kmrFlay3n3CGkB4UJggAdSemK77w/4f+z/6XdgsDgEgYwPQChs0qV4U1zXK3hLwwtpah5mHmN2HeuyiP2SJVQ5xwWXj9KgeSLeTHkKowvGKhluUbCDG1eNx65qGzy6kpVneRce9XHAwKlhuIcHc2fWqyRKUzwAR3pxtFYZjYDue1JNmTjHYnfZkEAHPTNU7lvLHDr+FJOjqqksAAahlG8g8MmPm9aTZcIruNkkDgDOT9ayY4TcaoE5wPertw/l4aPJpvh9S908rcsSQBjriurBQ5ql30JxM+SnZdSXXFM8kUICjPGDx2ptzKBGIQwKoAAo6CrExYySS7c8lFLc4461R8hXI353enaveR45AC0hHB2+p6nitiwbChM9fzqnxGihQMCrNiQZc4w2fTNNiRk+L7Uz27kMQc5PPpXBQo63aKRkBsE161exQtHsc7Qc5rk9e0m3sLKS9af5U+YKcDJ7fWhPoDXU5WRRc+IX2j5Y0C8DqTXpvh+0EFrECTkDJ4zz6V5/4MjbVZJrzad00vAX0GAK9OiBt4FjUgbRk+pPvjvVzeliY9yvqNwY0aM8MOcg0ViarebVduhB55oqUhtmfqF4ZwmSAA2SDwfyqa1lBA5xgetc69wJPlJ/E/wA6v6dceYoDsMjgf4V5OPpWakj1MFO6cTpWdWKOAHPRvUf57Ul8ZWYxpl0VTlSvQdc8EiorWeIQ7iWCsduVfGPx7U29eMxqF2SL/fwQfY9etecztj8Ry2sXDQTSeU2FI+6vA/AV4H49vHm16dTwFwAM+te963F5inhTkcc4rwPxhYzN4muRtztw2PbArtwNufUWLbVPQq2oZipY4AXGM9q0LdSkZI59feqdkrBwrdB0zWykKqmWP3uQv+etddR6k0laKG243oQwGOzdcVcbzQgChXQccCqwdYfmGBn8c1Lb3aOdvA5zxWbRqn1NXSGG9d2eW/KtLVIo4RvDDB7VmQzJkeX1Hc9TUl0pniJ3FmPFZW1L1buUJtVZDsZR5OeKiS6jO4xcjr1rJeVElKXBd0BIZRx9OaqK8wZvLOO4yccVqqaZkq7i9Tf+0BnBVcuOc46U64tozbK7HMrNWHa3+ZMTA5BwT61durssV8tzt+tHI4s0lUVSNi4VRWA+9609XiVcFsDOOTWcGLA4OT71Wkdi2B24NS43NaWisbquBJjIJPBIOc/Sp3kDZ+XBHbFYMMyxnGSQOuKvwXEhwwztzgH39aylA61Zo6O0kQL5RBABDMsfQgfxfXFO8oTbUYqQzYOOgPsfT8azbKdlKtE23AIbZwcHr9a6KylgupFt5htXHyc5H1Gf1FZPQNFqgtHnsJ2RJZAQpVklJGAcHB+uODUk2uSxsBGuMvyNoDcds98Ut75SIjtasiknkZ2OAe3+FS215Yq4hbdEx4Z2AIx/tEjOO9CJe17XFi1a+vlU7PkiyiOy5wPT0zUEyTlyLnKOcEeg9OKuGWONZTFEkqrJjcHDfNjqCOvB69KSSBkUvN8srKG3OOSD0wD1FJrUUWijcWakqXuCF2EgN83PpxWHd6ddCFpoZ1mbfgQbTuI9QcYrfZkAZcMeCMgjP1HFUb6VlCsHVwODjr/9enGVhyp8y0MeGYnMEm8HP3AB+P0NWBMXjAQjcowTgHcPbp+Rq7JosUtg+pWwKsJMbFYkcDnjHH51buRELVI0thGxRXbzB834ccqexOT71q0rXONtoZZW3+hx3EsyqSdu3jP4e1R+Xc+ZiWJzg8OoyPzGRTIPMubZrWaRX4JhK4/dn3+tUrHzkSQG7a2dR821iAfyqUg52ty6148MkkUcgYHg8YBPt7VmTsBK0xEceBkK3UkenB5qG9a3hAK3G8Z+bjGKoyXkc7hYs470+R3N6deKWpdtb5pZtu5mDDbg89/8a0obZpUyzeWoP3mPb6VjxbIxnaiHuT39qtJfmIBWfhuQ3X9KUo9i1UT1LW428pRJgwQZyM1GZ2mZsvlmPVh1qOW4jZgibSSeSO1Ps4fPcICQPzqbWGpEirtO1yzDrhRyKdHcPGgkCqSmcdv8/St3SrHMRMyAFTwQOtVby1CXDBljKN0H/wCqjmRktyxpl2skO3I4Odu3p7g/0qxDNATtZsEnCH+H6eorn1tpYrtMIQh+6RwPwre8NeEdR1m6WebMNmGzkjlvpUSSCTS1HSzxLcLBD8srHhR0A79O1bem6ZLIfL3Nszkkg8/gf511EOiWtghNrFGWHBkI+f6Zq7YtAgEjQ7G9+/vmsXPohOsuXRCeGdHs7HLYVFc5d3OSRXRXjuW2W0oEIXjaMg/WsmSdHLorfu34H8WD796qWsc9rHKUMcgJ/hc5/DjFQckoucuZl+V1jULIgz1ABH50y1AlYY579On1qtCXl5dT5Z6AYz+P/wCqtSzi2AKpUH0IxxQkEvdRZjhBj+Yle33s0TRJEuPN6dOKglEgVis0aoPxOarTRFgBJcnBHPFBmo3e4+WQyjZu5+lQyylFwxxUcNtGjkidyfc0TQszZEg20jXRFC9uGaTapyPWi71EaTYIiHNxJ0wOmelLb2p/tNQ+CgGWI5p17BHPrKh490UQ38LmvawFLlhzPqeZjKnNPlXQ0xP5FrbrMd0jLubHcnnmo2mSRAQ42+nSuK1bVJbvUJ1WUpEpwq5wGA7VDba0yTjzNyr04OcmvR5WcNztpDjk4HPU1b00FiT36DHSsG2vo7gDc43gDkGt2zuoLe0dpmwoyd2ew7VL2BF2cgLmVtsQ5OO2K8e+IWvtfXX2W3b/AEaM4AHc1teOvFXmW/kWUvyE8sAK47w3prarqiPKC8aN0P8AE3pWlONveZM5dEemfD3TXttHtxs+aNd5J9TzW3qdyyswztPp/eqa3VbGJYejbd3pgYrm9WvD5smGLMelTu7lbIz7+cz3AjXlepB9aKdaosUXmuA7noCe57UUnIEjk/tIRiGJweCcirUF2ySxlWypGDn1H/1qyZldgTsBbtikS3vpLaQQQEiMeYCW647AfTNRXpKcGjbD1OSaZ19jcsZdwJAx6mtZrsyoMKOBgKoGf06muG0u/Mka7D8pA5rpra5xFgFVbHdc4+leDUptHvwakri35eZlCxgv2Bxg/WvJfFUBTXJZmHJO3H4V7HHbzSStMrfdG7JHt6V474veT+15S4yNxJJ71WH0ehpKKkrM5+G3DTSDBBySoq50typXnsx5waQLuEcm0Bw2CRwSKtunymNDuzzwe9dbepFrKxk3zHyEboy0yzBlKj8as6jaSx2weRSFPQ9jVG3cpjbj8K2WqON3TNeL90SN3P1rovDu25O1mRc/3sCuWCPKoKde/tV/Snlt5BgZPpWFRaHZRelmLqWhJPfzbnCqWPzAZq9Z6HYRYHlGQju5Jz+HSpRISoB6e9XIZIzgLIuQO9YupK1jpjhIbsxdW0qF1/cRogA5AGK52+tvskaBiDzn8K7e9IeNjn6j2rmdSt1aLLOCAe1b05t6M4a1LkldGQsuM7TjPFNPHTrTp9kaBRjPWoI33vxitWiqc+5NAuW5Brbs8vE+ZUTauMMwBx7VmQpg+o64q0jDcvygke2fzrKZ1wmpaI6YfYrqCPZbNbXMSbWaM5WY8ckE8cZ5FWpY0jwXZzvwV+YLnnncT/OudjumhJCAKM/exz+dWorpi581tynsOP17GsGh7bEpkBlcea0cX3l43c9sitqyj09FeJmZyBvaSOReOeNmcZ68qR9OlYt1bzNHC0aLhc4ZVAZhweSOuK3beXRLexs5Y8tqGWSVDlYxgfK4IxlsnPXsKaRpKzSsSRoUZZcbTIcmRjuGc9gOn0q+GkglEu1JzGM/MeB+fBFQabJAbWVVcSSo2RLGWBcfT8/TNQXLF5lLHEfUEAA/l61DJSvoyG6nYys/lBFclsDJA9vaqlwzFQpX5OuTz+WOlaML2w3h52DY4UJkH8Sa0UntrdkkVIMkqWJwSB69+PpSHzW6GXPqDS28FsjBYVXG0AAt/vHv9DxVS/1e0isjDCgL4+9yFc+6noR61b1q/tHsDHCYllQH5sAB88Y6dO3J6V51qUxQEbNsqtwQwKkfUVvThzdThr1UtkddY6woRVAjjwMHbjJ/H1pNT8qUeZbrvYjqB3rkLGYXDAMVRU5wMk/5+td3oEllaWwxcLKx+ZwFOB+NE4cjMl+8V0cjdC5mBjljIA9qpLbtanB+YH0rsdbuVmiYR7dpPGD0rFt9MuJkeQRhh2LHk1cZ6CaszPEr4GFJI7HrU48ycquCB645/GuksvDsYt1eR97YywJxg0ktkkLhVOEJwah1I7I1jIzbWB9ygRkj0A/r6V1OgacrSgsduRwMc060I+VYUMSsAAADgnvz7/5Fa+m30mjMZEaFmcFDGwDFQf8AP1rnnNnTCMpq0dy/JYYRFMqpnoM4zVJtEeTVI0v7lo4y4jaQLu8se4zVt9XTU9wltkZFwGKA7VPrx64P5V0Xh7TUjg3u0hDfcD5O0fj/ACrJStqa1IOlD3tw0fwtZW1zITMtyiuVRmXAIB4bB9a6y9gEUSPCdpjHJI4P41BBGzJhFVQOr/8A1u9MuHDKyOTLsBwFOD+RqW73Z50nKTWpHBE5tWllcZOSBjINV4lVJcvliRnIOOay4JLia5RZFZxuGMMOB9K6IySoysbeUr/tkCpsW1ylYKuZGMBkQ9Nj7W96a8E6srRZ8teiSNnHv71pRNG+ScxnHKs4JpCI8DCMV9d2PzqTPmdyjEjn+JeuTuG01YmQyKqlwCO+SKkYxOSiBSe+WzVa6lRAAPLwvVeM0Me7GzlivylT2Hy4qkLU5yzlSffmpZbuMhfMkaMnjbkUnmocDJ2+pB4/GhGmqI3tBxmQhvrVW5hdIyBMdo75qZpYzLjcWxn/ADiqtw/mSpGAQCewq6cOaSiiJy5U2zS0WPybB5mZt54yaryzbLCeQ53SORkelW5CbGzii8wMG6fLznsKx9YfascIYAIvPOOa+kpxUUoo8GpLmbkc3cwK8rA4Iz0zwaxrsuXIUFecGtl/NYtsYk9W9qqS7bdXdgw28ksP84rcxKfmXFpC0jny0HJJasPVPEkzp5aTSFQem481BqEt3q07JaxO6eqjgUln4XvZD+9Roh6kZNaJJaslt9Cz4a1CCS8I1DHlkdX5r1nwy9nIQ+n+WVGB8nY/SuB0X4d3dxL++mMcfYleTXqek6Rp3h3T2t7RCHYAux+8x9/apnJdBxT6i6vdbQ5DDkbck9K5QKbm7YscqMgD8Ku6vceZcBVxzzx2quEK24wCBnOfWs9i9yz5alVyCQPXpRQgaR1XBPFFQUY/9mqm1dv7zPJqVw1pEAq53HGMAV1KJEoAkRQ397r+Jpk2g+fGTGUZ89c5/Kne+4WPMrW3Ww1R4SpMbfvEx0IJ6fga6rT0OORke9S6l4Rvri5juIpoRLDkCIg/OD23djxxSWbGIBJkKSKcMrDkGvLxdPldz18JWvG3U1F85IpFjJMTdQK8e+ItvImrExhDtwWHG7n0716+ZsbQOc+ledfEiy2ahb3sYZipGcEAAcdR369q5KL9477vlOOWHYoKg/MATx0qzZQbpQszbc4BPU4rc1GyUWnmxbeQCBWRJG0cqNsxyPatk7lJ80Sxqdmq6bsllVlPPfg1zdppuyT5x8h6HFdJqMoSFIs5HUd6yxIxkYZwAOKuEmgdBSjzFhLVdvysB7GklZYxjbnHeo47hgxDAEDoRVhyjRqX+96ik5dwjDl2Kj3qpL8wbFTRTBUDA5J96VrZZvbnqRx9apriNckDIqeVHQqjtY0biTMWYyCfSsfU/ntPlHLVaDrtZw2MdiarTXEboMr8oNVBNHPXaaOaaR1LBxnsBTraREY7iR9a0r6KDzQyAEMO3rVRrRDJknt2rsUk0cCv0LkO442keoINIpkEhyTkHrTrKXygUwCPWr8qwfZBIznzW6gVhPQ6qUrPUcxLRqSQznr7CnNK8a7lB3dAetVbdiUJAJCjnHYVfRRhi+Bt6qTWLudalEfBM81qwL7Ap+4Dx9cdqbHBPIz4ZR6D1AqcOiqcZDEZDd1+h/oaktp1jlKbWeLI4B285698VDKjJp3I7W6khmZBmIkbcDP6+lbsAld42uiGJHy4bLe3Ssa/ijudhiiVXQHO3qee+ev1FLp9xLEoEiOYzwc54+nrSaLvzK5uSWnnxGVFkaIHDME4U1lTvLGOZCCPlA68f4VaS4lZ9isyxs2VUipL+xaMgykBsZAI5KnoR7UR8zGTaOX1GSfymITKjvnrXNXk08iECFvlPJrvWsjJwzkqeSDVG+05VtiA2T6dq6aU4xPPrwlM4VbpkTEWVb+IVqWmrsIuCR2NUNX06aN0ZFGGOBjrmopLWWyjUXOFcjITuPrXXKMJo46dSdKR0ltqImfBJI7nHFddY6naT2qKm5CoxgrkE15jZiWdQkYwM9a6m2ElpbIoZnGM9K5qlJLY6FU59WdoNTiEBDNkjqAOtZ8moRXEoWAYIPUnHNc3JqG/a0a4/hx3zSK8yzJtTcWPQfyrnVOx2Qimro9FsNXVomE4R5MZbooAHU49TxnHPFQandWt0FC4WVRncBnd6D3/AJ1yhtdQ83zIVIzgkA5x711nh/S/tEkBuId05bl2JAIHYgd++axnG2tzppVoxje2ppeBtFubm5kvJCdvRcHAOfX2r0rTrZbc7HDnPp0z7VDounLFDtRSwFbA3KoVY9zD0WuaTcmcteu5vUm+xgoH80hO3Q1SuNORmMjOvPGcc1oR5KLvhk29cHAx+tDSRsWG1NuO9M41KSZnRWkSFmePef72KsJNbI4WYKg9SMUy5uLdIyShQdc9B+prDutdgmf7Pa28t1MOeBuH+FF7Gyi56s3Z9Q0+LJQox/2QuTWVcahZzMQqsfXC5/lXPatqOpRgL/ZM0SdclVA/SsO61S/Db201iuACM4HH0pr3jSNKMdbnfrLaJHnDqRzjAAqpcXdjI+cFv+BYrzDU9Y1N2IS3kCn+Hdn/AOvWYZL2Q7nS5Rv9mSn7NPqVY9jSTTnGAg3DtjNRzOEUtbHeByVPUV5Pb6hq0Gdl46L2Esf9RV8a9rNtB5jxJcQKcnyX5+uDT9l2FY79tQg6H5HI6tT9GK3l+CoBRec5zk1wFl4xt7y5WKeI7icbXHOfSvS/DdukNo0zKEB6AfWuvB0Xz3fQ48ZU5YW7lrUQLi+X5cLCpOO2e39a5TVbnzruXady5AORyK2b65H2aaTLMZTgEHHArmoYN5eRMFu/OK9qKPHkS2sG98buO4HFNvfD1zfFYdxhs3OcKcs3/wBatPSbdZBjc29uMV2VvEiW6qxyVGB703KzEkcXZ6CunqEjjzF0z71tafpwDFygyDhSe5rVboQuBk4IPOas2ECJOm0knHHtSbGkh1vbGGJg6jdjnPb6Vi67ciKPbwxI4wOlb99dJCjuc8/KATXC6pK1zPweKSBlOJDKzOcbWPHqavwxvIQsakgdqXTrRpccYXNdJp9qsOGIOT+lDY0jD1LGlabI0gzNKNiD3NFY3i6/+16kIIidsHH40VcVpqQ3qdOVYEja20dfalheSDLRZI7qav8AyyqCSCCODT47YYOAuT+orItFeyuUnYZJEg6oTzUOtaQt2wmibZcBcdOCPQ1Pc29vuyrbXHpxTFupI2IcFlA+8Oo/xqZwU1Z7Fwm4O8TmVikR/LkBR87SPSsHxpaK2ns5USMpyM9u2a9EurOG9G9XCygYVgf51zmt6aLi0uLWc8shXIPHsa8atQlRnfoe3h8TGqrPc8lu7vJRC++IKCv19Kj80XIj8z7ynIHaqTQzxROJDl0yp70y3m2SEAkjqN2M1ql2N0uxau3E02ANpx1Hf3qt5PltuZuD2qy5VJSW5NV7pwz46VSRq6mlkNzGMjPJqZGCwhlIJzjk/lVGUKDjnOOv9KozX0iOUUjce+Oxo5LiVSx0EV0ytw+0A9B61VuSj8YH4c4rIikkkHMjcClilmdhtJ3A9B6Ucth2b1RalhZgyhcHvis52aFvLk4weK2LWQxuGPIPbHWszX/9ejAAZ5xWkNznqt7Fe4UPEkkTfMDyKW3USRb+N2cYqCJlY7WO003zhDLtx8p5rZp9DnpzV9TQjiKzKJFABx1HUetSXwWSc+WwOOAB3oEu21E+/wAw42qj8kCqRn+fdgg59az1Zpazui2u9NpYDA6H1qxkvgKw5ORjpn+lUvNaQgMR5fc+lW4Arbs/L3xnr/jUSRsnoSpG6nOST/EKvWUMomUqOfQEZb6Z61VjyMFM7fep0ywIXcD1HtWTNlO5pxovmkzo6Efwgc/zGBVqacNFHb+WNseSGVztyec9cVmCYwohDNvGfmDY/KoYHkVGJOfTGKmw3KxpfamjV1Q8EYIPf3pyysF8u4kAx0YEMAT+NZzTvuJUYI6gCoWuZQQpTeo+62OKOUakb0cqlUVVATO4HGMnv/8AqqC8EZjIHJJql558hdhwSc57GrML5w0keR6ijYmSTKD2qtLGzISqncQe1Y11Zza9fyRW0TZUZY98Vv3rPKzGIkLz27VX8MufNuVQsJSRgKMlsfyrWM2veOWdO+hQi0n+yyy3CnK4BGQf5VVvrKd5RJDKFifnd9e1dbeWiXFwiYjW4J+Z5G+UD1I71rxeFLN5pVgma7gOCZ3QL83fGD9306Ue0t7zM5U7aI5Twz4YkupfMuXZoUIAyMZr0iz020azk2R4EX39rDJx03D+oNWUtYLOzdIlAGw7eeM4/nUdvLHb6bI/KsBkhv4u2Ov1rlnXcmdVCi2rsr3YtYIg0Ct5knAUnr2x9K6LwnpbQhp58l5MbQe1c74fhfUdQ+0zj5VPyrjgfhXfWm3OxzhR/s1zzl0NqqUPdibFs623JwWPRc80z7ZK0+ditjpuqO1R45OZhs9gFOPf1qeeK3Iy7O47joP0xUrY4GkpalaS+naRo4rSCWXOD8xIH9BSXVzdJEQ80SyDgR28WfwyakWZUJSCNYkHf1qlc3cjqdmBnjeRyaTkkVGPkc6ILi+1AJesTHnpyTW3bS21shghRIWxjdtG0/jU9w1lYWPl2dwkt1IvzsvOPYHFY7HcpXoD1FJ3iW58+2iOjtI38obtjZ6dwamaNAn76MFenTNc3bXlxZ5EL8HjaRkVcj8QxLJtusR8cHHBq4zuYuDvoLqhs5UKzW0LNkAFkGcfUc1lR+GBd5e3UpF2Z8bR+NT3eowBiIBHPO3K7j8qj+tZ97c3Tsn2q7dlHIjUbVH4CnYtJrYjufD0aKwNxAzeiDP61gT6cbaQ7cgL1weK3TcLg7CfMPJGOtV5WyMMB8x5pq6K5rbmHp+kRX+t2hmhjcqQwcDDDHTNem35ENlHbJgu/BOKwfCVlCL2W5bdtCcE1pX18HuXlwNkIwufWvbwkGqd2eRi6nNPToZOuvhltYyFSNcdOp9ai07TGdFfJIz0xxVSSV57kyyHKdOBWxBdFR5Yb5QOcCu3ZHEaNlEbR1dVJYdCOlW0knA5VhEec981SiuG2kISc1pRFnVS7l2cYGBkCpZQ6IGSRRkgY/HFadqmNzyDtjrVe3WOQkqCNnQkCjU7ww2yxg7WxjpS3GZ2v3m/92mPl6n1rEtrfectzz+dPkJmnKknAPPFatnbgKAQc5zmh6AWLC3CKGbIHtV+5lS0snmONoBOKWNNsQx056Vynje/ENutsGO+U9j2pJXYPQ5ISPPdSTuMF3LHj1NFNRwF64OKK6NDM9N8xdu0jjOOT1p0LEhkVjnpkVVddzBj1z92nR3CxHBHAHpXOaFp4wAD6jqTUYAICoB6g54xUokWVQYwpbr9faoyrH0D9DkUAVJIXB3QEr329s1RnkbzNtwpJ71swq2MYw2c9KdJapKrZHJ6GlKKejKjJx2PE/FWh3dhc3VzGplspGLbl5Kd8N/jXHzLuKsMKR0x35r6FuNPaMFSTg+3FcN4q8HedbSy6fEsNwPm2quEfH8j+lcs8PbWJ6dDG6cszza6yq7t2SMHg1XaVpMNkZ9fao9TS4sX8u6ikikHBDAiqUMxVi6H6is+U6VPUutMACGBINZt9HvVnHbmrMjeYAQDg96qvuwxJPoRTWho3oZ0F6ygqScdK0LK5K4bcPzrGvPkkZh69MVD5nylkbB9M1u6akrmH1lw0Z1D3yxkMpIHvSXUouY/nxntiuZimctkkn2rYiRvsqt09qn2aiZyr+0ZSHyuwJ5pdsrENnOKS6UhwwBOfSlicgDJwfQ1p5ozW5fjkEijlt465pzR5HBwRxUUTALyfxFTwzFDyuR9KykjeD0sLbKUOc4HWrfnjO44JJ5xxmkBjlG1sLuwAxz8v19aqtE0UgyMr61kzZNM0jd5QAKoI46cn61btrgL8zIM4wMH+uayo3XALcntUiMWJUnAPT0rNxNIuxqb+SxIwxzk9R9acx2Ddk5PX2qrC6gMZQWA6YPI+vrTfNxIpOPXg9PpSsCeupZF0VUh2yAPTP5inLIxtgRIoQHGzIz9cVWUCVi7c9yTnH/1qJZsYChduMUrGkZdSzC+4FY1BI+8cdKs28h2NkbUHp3rLVvlIOQfQfzqx5qBMD8s4BqWhmpBMiwSyHaAR+P0rn9KldjJOo2sr4BXirtoftL+WFOT09BW3pukNqd/FY2HkKyRk5b5RIRzjI6mhOyBJXuyvYhfPAcEPnoeR+Vdnaym3twhUqo6GtPStNstNs5PMCnYA7RugJX6kdDx0rJ1B7i/kYxBY7ZgPlHA+vtWE530RMYpu72FiuTeCWKKQlAMuMY4qXTrF76VCVHk9B/tVX8PQPNiKOLETfeOOo9Sa7yx09IkUKvasZNROl1eVWQ3TNPSAqqoqDHQVr2dugZt25h781JbWiK25vL3Y461a3RpKpJCgjBxnms0m9WcFSpfRBBFCG/1eR0zjbS3eI7VzgFgeucmpAseSXBKEdjTBuQDyhuAOcZ6VZz3uzAupyiFmOF9agjntgdt4ZMFTt24Pze/tSaod8rgoOu7r0psl9ILVINiSIBxmPJH6VCi+x0SkrF2aTRm0siG1aO/GMMrHafXgmsgtioGeTP3H/75qGV2UZKt+VNxk+hMbLqWJ5iFyfzrA1KfcOtSX14FQ7m57VzN9fFpCA/FNQZrFomeeSKRmjlKN7GkXW2XK3Bd3HRs9PwrJeXceuahxvbAxWsY2HJpnVjVo5B8h+b1HetTTJTefu+Nu7GM8muDSBg/y5xXaeEozLrthGLbZOjb92euOehranFSkkctZ8sWzqhfQ2VubW1z5w4ZiO9ZWsTeRGkAYnfzIRzya2dfb7NunS3kmIfH7sZKn6VhWdndag5kmilDf7SkV70Eoo8OTbIbHcSRIN4J+Ue3rW/aW+Y1VTt5zgjNX9O0lWAMkfPrj+dbENjtBRE753ds0OQkjJitxvVVYt6471rxW78JggAde1W4oliztU56E1MpVTyOo4I44qWUQXgSzjL5AKjkmuQvbqS+uNo3YBz6VqeJbmSSZUBwg6D1qrp9s8shYoRgUbCJLC0Q/eGK3LWNUzkZPTjmmQQBM7Rk+9WWKBOAAcc+tS2UhqkndnGxeeBXl3ia5F9r05UkxI21fau9129GnaTNITkn5Vz1Jrzi3QvtYglmOTk+9aU11JkyxDAp27gCTjtRWjp8e4/Mv4+tFW2TY6Ca6ViFQ/8AAqRZCMEkMKpxW7ZBY7cdQeatxqVYd1rMpE8UhVg6naR6VfikWYAtgsO39azm5HDdetOhkIbAwD0ApWA1sHBxgH0NOXOT1DfWq0NwGIHQkYqwrFkBznnkUmiidVVuHFUri0eIExLle8Z6GtEKilThcn880iyb2IPDDqDkCpuM4jxF4dsNetGtL2B4nJyp6YPqDXivijwFrHhydpIoXu7A9JYxkj/eAr6guvs0kP75F9SB/SsF541cqrebCRjaw5FDgpGlOtKmz5ehddpDdM56UrIp2lFZm6k8/lXsPjP4fQayxvdBMcFz/HGRtD+5968o1KwvdEv2tdStzDMvzAHBDD1HYiuacHE9KlXVTYwb+zLMzLk98elZtvalpQGBwa6Ke5ikUiPIZuoA4BqjuUSDrkDHSqhNrQudFS1Y5IY4OcZxUomLLwuKtW8aTJh+DUc0SKSew9KnmuwVIzbhgSNvXvxQYmdPujcO1WhsLEEAikGSrcfLmrTMpQ1IYBjG41cQKSuScA/jVdFw47gmrKAAkgHHvSkJXTJlKJ/DkdqjnuC+eTz94jvSu/QKMkVE4YrkL9aixspW3Gh/mxnP1qzFJjG4444xVROG68+lSNyOOAeDzSaH7TUuI67CRyScYz+o/wAKkii3P95fct0qrA3lqwJHuCKV5CCVBzx19f8AGpaKUrmnNdIFXY6/Ku3b6ex9ahhD3DjZ949PWs2NGZwSce/StmylWDopLfXjH0qGrGql0HThIbdhKVVx+vtVO1H2pSQRnOMZ6Cn3he8mwDnJ496mgtmV9qHDdD6Cp2WpqrvRF7TpRBuRSTJ0wB2rrfBupppDmZg7k5QJtyCCOR1GPwql4b8PNPKpERYN1JOK62bTU0+2CyyDaDnyeoLdj15PvWE5a6Frktyy6mZdm9vL7eAIoXHzB2LMy+jeoHbNW1jmvlW2so2FtgCSUD/Wewz0Aq1p2jXV8++ZAiNycn5segrrrLTTDEsagKo4pKjVnsjOriaNLS+xV0+zWCFFVeAMc1tW+wMAykE0kVvgneRxU+ViC4Gc8cd62hl0m7zZ5tXHp7InSVVAUB/wpkyeb8uGRc9c02PezZbG369KexUcBs11QwNOO+pySxM3toKMRDBk7cCmNOuxsguCevQUrEMOVPtUTpuJGcA+tbxowjsjF1JPdkPzs+EQY7mqt1qUUBIznn8q0rfAdkY8EYHvXMaxYzxSEHlSx561tGMSHJlpdZTlsYHqatQarEwy20k+9cz5bKdmAwqeGHJKp8r+g5q3BEKTNuS7tZQPMjjYHswBzVC4tNIuSTLp1qT3+UCqwgbDEyex46U9dwHLAnpkdKhwiWpyXUgl8K6FdA/6N5RP9xiAKpTeC9ICsYLqeJ84AyGH61rCZNuDgH1piOXkzncBWcqEJbo0WIqR2ZixeDESYOmoAIDnmPn+dbHhTTLiy1y4ur+WOWRgWyuTgVaWQqpyGx2q94fYyy3DjByMZPUCpjh6cHdDliak1yyZPbhZ57o5wMirKSlWI++emTiqWlygi4Ykcsfxpyv8xwAB1zmuhGDNq2ZXwzfKwFWfMATjOay7Ttu3E45FW9zbeG470mgJGlwu0H8qqXNykSsWPbp3JpJpCu44GBVOONruYPIMIp+UetLYYsFg9wfPuD83ZM9BV+MGMjy4jnHSpIwA2eo9qmVgc4yrYx0qGNEIwqYYEOeoPrT0I+90OeaewBjA5Dd81BKVjVmZgeKQzhfH04mvIbZHwEG5lHqaz7GLAUMMr0+tR3Tfb9WuZ8FgWwueOBWraQcAMQcccV0JWVjJ6sv6ba5yMcYyDjvRWhYoMrgk+1FS2UgFuPKDK25DzSJhBkE49DXJ+FfE7FBbz7cds12K7WTzAcqwqWmgTuRlQULAA5OOKTywV4xgelSIuMbePUHvS45x0FAyKPhcjoPerUcrhRzgdvpUWwAHA49KUYAPIxQIupcHgk9KjnuZAhPU9OagjfGM49s0vEpw5PWgZFPK8kYAK5zUEcYBLkc+tWBH2foDwaRsgYTHHemIjjDqwkhfB+lZfiHSNO8Q232PV4VEnRJQOVPqD2raiGOScfhStbrIp4DA+1Jq+5SbTuj5u8ceA9V8MtJcQ/6Vp4biZPvKP9of16VwwvMMCy7mHWvsKdNsTQtGJ4sYKsK8j8XfB+0uIri/8O3TRS5L/Y5cbc+int9OankR0xxMtmzyKLVOuVI9CDzVo3izbQCwJqp9je2mZJUKOpKsGGCD6GpkChlJUdeCKxkorY7YSnuy5HbszA4GT3xU7hYk2g5cdSRTEmKqCvf1/nSPIXzk5Pc1ncu7kNjkCg4UHPbtSSMQwPBBpgypxnmlKr5ZOTnvQJoljKuQAcenvT3iHBWTg9h/Cff0qvaRZwT0Na0MK53DO4cg9c0mxOLKCQ7jgsuc46VL5JPHUDvirPlLuzlVb26fhTpJFjTauCSOuKlyGolKRQmAOfQ0JECdzkY/KhpNsmcZ9R1FSwOkuV+4ffnFJlpWLkMKtFuBB2/w9/r71FNIV6LweA1ClnYQRBpc9Ni5P4V1ul+AtSvmiknC2kRHIfJOPpSUHJjlVjBas5+1t3KL5Rwx7V0mi6VM8g2RNNKOpUcV2Wl+BLCxdZpp5rhlOcHAUf1rq7WK3iAjiRUA/uirWGb3ZhPMIx+HUyNH0e9jh2yzJCDyFAzgVr6do8NsxZh5kh58yTn8qullQc9DTBc/IdpGB3at4YeENUtTiqYupU3ZMoERIHJPT2qUNtyTyT0qnDdDawYjJPGR0psl1tXrg+tbWOa5aV85JOD3IpBtx8mR75rJudXtrKNjPMqBR3PWubv/AIhWMPEERkI9+KpRbE2luegKMqdhwAeT71IiFiCQAD3z3rx+5+JtwgIt7aJQTyWY1lz/ABM1Ikn90B25PFUqUiXUR70YmdhlgPUDvVhUjUbdwUDqSRXzXc/EvUywP2rafbNU3+JWo5Obg/Tmn7CQe1ifTTbEbd5gwO5NRXc1tc4EkmG7MBwa+bYPidqAGGlB92zVj/hYN9MwPmR5FHsJB7WJ7VqejzKPMQhgvOUPFQRw7sBgN1eV2vxJ1W3ACBGTPzBiTmt7SviXaTTp/aNl5BxgyRMSPyNU4TQuZNnePakABDjJz8vNQNCzMcqpwep4JrRsNQsr+xFxYTBkI+93qk8pkkYZB9OKzLI2tSyglePpQkSLhcDI6dqUsQyqVJJ5wRUiqrKxb+E5xQAnlqp+VjlQTwc1f09Ps9rKQR909epzVGdhBGuQuGIBrWZIXkhCj5MbmIPakxoghtfsliOfmbnNMt1CsBjLGpbuaSe6CqMBRxU8dvtIYn5v51S2EyWBXRRk5xyc9afLISMqPy7VI3JHOf6VQvpmQBVG526AVIEcshmnMSAle5rVt3RF27SCBgGqlpA0cYHUkZJqUsydeQPSp3GW9w74xwKezjG7PWqnnozBM49akLgECPnFKwEw9Tksea5/xleCCxCRkLNKCinNbDTsiHPB68Vwviy8+16iiZwsQ6D1pxV2DdkUNMiMUahjknqQK6Cz3FA2Bj371mWUQaIFhwTgDNbllFlQV7ckVq2QjV062LYZsD0FFW7ZPLRTn5sc0Vk2WfN1vqRjcFGxjnNdn4d8XPHIsM0m6I9Qa8zTGcZqVCV5ViPxrrcEzlU2j6GtLuK8iBgl+ozmleWaMlW57814fpmv31iwEc7hfrmu60TxzFOvlX43HoHFYyptG0aiZ38U2/2HpQIySWyf8KzbSeO6iE1rIrqf4c8irsM7EgA1BZOcgcjmnBhgAZHtTlZDH93mnrGByOnr60ANX5xjGSOmaAh3dO34Uq4HGPxqUtggngUhkKbsZGRn1HWpRlI/bocdaRWJYBu3PtSvlzyvHXigAijDhmA5I5BqOWzSZhldrD8qsxgBjt6dhVtAHGGwf1zSuB5X8RfAkGr2813BbhNSCZWRDgSY7N/jXgU0M0F48M6FJEO1lxyMV9qBYnJXapHcH0rkvFnw80PxAjytAtte9p4uD9CO9ZyjfVHVRr8mj2PlkuVZs5IPSmfaSFZVLYbqB3ru/F3gDUNFfMJW7gJPzxDJXHqK40weVIRIjAgc9qytbc61NS1iVVnLfeGCOOatbCY89fWoGRd5yvPrjBqdXAA68cYFJ26FJskiJCjrxVlbrgDOMntVHfub71XdN0281CURWUEkrtx8o4H1qeW5fNbckO9juDAimEDjcT9Aa7fRPh3cFlbVrkQoP+WcR3N+J6CustfD/h/TclbNJnH8Ux31aoSZjPF047anlWleHNT1mQixt2aMEBpG4UfjXoOg/DO1ii3avcPJKedkXyj8+tdI2rR24VYgqIBwqcD/AOtUbarI6M2/Cnsa3VBLc46mLlLbQ19L0fS9IhVbC1jTA5fqc+561f8AtCFQCRke2K5AapOync52DkYPSnprEWCWkB9zWihY5nNvc6e4lBTOSQOTzVaO5WMAgkHOMmsIa0hIAI9yO1U7nWAhbawJp8ornaRXQU/vTnuOKqy3sccp3NjPNcM+vyo3Ln2OaxdV8RzSPiJiffPSrjTbE5JHd6vry25LAqR356VxeqeN7ks8duU2DgEiuTvb6WbJllLc9M8ViXd0OgNaxpJbmTqN7Gnqeu3NwzPNMWJ9elYk2qOTy+fpWhofhvVPEFwi28LLBn5pWGABXs2i/Dzw/Z26xz6et3Lj5pJckn3ApuaiJRlI8AkvZH6ZNTW1rqN8221tppD/ALCE19K23gzRYmVoNItEx6xgn9a6jTdDtYANsaKMfdQBR+lQ6xapHy3Y+A/EuoPiPT5V95ML/Oups/gpqskBkv7+1tH/ALjZJ/QV9G+VBAjCGNVPqKxNShMjs0rMwx0zxWftWyvZo+WvE3hG+8O3bxzlZov4Zo+VasNVdDwelfUepaPY3UWyW3SUN94MM5rzTxb8MSqy3OhuCANxt2P8jWsanciVPseXxXTqepxVyK4JGS1ZtzDNaytHOjo69VYYIpInNaKRkd14Q8S3GjXgCsTbS8SIen1Few2c7yKksR3xOARjrj6185W0vP417L8Nb5rjTBC0h+RsDntUVI9TWnLWzO/DZAO1gccgnJpFcMx9O4IqCVHPCHHck9acgYKBtZhjPsawNiprU5PkIpBLHAxXVRW/kWyIzfvdo3E/yrnZrES7Lh+Np4FagzgMzEL2yaGJFsmOPGMbh3p32jOMEZqnvhPHXjrTlkRFO7he3vQMtidsHORj071LY225hNcZLHp7CqloPNk3yA7AflGOta6gldq4BP6VnJjSEKjcdxwpPBprRq2AxI4zipGj4KscjPehlITOCQO/tU3GVZ7VUR3ZiAKoC/gicZmGB2yKg17V/Jt3RTnI4xXIw2Jv5wWhbk/dViKtK+4mzo9e1tYrUvEwLfwgetcbaiSecyzbm3nJNJr9qbW6SGz8xcfMVZtwJrU0IieHLqMfxCtErK5G5oWMWFC4IUdq3tPVd+FU471UtogighcrxxWtaxjPyjA+lQ2Ui8WKqoZfxoqKV/lO4ngUVIz5OWYngHJpVmPIHX3ooruucRPHNnrxUiuuQQSKKKoC5b6hdWxBgnkTH91iK6vRfGF8FRJWD47t1ooqJRVi4ydzq18VMUCCGMsRxVSfxJflG58vA6jtRRXPZXN7mv4d8TreqIZ3xKO5710yTq6Y3dB+dFFKSswi7jjONoxgYpfNV25OPSiipKFW58sZAyOlL9rIGBnHqOtFFAAbwmNvn5rPvb2bbtDcex5oopoDKfczcNheuTVWfTLK+Ui7toZuMEtGDRRQ1cSbWxymtfDyyuGeTTpDbMeiMNyiuTT4d6w960bGGOEf8tmbgj2HWiis3TjudEK80rHWaf4S0LSFUzL9suFGS8v3c+w6VoSa1FAClvHGiDgBRiiitowSMJTlLdmNea68hwMj6d6orqcjsRkgdDk/yoorSKMmRSaiYywDZxTBqsoAJY/TNFFVZE3ZVn1qTkKxHtVEai2Tubr70UVSihNsP7RdeM8expYtTO4lue3NFFOyJuxl1dyTbd3TsBWfNcHfgUUUbLQe7L+keGNW11w8EJjticGV+B+Fen+H/h5pdjFG0tuLifA3SS/MM+woornnNm0Yo7cW+naPab7p4YI1GfmIz+Arkr/4k6faOy2UHnAH7zHGaKKIQUtxydtira/FCSV9sltGqegGK6TS/HC3TALEuCMdaKKcoKxMZtmkfE0JdUaP6471da5ivYxLF19Mc0UVi9DRMol4yzK/BHtis25vwj+WqFmz1xRRVIVzB1zQrXX9OeK8hQO2QsoT51PrmvF/Fvg/UvDm6aSMyWRbCzqPl+h9KKK0i2mROKaOehlKnjNdt8P9VNnqAXcfLfggmiit3sYR0Z77o7C5tRJvBx8uSckmthLSJYg8sY3Y60UVys64mXOrSeWmGIJ6+gqle3Lz3IhhyQDjFFFJPS4F6C1MJBmGDjpT0VpptqrtQetFFS5MpI2LVB5Z6ZB6Va+YRgJ+VFFZjGMxCgH061j67qi2dpKqsTIeNo7UUVUUJ7HIWlm17dLI0r9fu+3rXVQWq2kDOgC/J940UVcnrYlHM29s0ly4lYszHcDitRNPESlgSPTFFFNsLGhagFfukY71q2HUBufaiioYxL2QYwO/pRRRTQH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13734=[""].join("\n");
var outline_f13_26_13734=null;
var title_f13_26_13735="Identifying patients at risk for fatal asthma";
var content_f13_26_13735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Identifying patients at risk for fatal asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13735/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13735/contributors\">",
"     J Mark Madison, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13735/contributors\">",
"     Richard S Irwin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13735/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13735/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13735/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/26/13735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing patient risk for fatal asthma exacerbation is important because many, if not most, asthma-related deaths are preventable if risk factors are recognized and addressed early.",
"   </p>",
"   <p>",
"    Even though asthma is a prevalent disease, annual per capita mortality from asthma is relatively low worldwide, ranging from 1.51 per million population in the United Kingdom to 13.66 in the United States, 25.56 in Japan, 31.6 in Germany, and 86.92 in South Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/1\">",
"     1",
"    </a>",
"    ]. After reaching a peak in the 1990s, asthma mortality in the United States has been declining (",
"    <a class=\"graphic graphic_figure graphicRef59239 \" href=\"UTD.htm?39/12/40143\">",
"     figure 1",
"    </a>",
"    ), for reasons that are not clearly established [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and risk factors for fatal asthma are reviewed here. The evaluation and management of severe asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=see_link\">",
"     \"Evaluation of severe asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link\">",
"     \"Treatment of severe asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEMOGRAPHICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have frequent and severe asthma symptoms and evidence of airflow limitation are at greatest risk; however, fatal and near-fatal asthma exacerbations can occur sporadically and inexplicably in a minority of asthmatics whether the baseline level of disease activity is mild, moderate, or severe [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Therefore, any acute exacerbation of asthma may be a potentially fatal attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, fatalities from asthma most commonly occur in lower income, non-white, urban populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In 2009, the reported death rates from asthma per million population in the United States were 23 for non-Hispanic blacks, 10 for non-Hispanic whites, and 6 for persons of Hispanic origin, although data identifying Hispanic origin may not be strictly comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/7\">",
"     7",
"    </a>",
"    ]. Disparities in income, education, and access to health care are widely recognized as important contributors to differences in mortality rates among different sociodemographic groups. In this regard, an analysis showed that the higher risk of death in African-American patients compared to white patients is not explained by race differences in deaths occurring in hospital and are therefore likely due to differences that precede hospitalization, such as differences in management at home or during transportation to the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICOPATHOPHYSIOLOGICAL PROFILES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathology of acute severe asthma is complex and variable, possibly reflecting what may be different subtypes of the disease: slow onset and rapid onset (",
"    <a class=\"graphic graphic_table graphicRef81440 \" href=\"UTD.htm?26/28/27083\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/9\">",
"     9",
"    </a>",
"    ]. Deaths from status asthmaticus are ultimately due to the consequences of severe airway obstruction, but the cause of the obstruction varies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Slow onset fatal asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on clinical and pathologic observations, it has been estimated that approximately 80 to 85 percent of patients who die of asthma have a history of progressive symptoms for more than 12 hours and often for one to three weeks. At autopsy, the airways of patients who die of this \"slow-onset\" asthma typically feature an eosinophilic inflammation and obstruction of airway lumens by tenacious mucus and desquamated epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. These changes probably develop over days to weeks. This suggests that most of these patients would have had sufficient time to seek medical attention for worsening shortness of breath [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rapid onset fatal asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a minority of patients with fatal or near-fatal exacerbations of asthma, possibly up to 20 percent (8 to 14 percent of asthma exacerbations in general), death occurs less than 2 to 6 hours after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The airways of these patients with \"rapid-onset\" asthma do not have eosinophil-predominant inflammation or widespread mucus plugging typical of status asthmaticus. Instead, severe airway obstruction appears to be mainly due to smooth muscle bronchospasm and neutrophils are the predominant inflammatory cell in the airway mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, specific characteristics that would help the clinician predict which patients are predisposed to rapid-onset asthma attacks have not been identified. Neither the severity of baseline asthma symptoms, years of asthma, smoking habits, asthma medication use, nor history of hospitalization for asthma help in identifying these patients. However, patients with rapid onset asthma exacerbations may more commonly report sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/17\">",
"     17",
"    </a>",
"    ]. Rapid-onset asthma exacerbations do not appear to be due to anaphylaxis, although that diagnosis must be considered given the rapidity of the deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IDENTIFYING HIGH-RISK PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of potential risk factors for fatal or near fatal asthma exacerbations have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Major risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two elements of the clinical history are most useful in assessing risk for a future fatal or near-fatal asthma exacerbation in an individual patient (",
"    <a class=\"graphic graphic_algorithm graphicRef76827 \" href=\"UTD.htm?7/5/7248\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent history of poorly controlled asthma &mdash; Recent history of poor or only partial control of asthma symptoms indicates increased risk. While no single symptom is predictive of an impending severe attack, increases in dyspnea and wheezing, frequency of nocturnal awakenings, use of beta-adrenergic agonist rescue medications, and increased diurnal variability in peak expiratory flow rate (PEFR) all indicate a pattern of poor or partial control of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/13,21,22\">",
"       13,21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prior history of near-fatal asthma &mdash; Any past history of a prior near-fatal asthma exacerbation requiring endotracheal intubation and mechanical ventilation or a history of a prior intensive care unit admission for asthma should alert the clinician to the patient's propensity for near-fatal or fatal asthma exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/14,23-25\">",
"       14,23-25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a population-based case-control study, 71 percent of patients with a near-fatal asthma attack reported a prior history of intubation or cardiopulmonary resuscitation compared to only 6 and 2 percent in emergency department and community control subjects with asthma, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/24\">",
"     24",
"    </a>",
"    ]. In a prospective case-control study, univariate analysis showed that the odds ratio for a second near-fatal attack was 28 among patients with a history of previous mechanical ventilation and 10 if there was a history of a prior admission to an intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/14\">",
"     14",
"    </a>",
"    ]. A study of patients discharged after mechanical ventilation for near-fatal asthma showed a mortality rate of 10 percent at one year, 14 percent at three years, and 23 percent at six years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a previous history of mechanical ventilation is high among patients being evaluated for near-fatal or fatal attacks, the lack of such prior history in an individual patient does not rule out the possibility of a fatal attack and should not be reassuring to the clinician assessing risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Minor risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinical features also have been linked to near-fatal or fatal asthma, but the associations are not as strong as the factors noted above.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aeroallergens &ndash; Aeroallergen exposure, particularly pet ownership, is associated with episodes of near fatal asthma in sensitized individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and NSAIDs &ndash; Aspirin-induced asthma is one of the manifestations of aspirin exacerbated respiratory disease (",
"      <a class=\"graphic graphic_table graphicRef58651 \" href=\"UTD.htm?7/22/7531\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/28\">",
"       28",
"      </a>",
"      ]. These patients are at increased risk for fatal asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise &ndash; In an eight year period in the United States, 61 episodes of fatal asthma were identified that were precipitated by exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/29\">",
"       29",
"      </a>",
"      ]. Most subjects were white males between the ages of 10 and 14. Basketball and track were the most common sports associated with fatal asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"       \"Exercise-induced bronchoconstriction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic factors &ndash; While evidence has suggested that increased expression of the anaphylatoxin receptors C3aR and C5aR (on lung parenchymal and submucosal blood vessels and airway epithelium, respectively) is associated with fatal asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/30\">",
"       30",
"      </a>",
"      ], the beta-2-adrenergic receptor genotype does not appear to be a major determinant of near-fatal or fatal asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Illicit drugs &ndash; Cocaine and heroin usage is a frequent trigger for severe acute asthma exacerbations: both are associated with a higher rate of intubation, and cocaine use is associated with a longer ICU length of stay [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In a retrospective study of hospital admissions for asthma in patients age 16 and older, 27.6 percent were cocaine users and 30.9 percent were heroin users [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/32\">",
"       32",
"      </a>",
"      ]. Intubation and ICU admission were over 10 times more frequent among users compared with nonusers, even after controlling for cigarette smoking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several mechanisms contribute to the adverse effect that cocaine and heroin have on asthma: direct thermal injury from smoking the drugs, IgE mediated allergy to cocaine, direct bronchoconstriction by cocaine, and an irritant effect on respiratory epithelium from cocaine or insufflated heroin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menstruation &ndash; An increased frequency of near fatal asthma episodes at the time of menstruation has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory viruses &ndash; In one series, evidence of respiratory viral infection, particularly picornavirus and adenovirus, was found in 59 percent of patients presenting to a hospital with near fatal asthma exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Smoking &ndash; Current smoke exposure is predictive of acute care need for asthma and both in-hospital and post-hospital mortality are increased in smokers who require mechanical ventilation for asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/25,27\">",
"       25,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other factors &ndash; Other features associated with fatal and near fatal asthma, particularly slow onset fatal asthma, include: long duration of asthma, systemic glucocorticoid dependence, non-adherence to therapy, poor asthma control, psychosocial problems and less adaptive personality, delay in obtaining medical care, older age, co-morbid conditions, and atopy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/25,28,36-39\">",
"       25,28,36-39",
"      </a>",
"      ]. Noncompliance with inhaled glucocorticoids was high among patients who required mechanical ventilation for asthma (57 percent), but this was not different from other patients seen in the emergency department for acute asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Objective measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have observed that a low forced expiratory volume in one second (FEV1) is associated with an increased risk of asthma exacerbations and the lower the FEV1, the greater the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/27,40-43\">",
"     27,40-43",
"    </a>",
"    ]. In addition, air trapping and hyperinflation are associated with an increased frequency of serious asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. As an example, in a prospective study of severe or difficult to control asthma, postbronchodilator forced vital capacity (FVC) less than 70 percent was a predictor of asthma related emergency department visits and hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these associations, patients with subsequent fatal or near fatal asthma may have entirely normal baseline spirometry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Poor perception of dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinical or physiological features that have been noted in some asthmatics with a history of near-fatal asthma are reduced chemosensitivity to hypoxia, a poor perception of airway obstruction, a blunted perception of dyspnea, and difficulty communicating symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. These phenomena could be important in explaining, at least in part, the apparent delays these patients sometimes have in seeking medical attention during an asthma exacerbation. While no specific aspects of the medical history can identify a patient with such a blunted sense of dyspnea, Borg scale scoring of dyspnea during resistive loading, exercise, and breath-holding maneuvers hold promise for better identification of these patients in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link&amp;anchor=H10#H10\">",
"     \"Components of cardiac rehabilitation and exercise prescription\", section on 'Rating of perceived exertion (Borg scale)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one-third of asthma mortalities in the United States in the year 2000 occurred in hospitalized patients, suggesting that many patients who ultimately die from asthma must either fail to seek medical attention during the many hours or days of increased symptoms or are not hospitalized appropriately when they do [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/8\">",
"     8",
"    </a>",
"    ]. Therefore, efforts to decrease mortality from asthma have focused on educating patients to recognize the symptoms of an attack early and to begin an appropriate action plan that includes prompt medical evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13735/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"     \"What do patients need to know about their asthma?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efforts to modify risk factors for fatal and near fatal asthma include: avoidance of asthma triggers such as aeroallergens,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and NSAIDs; adherence to use of inhaled glucocorticoids; smoking cessation; appropriate treatment of exercise-induced bronchoconstriction; and avoidance of illicit drugs (",
"    <a class=\"graphic graphic_table graphicRef58651 \" href=\"UTD.htm?7/22/7531\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    While patients do better than clinicians, subjective assessments of the severity of airway obstruction, by either patients or clinicians, are widely recognized as poor and insensitive. Regular use of objective measures such as peak expiratory flow rate, forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) is an important component of assessing asthma control and the severity of an acute exacerbation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Near-fatal and fatal asthma exacerbations may occur in patients with mild, moderate, or severe asthma and the course may be either slow or rapid in onset (",
"      <a class=\"graphic graphic_table graphicRef81440 \" href=\"UTD.htm?26/28/27083\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Demographics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, fatalities from asthma most commonly occur in lower income, non-white, urban populations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Demographics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recent history suggestive of poor asthma control or any prior history of endotracheal intubation and mechanical ventilation for asthma should alert the asthma care provider that the patient is at high-risk for near-fatal asthma exacerbations (",
"      <a class=\"graphic graphic_algorithm graphicRef76827 \" href=\"UTD.htm?7/5/7248\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinicopathophysiological profiles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other clinical features, alone or in combination, may also suggest a high-risk patient: long duration of asthma, poor adherence to medical therapy, systemic glucocorticoid dependence, psychosocial problems,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"        aspirin",
"       </a>",
"       /NSAID",
"      </span>",
"      sensitivity, cigarette smoke exposure, prior hospitalization for asthma and atopy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Identifying high-risk patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Objective measures of airflow obstruction, such as spirometry or peak expiratory flow rate, obtained at the time of office visits may help predict which patients are at increased risk for future emergency department visits and hospitalization. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Objective measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Poor perception of dyspnea has been noted in survivors of near-fatal asthma and likely contributes to delays in seeking medical care. In the future, simple clinical tests to assess perception of dyspnea may help to identify patients at particularly high-risk for fatal asthma exacerbations. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Poor perception of dyspnea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identifying patients prone to severe exacerbations is important because education of the patient and provision of a detailed action plan for these patients can reduce the risk of fatal or near-fatal asthma (",
"      <a class=\"graphic graphic_table graphicRef58651 \" href=\"UTD.htm?7/22/7531\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     www.nationmaster.com/graph/mor_ast_percap-mortality-asthma-per-capita (Accessed on May 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/2\">",
"      Moorman JE, Rudd RA, Johnson CA, et al. National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/3\">",
"      Romagnoli M, Caramori G, Braccioni F, et al. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy 2007; 37:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/4\">",
"      Restrepo RD, Peters J. Near-fatal asthma: recognition and management. Curr Opin Pulm Med 2008; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     Akinbami L. Asthma prevalence, Health Care Use and Mortality: United States, 2003-05. National Center for Health Statistics, Centers for Disease Control and Prevention file://www.cdc.gov/nchs/products/pubs/pubd/hestats/ashtma03-05/asthma03-05.htm (Accessed on January 11, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/6\">",
"      Eisner MD, Katz PP, Yelin EH, et al. Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity. Respir Res 2001; 2:53.",
"     </a>",
"    </li>",
"    <li>",
"     National vital statistics report (NVSR) \"Deaths: Final data for 2009\" file://www.cdc.gov/nchs/data/dvs/deaths_2009_release.pdf (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/8\">",
"      Krishnan V, Diette GB, Rand CS, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006; 174:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/9\">",
"      Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005; 172:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/10\">",
"      de Magalh&atilde;es Sim&otilde;es S, dos Santos MA, da Silva Oliveira M, et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 2005; 35:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/11\">",
"      DUNNILL MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol 1960; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/12\">",
"      James AL, Elliot JG, Abramson MJ, Walters EH. Time to death, airway wall inflammation and remodelling in fatal asthma. Eur Respir J 2005; 26:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/13\">",
"      McFadden ER Jr, Warren EL. Observations on asthma mortality. Ann Intern Med 1997; 127:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/14\">",
"      Turner MO, Noertjojo K, Vedal S, et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998; 157:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/15\">",
"      Kolbe J, Fergusson W, Garrett J. Rapid onset asthma: a severe but uncommon manifestation. Thorax 1998; 53:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/16\">",
"      Rodrigo GJ, Rodrigo C. Rapid-onset asthma attack: a prospective cohort study about characteristics and response to emergency department treatment. Chest 2000; 118:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/17\">",
"      Plaza V, Serrano J, Picado C, et al. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. Eur Respir J 2002; 19:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/18\">",
"      Reid LM. The presence or absence of bronchial mucus in fatal asthma. J Allergy Clin Immunol 1987; 80:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/19\">",
"      Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993; 148:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/20\">",
"      Perskvist N, Edston E. Differential accumulation of pulmonary and cardiac mast cell-subsets and eosinophils between fatal anaphylaxis and asthma death: a postmortem comparative study. Forensic Sci Int 2007; 169:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/21\">",
"      Eisner MD, Lieu TA, Chi F, et al. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001; 17:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/22\">",
"      Malmstr&ouml;m K, Kaila M, Kajosaari M, et al. Fatal asthma in Finnish children and adolescents 1976-1998: validity of death certificates and a clinical description. Pediatr Pulmonol 2007; 42:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/23\">",
"      Dhuper S, Maggiore D, Chung V, Shim C. Profile of near-fatal asthma in an inner-city hospital. Chest 2003; 124:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/24\">",
"      Mitchell I, Tough SC, Semple LK, et al. Near-fatal asthma: a population-based study of risk factors. Chest 2002; 121:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/25\">",
"      Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 1992; 146:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/26\">",
"      Bush RK, Prochnau JJ. Alternaria-induced asthma. J Allergy Clin Immunol 2004; 113:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/27\">",
"      Osborne ML, Pedula KL, O'Hollaren M, et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 2007; 132:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/28\">",
"      Yoshimine F, Hasegawa T, Suzuki E, et al. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology 2005; 10:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/29\">",
"      Becker JM, Rogers J, Rossini G, et al. Asthma deaths during sports: report of a 7-year experience. J Allergy Clin Immunol 2004; 113:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/30\">",
"      Fregonese L, Swan FJ, van Schadewijk A, et al. Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma. J Allergy Clin Immunol 2005; 115:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/31\">",
"      Weir TD, Mallek N, Sandford AJ, et al. beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998; 158:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/32\">",
"      Levine M, Iliescu ME, Margellos-Anast H, et al. The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations. Chest 2005; 128:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/33\">",
"      Krantz AJ, Hershow RC, Prachand N, et al. Heroin insufflation as a trigger for patients with life-threatening asthma. Chest 2003; 123:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/34\">",
"      Martinez-Morag&oacute;n E, Plaza V, Serrano J, et al. Near-fatal asthma related to menstruation. J Allergy Clin Immunol 2004; 113:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/35\">",
"      Tan WC, Xiang X, Qiu D, et al. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med 2003; 115:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/36\">",
"      Strunk RC. Identification of the fatality-prone subject with asthma. J Allergy Clin Immunol 1989; 83:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/37\">",
"      Strunk RC. Death due to asthma. New insights into sudden unexpected deaths, but the focus remains on prevention. Am Rev Respir Dis 1993; 148:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/38\">",
"      Barr RG, Woodruff PG, Clark S, Camargo CA Jr. Sudden-onset asthma exacerbations: clinical features, response to therapy, and 2-week follow-up. Multicenter Airway Research Collaboration (MARC) investigators. Eur Respir J 2000; 15:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/39\">",
"      Watson L, Turk F, James P, Holgate ST. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med 2007; 101:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/40\">",
"      Gelb AF, Schein A, Nussbaum E, et al. Risk factors for near-fatal asthma. Chest 2004; 126:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/41\">",
"      Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004; 126:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/42\">",
"      Boushey H, Enright P. Spirometry enhances identification of high-risk patients with asthma. Chest 2007; 132:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/43\">",
"      Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/44\">",
"      Miller MK, Lee JH, Blanc PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006; 28:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/45\">",
"      Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/46\">",
"      Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994; 330:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/47\">",
"      Bijl-Hofland ID, Cloosterman SG, Folgering HT, et al. Relation of the perception of airway obstruction to the severity of asthma. Thorax 1999; 54:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/48\">",
"      Serrano J, Plaza V, Sureda B, et al. Alexithymia: a relevant psychological variable in near-fatal asthma. Eur Respir J 2006; 28:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/49\">",
"      Ruffin RE, Latimer KM, Schembri DA. Longitudinal study of near fatal asthma. Chest 1991; 99:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/50\">",
"      Motomura C, Odajima H, Tezuka J, et al. Perception of dyspnea during acetylcholine-induced bronchoconstriction in asthmatic children. Ann Allergy Asthma Immunol 2009; 102:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/51\">",
"      Magadle R, Berar-Yanay N, Weiner P. The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea. Chest 2002; 121:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/52\">",
"      Barreiro E, Gea J, Sanju&aacute;s C, et al. Dyspnoea at rest and at the end of different exercises in patients with near-fatal asthma. Eur Respir J 2004; 24:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/53\">",
"      Nannini LJ, Zaietta GA, Guerrera AJ, et al. Breath-holding test in subjects with near-fatal asthma. A new index for dyspnea perception. Respir Med 2007; 101:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/54\">",
"      George MR, O'Dowd LC, Martin I, et al. A comprehensive educational program improves clinical outcome measures in inner-city patients with asthma. Arch Intern Med 1999; 159:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13735/abstract/55\">",
"      Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest 1997; 112:1534.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 565 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FC043B0C43-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13735=[""].join("\n");
var outline_f13_26_13735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEMOGRAPHICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICOPATHOPHYSIOLOGICAL PROFILES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Slow onset fatal asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rapid onset fatal asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IDENTIFYING HIGH-RISK PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Major risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Minor risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Objective measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Poor perception of dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/565\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/565|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/5/7248\" title=\"algorithm 1\">",
"      Assessing fatal asthma risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/565|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/12/40143\" title=\"figure 1\">",
"      Asthma annual mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/565|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/28/27083\" title=\"table 1\">",
"      Fatal asthma subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/22/7531\" title=\"table 2\">",
"      Preventing fatal asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=related_link\">",
"      Evaluation of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_26_13736="Overview of the management of central nervous system tumors in children";
var content_f13_26_13736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of central nervous system tumors in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13736/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13736/contributors\">",
"     Ching Lau, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13736/contributors\">",
"     Wan-Yee Teo, MBBS, MRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13736/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13736/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13736/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/26/13736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies, after hematologic malignancies, and are the most common pediatric solid organ tumor (",
"    <a class=\"graphic graphic_table graphicRef69839 \" href=\"UTD.htm?31/51/32572\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the leading cause of death from childhood cancer, surpassing the mortality rate of acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/2\">",
"     2",
"    </a>",
"    ]. Although advances in surgical intervention, radiotherapy, and chemotherapy have improved the survival rates in children with CNS tumors, mortality and morbidity associated with these disorders persist, especially malignant brain tumors.",
"   </p>",
"   <p>",
"    A general overview of the management and prognosis of CNS tumors in children will be reviewed here. The management and prognosis of the following specific CNS tumors that occur in children are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-grade gliomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=see_link\">",
"       \"Management of low-grade glioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Malignant gliomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Brainstem glioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1832?source=see_link\">",
"       \"Diffuse pontine glioma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=see_link\">",
"       \"Focal brainstem glioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Optic glioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=see_link\">",
"       \"Optic pathway glioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Medulloblastoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=see_link\">",
"       \"Epidemiology, treatment, and prognosis of medulloblastoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Craniopharyngioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=see_link\">",
"       \"Craniopharyngioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ependymoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15161?source=see_link\">",
"       \"Ependymoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Focal brainstem glioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=see_link\">",
"       \"Focal brainstem glioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Germ cell tumors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"       \"Pediatric intracranial germ cell tumors\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Intradural nerve sheath tumors, such as schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28694?source=see_link\">",
"       \"Intradural nerve sheath tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Meningioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=see_link\">",
"       \"Treatment of benign (WHO grade I) meningioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spinal cord tumors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link\">",
"       \"Spinal cord tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tuberous sclerosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other tumors, including neuronal and neuronoglial tumors, choroid plexus tumors, primitive neuroectodermal tumors, atypical",
"      <span class=\"nowrap\">",
"       teratoid/rhabdoid",
"      </span>",
"      tumors, ependymoblastoma, and medulloepithelioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link\">",
"       \"Uncommon brain tumors\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of the clinical manifestations, diagnosis, and the epidemiology of CNS tumors in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=see_link\">",
"     \"Clinical manifestations and diagnosis of central nervous system tumors in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38230?source=see_link\">",
"     \"Epidemiology of central nervous system tumors in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MANAGEMENT STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of management of central nervous system (CNS) tumors includes a multimodal approach of surgery, radiotherapy, and chemotherapy. The confirmation of a CNS tumor warrants a referral to a neurosurgeon for further evaluation, tissue biopsy, and gross total resection where possible. Radiotherapy and chemotherapy are used as adjunct measures based on the histology of the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open surgical procedure is the preferred approach to obtain tissue for a histologic diagnosis and bulk removal of the tumor where possible. A pediatric neurosurgeon should be involved, if possible, as they are best able to perform tumor resection with limited long-term morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/3\">",
"     3",
"    </a>",
"    ]. In most cases, near-total resection can be achieved. However, complete resection is generally limited by the inability to remove the tumor with surrounding clear margins of normal tissue because of the risk of producing permanent neurologic deficits and to remove scattered tumor cells that have infiltrated beyond the margins of the resection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/4\">",
"     4",
"    </a>",
"    ]. Adjunct therapy (ie, radiotherapy and chemotherapy) is required.",
"   </p>",
"   <p>",
"    Deep seated tumors, such as diffuse infiltrative brainstem and globular chiasmatic gliomas, are associated with a high risk of irreversible neurological sequelae in an open surgical approach. In these cases, tissues for histologic diagnosis can be obtained using stereotactic biopsy techniques guided by magnetic resonance imaging (MRI) or computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Endoscopic biopsy is another option for intraventricular or periventricular tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical approaches and techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk of extensive tumor resection is injury to the surrounding tissue, especially in functionally critical parts of the brain, which can result in long-term neurological impairment. Advances in operative microscopy with better visualization of the interface between tumor and the surrounding normal tissue have resulted in safer surgical resection and lower neurologic morbidity.",
"   </p>",
"   <p>",
"    In cases where the tumor is in a functionally critical site",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is poor demarcation of the tumor from its surroundings, the following techniques have been used to minimize injury to the adjacent normal tissue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative stereotactic imaging to guide the surgical approach in order to minimize manipulation of normal tissue and maximize tumor resection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intraoperative MRI imaging, including functional MRI to aid in intraoperative decision making [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/5,7\">",
"       5,7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intraoperative neurophysiologic monitoring of visual, auditory, and somatosensory pathways in cases that involve functionally critical zones to minimize injury to normal tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postoperative imaging, preferably by MRI, is performed within the first 24 to 72 hours to determine the extent of tumor resection. This information is useful in the planning of subsequent therapy, including the need for repeat surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preoperative and perioperative considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to deciding the optimal surgical approach and technique to adopt for a child with a CNS tumor, the following preoperative and perioperative complications have to be addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased intracranial pressure (ICP) including obstructive hydrocephalus",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Endocrine abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Increased ICP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intracranial pressure (ICP) is a common finding in children with CNS tumors. In cases where the lesion is large resulting causing a significant mass effect, urgent resection is needed to prevent serious morbidity and death.",
"   </p>",
"   <p>",
"    Corticosteroid therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ), directed at reducing peri-tumor edema, is given to patients with increased ICP. Intravenous dexamethasone (0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is administered every six hours with a maximum dose of 16 mg per day) is given preoperatively and is continued intraoperatively and during the early postoperative period to reduce edema associated with the surgical procedure. In most cases, dexamethasone can be discontinued postoperatively because tumor volume is reduced following resection. However, children with tumors that are not amenable to resection (eg, brainstem lesions) may require protracted corticosteroid therapy. These children are at risk for the side effects of corticosteroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstructive hydrocephalus is a major cause of increased ICP. Although tumor resection may lead to resolution of hydrocephalus, preoperative shunting is often performed to relieve the increased ICP, reducing the potential risk of herniation. Shunting is usually performed by placing an external ventricular drain just prior to craniotomy for tumor resection. Postoperatively, the shunt allows drainage of bloody central spinal fluid (CSF) and debris. It is usually removed within a few days after normal CSF flow is re-established with tumor resection. In some cases with persistent obstruction of CSF flow, endoscopic third ventriculostomy, a procedure in which a perforation is made to connect the third ventricle to the subarachnoid space, or a ventriculoperitoneal shunt may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link\">",
"     \"Hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticonvulsant therapy is initiated in patients with CNS tumor complicated by seizures. Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    is the commonly utilized anticonvulsant in these cases, some clinicians avoid using phenytoin, because it induces the cytochrome P450 enzymes, which increases the clearance of some chemotherapeutic agents (eg, cytotoxic agents and corticosteroids) that are metabolized through this system. To avoid potential interactions with chemotherapeutic agents, anticonvulsants that do not induce hepatic cytochrome P450 enzymes, such as valproic acid&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    , may be considered.",
"   </p>",
"   <p>",
"    Anticonvulsant therapy has been used prophylactically in patients with lesions in a potentially epileptogenic site (eg, cerebral cortical lesion). However, published data have shown that prophylactic anticonvulsants do not affect the frequency of subsequent seizures in patients with brain tumors, including those who have undergone a neurosurgical procedure. In addition, anticonvulsants agents can have deleterious interactions with some chemotherapeutic agents, as described above. Thus, we do not recommend the use of prophylactic anticonvulsants in patients without a history of seizures. The one possible exception is the use of postoperative seizure prophylaxis at the discretion of neurosurgeons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=see_link\">",
"     \"Seizures in patients with primary and metastatic brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Endocrine abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lesions located in the hypothalamus or pituitary gland may present with endocrine abnormalities, such as growth failure due to either hypothyroidism or growth hormone deficiency. Tumor resection can exacerbate endocrine dysfunction. For example, patients whose posterior pituitary gland is injured or resected during surgery may have impaired fluid and electrolyte regulation with an initial phase of transient diabetes insipidus (DI), followed by a period of inappropriate antidiuretic hormone release, and a final persistent phase of DI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=see_link\">",
"     \"Craniopharyngioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\", section on 'Neurosurgery or trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of the specific endocrine abnormalities may require hormonal replacement therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiotherapy plays an integral role in the treatment of central nervous system (CNS) tumors in children. The histologic diagnosis of the tumor determines the use of radiotherapy. Planning the target volume (local versus craniospinal) and the dose of radiotherapy takes into consideration the tumor location, stage of the tumor, the expected patterns of spread, and in some cases, the regimen and timing of chemotherapy, and age of the patient. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Radiotherapy is generally delivered by conventional external beam. Other techniques include three-dimensional conformal radiotherapy (targeting the radiation to conform to the size and shape of the tumor), and stereotactic radiosurgery. The different techniques of radiotherapy administration are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although an effective adjunct, radiotherapy is associated with both acute and long-term complications, particularly in infants and young children whose nervous systems are still developing. The complications of cranial radiation can be categorized into three phases and are summarized as follows. A more detailed discussion of the complications of cranial radiation is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute reactions occur during treatment and are caused by injury to the brain that results in inflammation and edema. Symptoms include headache, nausea, drowsiness, focal neurological deficits, and fever.",
"     </li>",
"     <li>",
"      Early-delayed reactions occur from a few weeks to three months after radiation treatment, and are thought to be due to a combination of tumor response, peritumor edema, and demyelination. Findings include transient focal neurological deficits, somnolence syndrome (characterized by extreme sleepiness and signs of increased intracranial pressure (ICP), such as headache, nausea, vomiting, anorexia, and irritability), and asymptomatic magnetic resonance imaging (MRI) contrast enhancement, which may be difficult to distinguish from tumor progression.",
"     </li>",
"     <li>",
"      Late reactions occur more than 90 days after radiation treatment and generally are irreversible. They are due to radiation-induced brain necrosis at or near the site of the tumor that have received the highest radiation dose, diffuse white matter injury (ie, leukoencephalopathy), secondary malignancies, and vasculopathy. General findings include impaired neurocognitive function, and social and behavioral deficits. Depending on the location of the tumor and field of radiation, other complications, such as hearing impairment, hypothalamic and pituitary endocrinopathies, and visual impairment secondary to cataracts, optic neuropathy, retinopathy or cortical blindness, may arise. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"       \"Complications of cranial irradiation\", section on 'Late reactions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H25#H25\">",
"       \"Complications of cranial irradiation\", section on 'Neurocognitive effects in children'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"       \"Cataract in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Various strategies, such as decreasing the radiation dose for patients with relatively lower risk disease, and three-dimensional conformal radiation therapy have been adopted to minimize the long-term complications associated with radiotherapy. The latter minimizes radiation to adjacent normal tissue by customizing the treatment to deliver maximum radiation within the contour of the tumor volume, regardless of its shape. Proton beam therapy also minimizes the harmful effects of radiation to neighboring normal tissues because of its unique ability of depositing most of its energy (proton) at the targeted area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of chemotherapy in the treatment of central nervous system (CNS) tumors is dependent on the underlying tissue and the patient's age.",
"   </p>",
"   <p>",
"    Chemotherapy is routinely used in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older children with embryonal tumors (eg, medulloblastomas and primitive neuroectodermal tumors and high-grade astrocytomas) in combination with surgery and radiation therapy.",
"     </li>",
"     <li>",
"      Young children and infants with embryonal tumors, low-grade gliomas, and optic glioma after surgical resection. The goal of chemotherapy is to delay or replace radiation therapy. This reduces or eliminates the long-term effects of radiation (ie, neurocognitive impairment, developmental delay, and endocrine abnormalities) in this vulnerable population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    See the relevant reviews for specific histological types of tumors for more detailed information on chemotherapy. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of chemotherapy for CNS tumors poses a challenge to oncologists. The presence of the blood brain barrier limits the penetration of most systemically administered chemotherapeutic agents. The following approaches are used to administer these agents and are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link&amp;anchor=H18#H18\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Blood-brain barrier'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose or combination systemic therapy",
"     </li>",
"     <li>",
"      Intrathecal chemotherapy",
"     </li>",
"     <li>",
"      Intratumoral chemotherapy with direct administration of the chemotherapy into the tumor bed",
"     </li>",
"     <li>",
"      Systemic administration with disruption of the blood brain barrier by infusions of hypertonic arabinose or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased understanding of the molecular pathways involved in signal transduction, angiogenesis, and cell growth has led to the development of targeted agents in the treatment of malignant gliomas and other tumors. For example, drugs have been developed that disrupt the vascular endothelial growth factor (VEGF) pathway, which is involved in the formation of the abnormal vasculature observed in malignant gliomas and other tumors. These agents include monoclonal antibodies that bind VEGF, inhibitors of tyrosine kinases within the VEGF pathway, and inhibitors of protein kinase C, a major component of the VEGF pathway. Other new drugs either target additional molecular pathways involved in tumor pathogenesis, such as the epidermal growth factor, platelet derived growth factor, integrin, sonic hedgehog, and histone deacetylase",
"    <span class=\"nowrap\">",
"     systems/pathways.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link&amp;anchor=H4#H4\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Targeted systemic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biologic agents, such as interferons (IFN alpha and beta) and gene therapy, have also shown promise in the treatment of malignant gliomas and other CNS tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link&amp;anchor=H14#H14\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Biologic approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival after the diagnosis of a central nervous system (CNS) neoplasm has improved, in part, due to advances in diagnostic techniques and histological classification of tumors, improvement in neurosurgical and radiation oncology techniques, and the utilization of new single and combination chemotherapeutic agents. Despite advances in the care of children with CNS tumors, mortality and morbidity associated with these disorders persist. Improvement in survival and durable remissions has been slower in patients with CNS tumors compared with other cancers, particularly leukemias and lymphomas.",
"   </p>",
"   <p>",
"    In the United States, although the death rate due to CNS tumors in children has decreased from to 7.9 to 6.9 deaths per 1 million children below 19 years of age from 1990 to 2004, CNS tumors still account for one-fourth of cancer deaths in children in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/9\">",
"     9",
"    </a>",
"    ]. Based upon data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute from 1975 to 1998, which was classified by the International Classification of Childhood Cancer, the 15-year survival rate for patients younger than 20 years of age exceeded 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/2\">",
"     2",
"    </a>",
"    ]. The five-year survival rate based upon the SEER data from 1999 to 2005 is 71 percent.",
"   </p>",
"   <p>",
"    In a report from a single center of 643 children with primary CNS tumors, the 10-year and 15-year survival rates for patients who survived five or more years were 90 and 85 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/10\">",
"     10",
"    </a>",
"    ]. The specific tumor type affected the survival rate, with the highest survival rate associated with low-grade glioma (10-year and 15-year survival rates of 97 and 91 percent, respectively) and the lowest with high-grade gliomas (10-year and 15-year survival rates of 67 and 61 percent, respectively). Of the 66 deaths, 38 were due to progressive disease, 14 from a second malignant tumor, and 12 died from a secondary medical condition that included sepsis (7 patients), cardiovascular disease (2 patients), stroke (2 patients), respiratory failure (1 patient), and shunt failure (1 patient).",
"   </p>",
"   <p>",
"    In a retrospective study from the Childhood Cancer Survivor Study of five-year survivors of childhood nervous system tumors (n = 2821), the cumulative mortality at 30 years of age was 25.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/11\">",
"     11",
"    </a>",
"    ]. Deaths primarily were due to either recurrence or progression of the primary CNS tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long-term morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric survivors with CNS tumors often have neurologic, cognitive, psychological, and endocrine complications that are due to damage from the tumor itself, its treatment (ie, surgery, radiation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy), or subsequent secondary malignancy. The risk of these complications is increased in patients who are younger at the time of diagnosis and treatment (less than 3 years of age), have hydrocephalus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are treated with cranial radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the previously mentioned report from the Childhood Cancer Survivor Study, of the 2821 five-year survivors (median age at diagnosis was 7.5 years) who were evaluated, 82 percent reported having at least one chronic medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/11\">",
"     11",
"    </a>",
"    ]. Compared with siblings, survivors had an increased risk of developing a new endocrine condition (HR 19.8, 95% CI 14.5- 27.1), sensory deficit (eg, hearing loss) (HR 12.5, 95% CI 8.9-17.6), and neurologic problem (HR 5.6, 95% CI 4.8-6.7). Cranial radiation therapy was associated with an increased risk of subsequent malignancy and neurocognitive impairment.",
"   </p>",
"   <p>",
"    Specific long-term follow-up guidelines for survivors of childhood CNS tumors have been published by the Children's Oncology Group, and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    (accessed",
"    <span class=\"nowrap\">",
"     1/19/2010)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Neurocognitive effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurocognitive impairment is common complication in children with CNS tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Scholastic impairment was illustrated in a study from the Finnish Cancer Registry that compared school performance at age 16 years of patients with CNS tumors with age matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/16\">",
"     16",
"    </a>",
"    ]. Although 94 percent of patients were able to finish their education at the usual age, patients had lower grades in all school subjects compared with controls, with the greatest difference in foreign language. In particular, brain tumor survivors who were diagnosed as preschoolers had 18-fold higher odds (95% CI 15-23.5) of a special education history than did those in the sibling group.",
"   </p>",
"   <p>",
"    In a report from the Children's Oncology Group of 93 patients with a low-grade brain tumor who were treated only with surgical excision, patients were more likely to have below average scores compared with published normative scores in intelligence quotient (IQ), academic performance, visual and motor skills, and adaptive behavior (55 percent compared with the expected normative rate of 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Psychological effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study from the Childhood Cancer Survivor Study group, adult survivors of childhood brain cancer compared with their siblings had an increased rate of symptoms of physiologic distress, particularly depression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/19\">",
"     19",
"    </a>",
"    ]. Multivariate analyses of risk factors demonstrated no association of distress with any treatment-related variable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Social effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of brain tumors are at a particular risk for lower rates of unemployment (RR 0.74, 95% CI 0.71-0.76) compared with siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, survivors of brain tumors were more likely to have never married compared with all survivors of childhood malignancies (78 versus 62 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Endocrine abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report from the Childhood Cancer Survivor Study group, adult survivors of childhood brain tumors compared with their siblings are at increased risk for endocrine abnormalities, including growth hormone deficiency (RR 278, 95% CI 111-694), the need for medications to induce puberty (RR 86, 95% CI 31-238), hypothyroidism (RR 14.3, 95% CI 9.7-21), and medical complications such as stroke (RR 43, 95% CI 16.7-1110), and blood clots (RR 5.7, 95% CI 3.2-10) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/12\">",
"     12",
"    </a>",
"    ]. In female survivors, radiotherapy and diagnosis before 4 years of age are associated with an increased risk for menarche abnormalities, including both late and early menarche [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PALLIATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central nervous system (CNS) tumor is a life-threatening condition in most affected children, and palliative care, which seeks to improve the quality of life of all children with life-threatening conditions, should be initiated at the time of diagnosis. Children with brain tumors at the end-of-life have progressive neurologic deterioration, including loss of the ability to communicate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13736/abstract/22\">",
"     22",
"    </a>",
"    ]. End-of-life care for these patients needs to provide early anticipatory guidance for families and comfort measures that address the distinct issues in the care of dying child with a brain tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28058?source=see_link\">",
"     \"Pediatric palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For confirmation of a central nervous system (CNS) tumor, referral to a neurosurgeon is required for histologic diagnosis. An open surgical procedure is the preferred approach for most childhood brain tumors to obtain tissue for a histologic diagnosis and bulk removal where possible. Tumors deeply located in the brain are not amenable to open surgical intervention because of the high risk of irreversible neurological impairment. In these cases, histologic diagnosis can be obtained using stereotactic biopsy techniques guided by magnetic resonance imaging (MRI) or computed tomography (CT). Intraventricular and periventricular lesions could also be biopsied endoscopically. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Management strategy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a child with a CNS tumor and increased intracranial pressure, we suggest corticosteroid therapy to reduce peritumoral edema (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In our practice, children with increased ICP due to a mass lesion receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (0.25 to 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 6 hours, with a maximum dose of 16 mg per day). In children with increased ICP and obstructive hydrocephalus, preoperative shunting may relieve increased ICP, and is performed based upon the clinical judgment of the neurosurgeon. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Increased ICP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a child with a CNS tumor and seizures, we recommend monotherapy with a standard anticonvulsant agent (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). To avoid potential interactions with chemotherapeutic agents and targeted molecular drugs, anticonvulsants that do not induce hepatic cytochrome P450 enzymes, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/0/25608?source=see_link\">",
"       levetiracetam",
"      </a>",
"      , valproic acid, or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"       topiramate",
"      </a>",
"      , may be considered. We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using prophylactic anticonvulsants in patients without a history of seizures (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The one possible exception is the use of postoperative seizure prophylaxis at the discretion of neurosurgeons. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Seizures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=see_link\">",
"       \"Seizures in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with brain tumors may have endocrine abnormalities, especially those with lesions located in the hypothalamus or pituitary gland. Management is focused on treating the specific endocrine abnormalities and may require hormonal replacement therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Endocrine abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of radiotherapy is dependent on the histologic diagnosis of the tumor. Although radiotherapy is an effective adjunct, it is associated with both acute and long-term complications. In particular, infants and young children with developing nervous systems are at increased risk for long-term neurodevelopmental impairment. Long-term complications are generally irreversible and include radiation-induced brain necrosis, white matter injury, vasculopathy and secondary malignancies. The timing, dose, and field of radiation is based on the histology, tumor location and size, stage of the tumor, the expected patterns of spread, and the availability of effective chemotherapy agents. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H25#H25\">",
"       \"Complications of cranial irradiation\", section on 'Neurocognitive effects in children'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of chemotherapy is dependent on the underlying tissue histology. It is routinely used in combination with surgery and radiation therapy for older children to treat embryonal tumors (eg, medulloblastomas). In young children and infants with embryonal tumors, low-grade gliomas, and optic glioma, chemotherapy is used after surgical resection to delay or avoid the need for radiation therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite advances in the care of children with CNS tumors, CNS tumors still account for one-quarter of deaths in childhood cancer. In addition, pediatric survivors with CNS tumors often have neurological, cognitive, endocrine, social, and psychological sequelae. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediatric palliative care should be provided to children with life-threatening CNS tumors, while maintaining their quality of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28058?source=see_link\">",
"       \"Pediatric palliative care\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/1\">",
"      Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008; 112:416.",
"     </a>",
"    </li>",
"    <li>",
"     Homer MJ, Ries, LAG, Krapcho, M, et al (eds). SEER Cancer Statistis Review, 1975-2006 file://seer.cancer.gov/csr/1975_2006/ (Accessed on May 20, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/3\">",
"      Albright AL, Sposto R, Holmes E, et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 2000; 47:879.",
"     </a>",
"    </li>",
"    <li>",
"     Blaney SM, Hass-Kogan D, Poussaint TY, et al. Gliomas, ependymomas, and other nonembryonal tumors of the central nervous system. In: Principles and practice of pediatric oncology, 6th, Pizzo, P, Poplack, D (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.717.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/5\">",
"      Hall WA, Truwit CL. 1.5 T: spectroscopy-supported brain biopsy. Neurosurg Clin N Am 2005; 16:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/6\">",
"      Ahn ES, Goumnerova L. Endoscopic biopsy of brain tumors in children: diagnostic success and utility in guiding treatment strategies. J Neurosurg Pediatr 2010; 5:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/7\">",
"      Matthews PM, Wylezinska M, Cadoux-Hudson T. Novel approaches to imaging brain tumors. Hematol Oncol Clin North Am 2001; 15:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/8\">",
"      Yamaguchi F, Takahashi H, Teramoto A. Intra-operative detection of motor pathways using a simple electrode provides safe brain tumor surgery. J Clin Neurosci 2007; 14:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Trends in childhood cancer mortality--United States, 1990-2004. MMWR Morb Mortal Wkly Rep 2007; 56:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/10\">",
"      Morris EB, Gajjar A, Okuma JO, et al. Survival and late mortality in long-term survivors of pediatric CNS tumors. J Clin Oncol 2007; 25:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/11\">",
"      Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/12\">",
"      Gerber NU, Zehnder D, Zuzak TJ, et al. Outcome in children with brain tumours diagnosed in the first year of life: long-term complications and quality of life. Arch Dis Child 2008; 93:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/13\">",
"      Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/14\">",
"      Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005; 23:7152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/15\">",
"      Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/16\">",
"      L&auml;hteenm&auml;ki PM, Harila-Saari A, Pukkala EI, et al. Scholastic achievements of children with brain tumors at the end of comprehensive education: a nationwide, register-based study. Neurology 2007; 69:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/17\">",
"      Ris MD, Beebe DW, Armstrong FD, et al. Cognitive and adaptive outcome in extracerebellar low-grade brain tumors in children: a report from the Children's Oncology Group. J Clin Oncol 2008; 26:4765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/18\">",
"      DE Ruiter MA, VAN Mourik R, Schouten-VAN Meeteren AY, et al. Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis. Dev Med Child Neurol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/19\">",
"      Zebrack BJ, Gurney JG, Oeffinger K, et al. Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. J Clin Oncol 2004; 22:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/20\">",
"      Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/21\">",
"      Armstrong GT, Whitton JA, Gajjar A, et al. Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer 2009; 115:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13736/abstract/22\">",
"      Zelcer S, Cataudella D, Cairney AE, Bannister SL. Palliative care of children with brain tumors: a parental perspective. Arch Pediatr Adolesc Med 2010; 164:225.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6253 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13736=[""].join("\n");
var outline_f13_26_13736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MANAGEMENT STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical approaches and techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preoperative and perioperative considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Increased ICP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Endocrine abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long-term morbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Neurocognitive effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Psychological effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Social effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Endocrine abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PALLIATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6253\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6253|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/51/32572\" title=\"table 1\">",
"      Common childhood cancers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=related_link\">",
"      Clinical manifestations and diagnosis of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=related_link\">",
"      Craniopharyngioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1832?source=related_link\">",
"      Diffuse pontine glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15161?source=related_link\">",
"      Ependymoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38230?source=related_link\">",
"      Epidemiology of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40585?source=related_link\">",
"      Focal brainstem glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28694?source=related_link\">",
"      Intradural nerve sheath tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=related_link\">",
"      Management of low-grade glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=related_link\">",
"      Optic pathway glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=related_link\">",
"      Pediatric intracranial germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28058?source=related_link\">",
"      Pediatric palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_26_13737="Patient assessment for air travel";
var content_f13_26_13737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient assessment for air travel",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13737/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13737/contributors\">",
"     Matthew Prout, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13737/contributors\">",
"     Jeffrey R Pine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13737/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13737/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13737/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/26/13737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are frequently asked to make recommendations to patients about travel safety. This topic review will present an overview of issues for clinicians to consider when evaluating the risks posed by commercial air travel.",
"   </p>",
"   <p>",
"    Multiple topics in UpToDate discuss specific aspects of air travel. Related topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link\">",
"       \"Jet lag\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link\">",
"       \"High altitude, air travel, and heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"       \"Traveling with oxygen aboard commercial air carriers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7417?source=see_link\">",
"       \"Management of inflight medical emergencies on commercial airlines\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL SCREENING AND HEALTH COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Air Carrier Access Act of 1986 requires the US Department of Transportation to ensure that persons with disabilities are able to fly without being discriminated against [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, people with chronic medical conditions often travel on commercial flights.",
"   </p>",
"   <p>",
"    As a general rule, patients with unstable medical conditions should not fly on a commercial aircraft (",
"    <a class=\"graphic graphic_table graphicRef72315 \" href=\"UTD.htm?13/31/13821\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ]. Individuals with a medical condition that could lead to inflight illness, injury, or risk to other passengers may be required by the airline to have a medical certificate from their clinician. The certificate should state that the patient is currently stable and fit for air travel, and, if applicable, not contagious.",
"   </p>",
"   <p>",
"    Screening questions should include the length of the journey, history of tolerating prior air travel, and the conditions of the destination (eg, altitude, public health risks, and access to medical care). The clinician should assess any worsening of the patient's chronic medical conditions and any relevant medical history. Of particular concern are: cardiovascular disease, thromboembolic disease, asthma, COPD, epilepsy, stroke, recent surgery or trauma, diabetes, infectious disease, and mental illness.",
"   </p>",
"   <p>",
"    All patients preparing for air travel should be counseled on: adjusting the timing of their medicines (especially if crossing time zones), keeping unexpired medicines with them in carry-on luggage (preferably in their original, labeled containers), and requesting assistance when needed. Adjusting medication schedules can be difficult, and strategies vary depending on the medication, the distance traveled, and the duration of the visit. Three basic strategies exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain normal schedule using the time of the patient's home country (best for short trips; may help to keep a watch on home time).",
"     </li>",
"     <li>",
"      Gradually adjust schedule by an hour or two daily, until medication is taken according to local time.",
"     </li>",
"     <li>",
"      Immediately change schedule so medication is taken according to local time (may lead to extended delays between doses; not to be used with insulin). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diabetes'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should bring prescriptions with them, especially if they need to carry needles or other sharps on board for a medical reason [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/3\">",
"     3",
"    </a>",
"    ]. Vaccinations against diseases likely to be present in destination countries should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8967?source=see_link\">",
"     \"Travel advice\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending on their illnesses, patients should carry on their person (ie, not check with their baggage) the following items [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Detailed list of all diseases",
"     </li>",
"     <li>",
"      Detailed list of all medications, including dosages and allergies",
"     </li>",
"     <li>",
"      Any medication that may be needed during flight (eg, insulin, bronchodilator,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Medical alert bracelet for severe diseases and allergies",
"     </li>",
"     <li>",
"      Copy of a recent ECG",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a clinician is uncertain about a patient's ability to fly on a commercial airline, they may consider referral to an expert in aerospace medicine or review",
"    <a class=\"external\" href=\"file://www.asma.org/asma/media/asma/Travel-Publications/medguid.pdf\">",
"     AsMA's Medical Guidelines for Airline Travel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIFIC PREEXISTING CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for specific medical conditions to be considered prior to air travel are discussed below. Particular attention should be given to patients with conditions that may worsen with the decreased partial pressure of oxygen during flight: primarily cardiac, pulmonary, and neurovascular conditions (",
"    <a class=\"graphic graphic_table graphicRef72315 \" href=\"UTD.htm?13/31/13821\">",
"     table 1",
"    </a>",
"    ). A more detailed description of the cabin environment is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7417?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of inflight medical emergencies on commercial airlines\", section on 'Cabin environment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with well-compensated heart disease can travel without difficulty. A variety of practical tips for the cardiopulmonary patient traveling by air are found in the following table (",
"    <a class=\"graphic graphic_table graphicRef52930 \" href=\"UTD.htm?22/6/22636\">",
"     table 2",
"    </a>",
"    ). A discussion of air travel for patients with heart disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link&amp;anchor=H17#H17\">",
"     \"High altitude, air travel, and heart disease\", section on 'Air travel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with poorly-controlled heart disease should be advised against air travel. The key cardiac contraindications to air travel include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unstable angina",
"     </li>",
"     <li>",
"      High-grade ventricular premature beats or uncontrolled ventricular or supraventricular arrhythmias",
"     </li>",
"     <li>",
"      Severe decompensated heart failure (HF) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. Patients with class III or IV New York Heart Association HF should be carefully assessed to determine whether they will need inflight oxygen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"       \"Traveling with oxygen aboard commercial air carriers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic valvular heart disease is a relative contraindication to airline travel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12301545\">",
"    <span class=\"h3\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigorous evidence is lacking on the safety of air travel after an acute coronary syndrome (ACS), and expert guidelines vary. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guidelines prepared by the British Cardiovascular Society suggest that patients with a recent acute coronary syndrome may be divided into three categories [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/6\">",
"       6",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Those at very low risk (defined as age &lt;65 years, first event, successful reperfusion, ejection fraction &gt;45 percent, no complications or additional planned interventions) may fly as soon as three days after the event.",
"     </li>",
"     <li>",
"      Those with low risk (ejection fraction &gt;40 percent, no heart failure, no evidence of inducible ischemia or arrhythmia, and no further planned interventions) may fly from 10 days onward, if they are tolerating usual daily activities.",
"     </li>",
"     <li>",
"      Those at high risk of complications should defer commercial flying until they have been stabilized (ejection fraction &lt;40 percent, signs and symptoms of heart failure, pending further investigation for potential revascularization or device therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guidelines from the Aerospace Medical Association state that patients with recent uncomplicated myocardial infarction should not fly for at least two to three weeks and have resumed usual daily activities [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients with complicated myocardial infarctions should wait longer and at least until stabilized on a treatment regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The British Cardiovascular Society guidelines may be viewed as minimum safety guidelines for necessary travel. However, for elective travel, advising patients to demonstrate clinical stability for two to three weeks may be prudent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pacemakers and ICDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medically stable patients with pacemakers and implantable cardioverter-defibrillators (ICDs) are at low risk for inflight emergencies. They should carry a pacemaker card along with a copy of the most recent ECG done with and without a magnet. There is no evidence that airline electronics or airport security devices interfere with implanted pacemakers or ICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. There is a theoretical risk that the ICD might detect the alternating magnetic field created by the handheld wand, which could lead to an inadvertent shock or inhibition of the ICD's pacemaker output. Thus, patients with ICDs should request a hand search [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/4\">",
"     4",
"    </a>",
"    ]. Consult a representative from the pacemaker company if there is a question. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link&amp;anchor=H26#H26\">",
"     \"High altitude, air travel, and heart disease\", section on 'Implanted devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have recently suffered a stroke or other acute neurologic event should have ample time to recover and demonstrate stability before confronting the stresses of flying. Guidelines from the Aerospace Medical Association advise that a stroke within the past two weeks is a contraindication to air travel [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ]. However, this is on the basis of expert opinion rather than explicit evidence. Stable post-stroke patients may travel when considered safe by their neurologist, although we would suggest that a two-week period of observation post-stroke, when feasible, is reasonable to assess stability. &nbsp;",
"   </p>",
"   <p>",
"    Patients with migraines have reported travel in airplanes or trains as triggers of their headaches. The cause is unclear, and may relate to the stress of travel, sleep deprivation, high altitude, or other environmental stressors. Migraineurs, as with other patients, should be advised to maintain their prophylactic medicines and to carry rescue medication with them [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epilepsy is generally not a contraindication to flying; however, patients with frequent, severe seizures should not fly until their epilepsy is better controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significant cardiopulmonary disease can be severely compromised by even the small degree of hypoxia that occurs aboard commercial flights. The screening clinician must determine the degree of respiratory compromise, the ability to tolerate the inflight environment, and whether arrangements should be made for supplemental oxygen. A detailed discussion of how to determine the need for supplemental oxygen is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe, unstable asthma and those who have required recent hospitalization should not fly. Asthmatic patients who do fly should carry on their person a beta-2 selective adrenergic agonist metered dose inhaler and a course of oral steroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cystic fibrosis, bronchiectasis, or comparable diseases should be provided with appropriate antibiotic and secretion-clearing medications to be used before and during flight. They should stay well hydrated and use oxygen in flight, if indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Traditionally a pneumothorax is an absolute contraindication to air travel, and we still recommend not traveling until the pneumothorax resolves fully. Patients should have a chest x-ray to confirm resolution of a pneumothorax before flying. Guidelines from the British Thoracic Society recommend that it is prudent to wait seven days after x-ray resolution before flying and to delay flying for two weeks after traumatic pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/8\">",
"     8",
"    </a>",
"    ]. However, an observational study of 65 patients with a pneumothorax after percutaneous lung biopsy observed no complications with air travel within 14 days, including 50 patients with a residual pneumothorax on the chest x-ray taken within four days of travel [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35271?source=see_link\">",
"     \"Pneumothorax and air travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with sleep-disordered breathing diagnoses who use CPAP or BiPAP may plan to sleep during a flight. If so, they should be encouraged to bring their home machine onto the flight and to first check with the airline about policies and power supply for the machine (battery versus using the airplane&rsquo;s supply) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged travel appears to confer a two- to four-fold increase in risk of venous thromboembolism (VTE) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/11-20\">",
"     11-20",
"    </a>",
"    ]. This phenomenon was initially termed the \"economy class syndrome\" when applied to air travel but occurs in all air travel classes and is now referred to as &ldquo;traveler&rsquo;s thrombosis.&rdquo; The World Health Organization Research Into Global Hazards of Travel (WRIGHT) Project found that prolonged travel in general, including car or train, increased VTE risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/21\">",
"     21",
"    </a>",
"    ]. The period of risk for developing VTE after travel has been considered in various studies to range between two and eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 14 studies, the pooled risk for VTE in travelers, compared with nontravelers, was 2.8 (95% CI 2.2-3.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/19\">",
"     19",
"    </a>",
"    ]. The absolute incidence of symptomatic VTE in the month following a flight of at least four hours has been reported as 1 in 4600 flights [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/23\">",
"     23",
"    </a>",
"    ] or 1 in 6000 (16.6 per million) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/21\">",
"     21",
"    </a>",
"    ]. Several meta-analyses report an increased risk of deep vein thrombosis (DVT) among patients with baseline risk factors who flew longer than eight hours or further than 5000 kilometers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. One meta-analysis reports that the risk of DVT increases by 26 percent for every two-hour increment of air travel time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk is increased in individuals who have prior risk factors for VTE (eg, recent major surgery, including hip or knee arthroplasty within six weeks, increased age, obesity, prior VTE, use of oral contraceptives, malignancy, heart failure, hereditary thrombophilia) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/4,14,16,17,27-30\">",
"     4,14,16,17,27-30",
"    </a>",
"    ]. Prolonged air travel may pose an even higher thrombotic risk in those with two or more risk factors for VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Additionally, risk for pulmonary embolism with air travel is higher in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of DVT is likely to be higher than currently recognized, because asymptomatic thromboses are not likely to be identified unless complications ensue. In a randomized trial of previously-healthy patients who traveled at least eight hours per flight (median duration 24 hours), duplex ultrasonography revealed an asymptomatic DVT in 10 percent (12 of 116) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms of hypercoagulability with air travel are not completely clear. Immobility, with attendant venous stasis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/34\">",
"     34",
"    </a>",
"    ], is felt to explain much of the increased risk of prolonged travel. Other contributing factors may include hemoconcentration if fluid intake is restricted and hypobaric hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/4,35-37\">",
"     4,35-37",
"    </a>",
"    ] that may lead to activation of coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/31,37\">",
"     31,37",
"    </a>",
"    ], although not all studies confirm this [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated levels of coagulation factors (FII, FVIII, FIX, and fibrinogen) increased the risk of thrombosis in air travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/32\">",
"     32",
"    </a>",
"    ]. Targeted screening for levels of coagulation factors and prophylaxis might be justified for air travelers with other risks, although routine screening is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers may benefit from a number of maneuvers to prevent VTE during extended travel times (ie, flights of greater than six to eight hours duration). These include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moving about every hour or two",
"     </li>",
"     <li>",
"      Requesting bulkhead seating",
"     </li>",
"     <li>",
"      Refraining from smoking",
"     </li>",
"     <li>",
"      Avoiding constrictive clothing",
"     </li>",
"     <li>",
"      Flexing and extended the ankles and knees periodically; avoidance of leg crossing",
"     </li>",
"     <li>",
"      Frequent changes of position while seated",
"     </li>",
"     <li>",
"      Adequate consumption of fluids to avoid dehydration",
"     </li>",
"     <li>",
"      Avoiding agents that may promote immobility (eg, sedative drugs, alcoholic beverages)",
"     </li>",
"     <li>",
"      Use of below-knee compression stockings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compression stockings can decrease the incidence of DVT associated with prolonged flights. In a trial cited above in which the median duration of travel was 24 hours, duplex ultrasonography revealed an asymptomatic DVT in 10 percent of patients who did not wear below-knee compression stockings but in no patient assigned to the use of compression stockings [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/14\">",
"     14",
"    </a>",
"    ]. A systematic review of 10 randomized trials concluded that the use of compression stockings on flights lasting at least four hours led to a substantial reduction in the incidence of asymptomatic DVT (odds ratio 0.10; 95% CI 0.04-0.25) and leg edema [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/42\">",
"     42",
"    </a>",
"    ]. Guidelines from the British Committee for Standards in Hematology do not recommend global use of compression stockings, recommending their use for travellers at the highest risk who are on journeys of three hours duration or more [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients considered to be at high risk for VTE (previous VTE, recent surgery or trauma, active malignancy, pregnancy, estrogen use, limited mobility, severe obesity, or known thrombophilic disorder), use of properly fitted, below-knee graduated compression stockings (15 to 30 mmHg at the ankle) is recommended in guidelines from the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/43\">",
"     43",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    or other antiplatelet drugs are not effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/22,26,40,41,44\">",
"     22,26,40,41,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of anticoagulation therapy in decreasing risk for high-risk patients is unclear; an observational study of 608 patients who were anticoagulated and who traveled within six weeks of hip arthroplasty found a 1 percent incidence of symptomatic DVT, and no cases of pulmonary embolus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/45\">",
"     45",
"    </a>",
"    ]. In one small study, low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) (1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    given two to four hours prior to travel was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    started 12 hours prior to flight or control; there were no symptomatic DVTs among any passengers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/44\">",
"     44",
"    </a>",
"    ]. Asymptomatic DVTs occurred less frequently in the LMWH group (4.8 percent in controls, 3.6 percent with aspirin, and none in the LMWH group). The 2012 guidelines from the American College of Chest Physicians suggest against use of LMWH, pending stronger evidence that benefits outweigh the risk of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercial airline travel is generally safe for women with uncomplicated pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. There is no official national aviation policy regarding pregnant crew members or passengers. Fetal hemoglobin has a high affinity for oxygen, and the fetus is generally not at risk due to the hypoxic cabin environment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2,50\">",
"     2,50",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists does not recommend flight restrictions on women with uncomplicated pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/48,51\">",
"     48,51",
"    </a>",
"    ]. Some airlines require medical certificates for women who are pregnant beyond 36 or 37 weeks gestation.",
"   </p>",
"   <p>",
"    Any patient in her first trimester with abdominal pain or bleeding should be evaluated and ectopic pregnancy ruled out prior to flight. Furthermore, any patient at risk for premature delivery (eg, prior history, multiple gestations, cervical incompetence), with a condition that lowers placental respiratory reserve (eg, intrauterine growth retardation), or who is considered high risk (eg, preeclampsia, placenta previa) should probably not fly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial prenatal assessment and patient education\", section on 'Airline travel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstruction of the vena cava from uterine compression and altered clotting factors combined with immobility and dehydration place the pregnant passenger at especially increased risk for DVT. She should be encouraged to ambulate every hour or two and to follow the recommendations for DVT prevention. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Deep vein thrombosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active or contagious respiratory infections (eg, tuberculosis, pneumonia) are a contraindication to air travel until there is objective evidence of effective treatment (ie, two consecutive negative sputum cultures after at least six weeks of incubation) and the patient is clinically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/52\">",
"     52",
"    </a>",
"    ]. As of June 2007, federal agencies in the US have instituted a Do Not Board (DNB) list, restricting use of commercial air travel to persons who meet the following criteria: have a communicable disease that would be a threat to others, are nonadherent with public health recommendations, and are likely to attempt commercial travel [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/53\">",
"     53",
"    </a>",
"    ]. In the first year, all 33 persons on the DNB list had infectious pulmonary tuberculosis.",
"   </p>",
"   <p>",
"    An upper respiratory infection (URI), or cold, can cause blockage of the Eustachian tube making it difficult to equilibrate the air pressure in the middle ear during descent. This can lead to a number of problems including pain, vertigo, and tympanic membrane rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7417?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of inflight medical emergencies on commercial airlines\", section on 'Cabin environment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with URIs who cannot avoid flying may benefit from an oral decongestant and a nasal spray containing a vasoconstrictor used 30 minutes before descent. One randomized controlled trial found that oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    (120 mg taken at least 30 minutes before departure) reduced barotrauma in adults during flight; no trial has demonstrated the efficacy of nasal decongestants [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Patients should avoid alcoholic beverages and drink plenty of fluids to ensure hydration and to keep secretions thin and easier to clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nasal and sinus disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercial air travel is contraindicated for patients with severe sinusitis, large obstructing polyps, recent nasal or facial surgery, or severe recurrent epistaxis. Such conditions can obstruct sinus ostia preventing pressure equilibration and predisposing to extension of disease into the orbits or central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with allergic rhinitis, oral antihistamines and nasal steroids are helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;More patients now travel far from home for surgery and fly home soon after their procedure. Patients with significant comorbidities, pulmonary surgery, or postoperative anemia are at greater risk during flight and should be carefully assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. General anesthesia is not usually a concern, but postspinal headache has been reported seven days after a spinal anesthetic, possibly because changes in cabin pressure induced a dural leak [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Invasive procedures introduce air into isolated body cavities that could expand at altitude in a pressurized cabin and cause barotrauma. Thus, patients should postpone air travel until at least 10 to 14 days after most surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2,50\">",
"     2,50",
"    </a>",
"    ]. This delay should provide enough time for air in the intrathoracic, intraabdominal, or other cavities to be resorbed, and reduces the risk for barotrauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7417?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of inflight medical emergencies on commercial airlines\", section on 'Cabin environment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35271?source=see_link\">",
"     \"Pneumothorax and air travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laparoscopic abdominal procedures are less often associated with ileus than open procedures. The carbon dioxide introduced into the peritoneum during the procedure rapidly diffuses into the tissues, and patients can usually fly the next day if they do not have bloating. However, this has not been evaluated in a clinical trial.",
"   </p>",
"   <p>",
"    Patients who have undergone a colonoscopy with polypectomy should wait at least 24 hours before flying because of the large amount of gas often present in the colon and the risk of bleeding or perforation at the polypectomy site.",
"   </p>",
"   <p>",
"    Patients with colostomies are not at increased risk inflight, but increased fecal output resulting from intestinal distention may occur. A larger bag or frequent changes may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have had intraocular surgery within one week need to consult with their ophthalmologist. If there is gas in the globe, it is necessary to wait until total absorption occurs. This could be up to six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with full-leg casts, for safety reasons, may be required to travel by stretcher, purchase an extra seat, or fly business or first class. Casts applied within 48 hours should be split lengthwise along each side (ie, bivalved) to avoid injury from the expansion of air trapped between the skin and the cast if the limb swells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ]. Pneumatic splints should be partially deflated to avoid rupture from expanding gas.",
"   </p>",
"   <p>",
"    Patients with a fractured jaw that is wired require travel with wire cutters and an escort familiar with what to do, unless the individual is fitted with self quick-release wiring. Emergency release of wires may be needed in the event of a compromised airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemoglobin below 8.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    generally should be given supplemental oxygen, unless the anemia is known to be well compensated. Anemic patients are at risk for lightheadedness and loss of consciousness during flight, even with minimal exertion, eg, walking to the lavatory. The relative hypoxia in the cabin poses a particular risk to patients with sickle cell anemia. Such patients should use supplemental oxygen and be kept well hydrated. Those with sickle cell trait are not considered at risk for flights at normal altitudes under usual conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2,50\">",
"     2,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Scuba diving and decompression sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A passenger who has recently been scuba diving is at increased risk for developing decompression sickness (DCS) inflight [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/3\">",
"     3",
"    </a>",
"    ]. Dive computers are now widely available that calculate when flying is safe, based upon the number, depth, and duration of dives in days preceding the anticipated flight. When such technology is not available, passengers who have been making only one dive per day should be advised to wait 12 hours before flying. Individuals who have participated in multiple dives, or dives requiring decompression stops, should consider waiting 24 hours, and up to 48 hours, before flying [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of scuba diving\", section on 'Decompression sickness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nitrogen dissolved in body tissues may not create problems at sea level; at altitude, however, nitrogen may come out of solution and form bubbles, causing DCS. This diagnosis may be considered in patients with appropriate physical complaints and a history of recent scuba diving. Complaints can vary widely in severity and may include musculoskeletal pain, air embolism, and a range of neurologic problems, varying widely in severity, from tingling and mild confusion to paraplegia. All symptoms should resolve with recompression.",
"   </p>",
"   <p>",
"    The patient should be made comfortable with analgesics, and supplemental oxygen should be given. Arrangements should be made for rapid transport to a hyperbaric chamber for decompression. A 24-hour emergency hotline for the Divers Alert Network (DAN) is available (",
"    <a class=\"external\" href=\"file://www.diversalertnetwork.com/\">",
"     www.diversalertnetwork.com",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of scuba diving\", section on 'Decompression sickness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic patients generally tolerate travel without difficulty. Wearing a medical alert bracelet is recommended. Preflight planning is important to ensure ready access to simple sugars and insulin, and to adjust insulin dosing schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"     2",
"    </a>",
"    ]. As a general rule, when traveling east the day is shortened and less insulin may be needed; when traveling west the day is lengthened and more insulin may be needed.",
"   </p>",
"   <p>",
"    Clinicians should emphasize the importance of having both snacks and fast-acting insulin with all necessary equipment on their person when flying. Insulin will denature if exposed to extreme cold and should not be checked. According to the American Diabetes Association, unrefrigerated insulin remains usable for up to one month if kept at temperatures below 30&ordm;C (86&ordm;F).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mental illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with psychiatric disorders that predispose to violent, disruptive, unsafe, or unpredictable behavior should not travel by air, nor should patients at risk for alcohol or drug withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RESOURCES FOR CLINICIANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Aerospace Medical Association (AsMA) can provide support for medical information. AsMA can be contacted by telephone (703-739-2240). Their website (",
"    <a class=\"external\" href=\"file://www.asma.org/\">",
"     www.asma.org",
"    </a>",
"    ) provides links to many national and international aerospace medical organizations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=see_link\">",
"       \"Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients preparing for air travel should be counseled on adjusting the timing of their medicines. Patients should carry on their person (not checked with baggage) a list of all medical conditions and allergies, list of all medications, unexpired medicines in their original labeled containers, and a recent electrocardiogram (ECG) for cardiac patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General screening and health counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are fully ambulatory and at very low risk of complications after an uncomplicated myocardial infarction or an uncomplicated percutaneous coronary intervention (age &lt;65 years, ejection fraction &gt;45 percent, no symptoms of angina or heart failure) are likely safe flying after three days, with appropriate precautions. Patients who have had an acute coronary syndrome and who do not meet these criteria should not fly until stable and at least two to three weeks have passed. Unstable angina is a contraindication to air travel; stable angina is generally well tolerated during flight. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cardiovascular'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link&amp;anchor=H17#H17\">",
"       \"High altitude, air travel, and heart disease\", section on 'Air travel'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have had a stroke should be observed for stability prior to travel. We advise that a two-week period, when feasible, is appropriate for this observation; earlier travel may be reasonable for stable patients at the discretion of their neurologist. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Neurologic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with significant cardiopulmonary disease can be severely compromised by the small degree of hypoxia that occurs aboard commercial flights and should be evaluated for the need for supplemental oxygen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"       \"Traveling with oxygen aboard commercial air carriers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolonged travel appears to confer a two- to fourfold increase in risk of venous thromboembolism (VTE). Moving about during the flight, frequent change of positions, and maintaining hydration may help prevent VTE. For patients considered to be at high risk for VTE, the treating physician may recommend use of properly fitted, below-knee graduated compression stockings. There is insufficient evidence to recommend pharmacologic prophylaxis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Deep vein thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with significant respiratory infection (eg, pneumonia or tuberculosis) should not fly. Air travel is contraindicated for patients with severe sinusitis, recent facial surgery, or recurrent severe epistaxis. Patients with upper respiratory infections (URIs) who cannot avoid flying may benefit from an oral decongestant and a nasal spray containing a vasoconstrictor used 30 minutes before descent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Respiratory infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Nasal and sinus disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should postpone air travel until at least 10 to 14 days after most open surgical procedures. Patients who have undergone a colonoscopy with polypectomy should wait at least 24 hours before flying. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hemoglobin below 8.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      generally should be given supplemental oxygen, unless the anemia is known to be well compensated. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recent scuba diving increases risk for developing decompression sickness (DCS) inflight [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13737/abstract/3\">",
"       3",
"      </a>",
"      ]. Passengers may use a dive computer, if available, to calculate time for safe flight; alternatively, those who have made one dive per day should wait 12 hours before flying, and individuals who have participated in multiple dives, or dives requiring decompression stops, should wait up to 48 hours before flying. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Scuba diving and decompression sickness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/1\">",
"      Office of Secretary, Department of Transportation (DOT). Non discrimination on the basis of disability in air travel. Final rule. Fed Regist 2001; 66:22107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/2\">",
"      Aerospace Medical Association Medical Guidelines Task Force. Medical Guidelines for Airline Travel, 2nd ed. Aviat Space Environ Med 2003; 74:A1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/3\">",
"      Gendreau MA, DeJohn C. Responding to medical events during commercial airline flights. N Engl J Med 2002; 346:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/4\">",
"      Possick SE, Barry M. Evaluation and management of the cardiovascular patient embarking on air travel. Ann Intern Med 2004; 141:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/5\">",
"      Johnson AO. Chronic obstructive pulmonary disease * 11: fitness to fly with COPD. Thorax 2003; 58:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/6\">",
"      Smith D, Toff W, Joy M, et al. Fitness to fly for passengers with cardiovascular disease. Heart 2010; 96 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/7\">",
"      Evans RW, Purdy RA, Goodman SH. Airplane descent headaches. Headache 2007; 47:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/8\">",
"      Ahmedzai S, Balfour-Lynn IM, Bewick T, et al. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2011; 66 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/9\">",
"      Tam A, Singh P, Ensor JE, et al. Air travel after biopsy-related pneumothorax: is it safe to fly? J Vasc Interv Radiol 2011; 22:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/10\">",
"      Walker J, Kelly PT, Beckert L. Airline policies for passengers with obstructive sleep apnoea who require in-flight continuous positive airways pressure. Respirology 2010; 15:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/11\">",
"      P&eacute;rez-Rodr&iacute;guez E, Jim&eacute;nez D, D&iacute;az G, et al. Incidence of air travel-related pulmonary embolism at the Madrid-Barajas airport. Arch Intern Med 2003; 163:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/12\">",
"      Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic disease: a case-control study. Chest 1999; 115:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/13\">",
"      Kelman CW, Kortt MA, Becker NG, et al. Deep vein thrombosis and air travel: record linkage study. BMJ 2003; 327:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/14\">",
"      Scurr JH, Machin SJ, Bailey-King S, et al. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet 2001; 357:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/15\">",
"      Giangrande PL. Air travel and thrombosis. Br J Haematol 2002; 117:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/16\">",
"      Schwarz T, Siegert G, Oettler W, et al. Venous thrombosis after long-haul flights. Arch Intern Med 2003; 163:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/17\">",
"      Martinelli I, Taioli E, Battaglioli T, et al. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. Arch Intern Med 2003; 163:2771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/18\">",
"      Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001; 345:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/19\">",
"      Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med 2009; 151:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/20\">",
"      MacCallum PK, Ashby D, Hennessy EM, et al. Cumulative flying time and risk of venous thromboembolism. Br J Haematol 2011; 155:613.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Reserach Into Global Hazards of Travel (WRIGHT) Project. Final report of phase 1. Available at: www.who.int/cardiovascular_diseases/wright_project/phase1_report/WRIGHT%20REPORT.pdf (Accessed on May 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/22\">",
"      Watson HG, Baglin TP. Guidelines on travel-related venous thrombosis. Br J Haematol 2011; 152:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/23\">",
"      Kuipers S, Cannegieter SC, Middeldorp S, et al. The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med 2007; 4:e290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/24\">",
"      Watson HG. Travel and thrombosis. Blood Rev 2005; 19:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/25\">",
"      Adi Y, Bayliss S, Rouse A, Taylor RS. The association between air travel and deep vein thrombosis: systematic review &amp; meta-analysis. BMC Cardiovasc Disord 2004; 4:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/26\">",
"      Philbrick JT, Shumate R, Siadaty MS, Becker DM. Air travel and venous thromboembolism: a systematic review. J Gen Intern Med 2007; 22:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/27\">",
"      Paganin F, Bourd&eacute; A, Yvin JL, et al. Venous thromboembolism in passengers following a 12-h flight: a case-control study. Aviat Space Environ Med 2003; 74:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/28\">",
"      Gajic O, Warner DO, Decker PA, et al. Long-haul air travel before major surgery: a prescription for thromboembolism? Mayo Clin Proc 2005; 80:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/29\">",
"      Arya R, Barnes JA, Hossain U, et al. Long-haul flights and deep vein thrombosis: a significant risk only when additional factors are also present. Br J Haematol 2002; 116:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/30\">",
"      Hughes RJ, Hopkins RJ, Hill S, et al. Frequency of venous thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Traveller's Thrombosis (NZATT) study. Lancet 2003; 362:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/31\">",
"      Schreijer AJ, Cannegieter SC, Meijers JC, et al. Activation of coagulation system during air travel: a crossover study. Lancet 2006; 367:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/32\">",
"      Kuipers S, Cannegieter SC, Doggen CJ, Rosendaal FR. Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. Blood 2009; 113:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/33\">",
"      Lapostolle F, Le Toumelin P, Chassery C, et al. Gender as a risk factor for pulmonary embolism after air travel. Thromb Haemost 2009; 102:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/34\">",
"      Delis KT, Knaggs AL, Sonecha TN, et al. Lower limb venous haemodynamic impairment on dependency: quantification and implications for the \"economy class\" position. Thromb Haemost 2004; 91:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/35\">",
"      Arfvidsson B, Eklof B, Kistner RL, et al. Risk factors for venous thromboembolism following prolonged air travel. Coach class thrombosis. Hematol Oncol Clin North Am 2000; 14:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/36\">",
"      B&auml;rtsch P, Straub PW, Haeberli A. Hypobaric hypoxia. Lancet 2001; 357:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/37\">",
"      Schreijer AJ, Hoylaerts MF, Meijers JC, et al. Explanations for coagulation activation after air travel. J Thromb Haemost 2010; 8:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/38\">",
"      Boccalon H, Boneu B, Emmerich J, et al. Long-haul flights do not activate hemostasis in young healthy men. J Thromb Haemost 2005; 3:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/39\">",
"      Toff WD, Jones CI, Ford I, et al. Effect of hypobaric hypoxia, simulating conditions during long-haul air travel, on coagulation, fibrinolysis, platelet function, and endothelial activation. JAMA 2006; 295:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/40\">",
"      Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/41\">",
"      Chee YL, Watson HG. Air travel and thrombosis. Br J Haematol 2005; 130:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/42\">",
"      Clarke M, Hopewell S, Juszczak E, et al. Compression stockings for preventing deep vein thrombosis in airline passengers. Cochrane Database Syst Rev 2006; :CD004002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/43\">",
"      Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e195S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/44\">",
"      Cesarone MR, Belcaro G, Nicolaides AN, et al. Venous thrombosis from air travel: the LONFLIT3 study--prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology 2002; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/45\">",
"      Ball ST, Pinsorsnak P, Amstutz HC, Schmalzried TP. Extended travel after hip arthroplasty surgery. Is it safe? J Arthroplasty 2007; 22:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/46\">",
"      Daniell WE, Vaughan TL, Millies BA. Pregnancy outcomes among female flight attendants. Aviat Space Environ Med 1990; 61:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/47\">",
"      Huch R, Baumann H, Fallenstein F, et al. Physiologic changes in pregnant women and their fetuses during jet air travel. Am J Obstet Gynecol 1986; 154:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/48\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 443: Air travel during pregnancy. Obstet Gynecol 2009; 114:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/49\">",
"      Freeman M, Ghidini A, Spong CY, et al. Does air travel affect pregnancy outcome? Arch Gynecol Obstet 2004; 269:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/50\">",
"      Bettes TN, McKenas DK. Medical advice for commercial air travelers. Am Fam Physician 1999; 60:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/51\">",
"      Breathnach F, Geoghegan T, Daly S, Turner MJ. Air travel in pregnancy: the 'air-born' study. Ir Med J 2004; 97:167.",
"     </a>",
"    </li>",
"    <li>",
"     Tuberculosis and air travel: Guidelines for prevention and control. World Health Organization. 3rd ed. 2008. Available at: file://www.who.int/tb/publications/2008/WHO_HTM_TB_2008.399_eng.pdf (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Federal air travel restrictions for public health purposes--United States, June 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/54\">",
"      Mirza S, Richardson H. Otic barotrauma from air travel. J Laryngol Otol 2005; 119:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/55\">",
"      Jones JS, Sheffield W, White LJ, Bloom MA. A double-blind comparison between oral pseudoephedrine and topical oxymetazoline in the prevention of barotrauma during air travel. Am J Emerg Med 1998; 16:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/56\">",
"      Vacanti JJ. Post-spinal headache and air travel. Anesthesiology 1972; 37:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/57\">",
"      Sheffield PJ. Flying after diving guidelines: a review. Aviat Space Environ Med 1990; 61:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13737/abstract/58\">",
"      Freiberger JJ, Denoble PJ, Pieper CF, et al. The relative risk of decompression sickness during and after air travel following diving. Aviat Space Environ Med 2002; 73:980.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2788 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13737=[""].join("\n");
var outline_f13_26_13737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL SCREENING AND HEALTH COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIFIC PREEXISTING CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12301545\">",
"      - Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pacemakers and ICDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nasal and sinus disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Scuba diving and decompression sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mental illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RESOURCES FOR CLINICIANS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/31/13821\" title=\"table 1\">",
"      Contraindications air travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/6/22636\" title=\"table 2\">",
"      Recommendations to cardiopulmonary patients who fly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=related_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=related_link\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7417?source=related_link\">",
"      Management of inflight medical emergencies on commercial airlines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=related_link\">",
"      Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35271?source=related_link\">",
"      Pneumothorax and air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8967?source=related_link\">",
"      Travel advice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_26_13738="Overview of treatment for adolescent depression";
var content_f13_26_13738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of treatment for adolescent depression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13738/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13738/contributors\">",
"     Liza Bonin, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13738/contributors\">",
"     C Scott Moreland, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13738/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13738/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13738/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/26/13738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/26/13738/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/26/13738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression among adolescents, which typically presents in primary care, is underdiagnosed and undertreated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/1\">",
"     1",
"    </a>",
"    ]. An estimated 70 percent of depressed teenagers do not receive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the treatment of adolescent depression. The diagnosis of depression in adolescents is discussed separately, as is the treatment of depression in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been few well-designed controlled trials of treatments for adolescent depression. Current practice guidelines for treating adolescent depression are based upon existing data from studies in depressed adolescents, adult depression research, and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Two major multisite NIMH initiatives have been implemented to address the lack of objective information regarding the treatment of adolescent depression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Treatment for Adolescents with Depression Study (TADS) was launched in 1998. This trial was designed to evaluate the short- (12-week) and long-term (36-week) efficacy of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (a selective serotonin reuptake inhibitor [SSRI]), cognitive behavioral therapy (CBT), fluoxetine plus CBT, and pill placebo in adolescents with major depressive disorder (MDD) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/9\">",
"       9",
"      </a>",
"      ]. Adolescents considered to be at high risk of suicide (suicide attempt requiring medical attention within the previous six months, clear intent or active plan to commit suicide, or suicidal ideation with a family unable to guarantee safety) were excluded from the study. Both phases of the trial have been completed [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]; the results are summarized below. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'TADS'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The Treatment of Resistant Depression In Adolescents (TORDIA) study was initiated in 2001 to determine how to best treat the 40 percent of adolescents with MDD whose depressive symptoms do not respond to the first SSRI they have tried. Participants (334 patients aged 12 to 18 years) were randomly assigned to one of four groups: switching to an alternative SSRI (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ); switching to a non-SSRI antidepressant (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ); switching to an alternative SSRI and CBT; or switching to venlafaxine and CBT. Results were published in 2008 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/12\">",
"       12",
"      </a>",
"      ]. The results of this study are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link&amp;anchor=H36#H36\">",
"       \"Psychopharmacological treatment for adolescent depression\", section on 'Resistant depression'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TADS and TORDIA provide evidence-based guidelines for how to best initiate treatment for adolescents with depression and how to respond if the first intervention is not effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical course of a major depressive episode in adolescence is seven to nine months; 90 percent of adolescent depressions remit within two years. Relapse is common; the cumulative probability of recurrence is 40 percent by two years and 70 percent by five years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/3,5,13-16\">",
"     3,5,13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major depressive disorder and the terms used to describe its clinical course are defined below [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,13,17-19\">",
"     5,13,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major depressive disorder &mdash; Major depressive disorder (MDD) is characterized by a history of one or more major depressive episodes in the absence of manic, hypomanic, or mixed episodes of mood disturbance. To meet DSM-IV criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/20\">",
"       20",
"      </a>",
"      ], the adolescent must display at least five depressive symptoms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Depressed or irritable mood",
"     </li>",
"     <li>",
"      Markedly diminished interest or pleasure in almost all activities",
"     </li>",
"     <li>",
"      Change in appetite or weight",
"     </li>",
"     <li>",
"      Insomnia or hypersomnia",
"     </li>",
"     <li>",
"      Psychomotor agitation or retardation",
"     </li>",
"     <li>",
"      Fatigue or loss of energy",
"     </li>",
"     <li>",
"      Feelings of worthlessness or guilt",
"     </li>",
"     <li>",
"      Impaired concentration, indecisiveness",
"     </li>",
"     <li>",
"      Recurring thoughts of death or suicide",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the symptoms must be either depressed mood or loss of interest or pleasure that is present for most of the day, nearly every day, for at least two weeks, with the remaining symptoms present during the same period. The symptoms must cause clinically significant distress or impairment and represent a change from previous functioning. They must not be caused by the direct effects of a substance (eg, drug abuse or medications) or a medical condition (eg, hypothyroidism), and they must not be better accounted for by bereavement. A history of a prior manic episode in addition to these criteria suggests the diagnosis of bipolar disorder.",
"   </p>",
"   <p>",
"    Additional features of MDD and diagnosis of MDD in adolescents are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical course is classified using six categories [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,17,21\">",
"     5,17,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Response &mdash; Significant reduction (usually &gt;50 percent) of depressive symptoms during the acute treatment phase. Response usually coincides with the onset of remission. Clinical improvement typically is monitored using standardized depression rating scales as well as measures of overall psychosocial functioning (",
"      <a class=\"graphic graphic_table graphicRef70455 \" href=\"UTD.htm?22/48/23309\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Remission &mdash; A period of &ge;2 weeks and &lt;2 months with no clinically significant depressive symptoms, as listed above (eg, depression rating scale scores and psychosocial functioning indices within normal limits, (",
"      <a class=\"graphic graphic_table graphicRef70455 \" href=\"UTD.htm?22/48/23309\">",
"       table 1",
"      </a>",
"      )).",
"     </li>",
"     <li>",
"      Partial remission &mdash; A period of &ge;2 weeks and &lt;2 months with one or more clinically significant depressive symptom(s), but fewer symptoms than the full MDD syndrome.",
"     </li>",
"     <li>",
"      Relapse &mdash; An episode of depression during the period of remission.",
"     </li>",
"     <li>",
"      Recovery &mdash; A asymptomatic period of more than two months.",
"     </li>",
"     <li>",
"      Recurrence &mdash; The emergence of symptoms of MDD during the period of recovery (a new episode).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment requires cooperation and involvement of the parents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ]. Parents and professionals must work together to establish the optimal treatment while weighing the risks and benefits of the interventions.",
"   </p>",
"   <p>",
"    Education of the adolescent and his or her family is an important component of depression treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,6,22-25\">",
"     5,6,22-25",
"    </a>",
"    ]. Education helps patients and family members to become informed partners in the treatment team. In addition, it may help other family members to identify their own depressive symptoms and need for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,22,23\">",
"     5,22,23",
"    </a>",
"    ]. Finally, adequate education decreases the likelihood of withdrawal from treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,26\">",
"     5,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Education may provide relief for many adolescents and their families by providing a framework for understanding the symptoms of depression and the ways in which the symptoms have affected their personal interactions. With education, patients and family members can understand depression as an illness, which reduces feelings of stigmatization and highlights the importance of compliance with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ]. Education can help the patient and family members to identify signs and symptoms of depression and address psychosocial deficits. The development of supportive and understanding relationships can improve the family's global functioning and the treatment outcome for the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topics to be addressed in the educational component include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Developmentally appropriate signs and symptoms of depression (so that they can recognize relapse early in its course). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of medication in therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link\">",
"       \"Psychopharmacological treatment for adolescent depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical course of depression, including the likelihood of relapse and recurrence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical course and definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The impact of depression on peer and family relationships, school attendance, and academic functioning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link&amp;anchor=H3#H3\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\", section on 'Impact of depression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of parents and teachers in recovery.",
"     </li>",
"     <li>",
"      The importance of taking active steps to limit an adolescent's access to means for self-harm (eg, dangerous medications, weapons, etc), particularly when there are concerns about suicidal ideation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link\">",
"       \"Evaluation and management of suicidal behavior in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A topic review for parents and adolescents that discusses depression in adolescents is available separately. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Information for patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TYPES OF INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three general categories of intervention for adolescent depression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychosocial interventions",
"     </li>",
"     <li>",
"      Pharmacologic therapy",
"     </li>",
"     <li>",
"      Combination therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Psychosocial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial interventions teach patients and their families to understand themselves and the nature of depression, as well as to effectively manage relationships and life stressors associated with depression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ]. They help the patient to cope with depressive symptoms, improve social and self-management skills, and increase self-confidence. In addition, psychological interventions may prevent onset of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychosocial treatments include, but are not limited to, cognitive-behavioral therapy (CBT), interpersonal therapy for adolescents (IPT-A), family therapy, dynamic therapy, group therapy, and supportive therapy. Among these, only CBT and IPT-A are considered to be evidence-based by the American Psychological Association's Society of Clinical Psychology. Psychosocial treatment for adolescent depression is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=see_link\">",
"     \"Psychosocial treatment for adolescent depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic agents that have been used to treat adolescent major depression include tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) and related compounds. There is some evidence from published studies to support the use of SSRI, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , in the treatment of adolescent depression. However, the use of antidepressants in children and adolescents has been associated with a slightly increased risk of suicidal thoughts and behaviors.",
"   </p>",
"   <p>",
"    The use of TCA and SSRI in the treatment of adolescent major depression and the risk of suicide with antidepressant therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link\">",
"     \"Psychopharmacological treatment for adolescent depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Combination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy uses both psychosocial and pharmacologic interventions. We suggest combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and CBT as the initial treatment for adolescents with MDD.",
"   </p>",
"   <p>",
"    Balancing the risks and benefits, as discussed below, combination therapy appears to be superior to monotherapy with SSRI or CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10,11,32-37\">",
"     10,11,32-37",
"    </a>",
"    ]. However, findings from the Adolescent Depression Antidepressant and Psychotherapy Trial (ADAPT) suggest that monotherapy with SSRI may be a reasonable option for adolescents with moderate to severe depression, particularly if access to CBT may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, long-term follow-up for up to five years after treatment found no significant difference in the rate of recovery or recurrence between combination treatment and monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     TADS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term combination therapy is supported by the results of the Treatment for Adolescent Depression Study (TADS), which compared the effectiveness of four treatments for MDD in adolescents:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (an SSRI); CBT; combination fluoxetine and CBT; and pill placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. After the first 12 weeks, patients were treated openly; the analysis of long-term (36 weeks) safety and effectiveness included only those 327 patients who were initially assigned to an active treatment group.",
"   </p>",
"   <p>",
"    The primary outcome measures were the Children's Depression Rating Scale-Revised (CDRS-R) and a dichotomized Clinical Global Impression improvement (CGI-I) score, in which a positive response was defined as a CGI score of 1 or 2: very much improved or much improved, respectively (",
"    <a class=\"graphic graphic_table graphicRef70455 \" href=\"UTD.htm?22/48/23309\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over the course of therapy, all groups had improved scores on the CDRS-R (",
"      <a class=\"graphic graphic_table graphicRef70455 \" href=\"UTD.htm?22/48/23309\">",
"       table 1",
"      </a>",
"      ). During the first 12 weeks, the greatest improvement in depressive symptoms based upon the CDRS-R occurred in the group treated with combination",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      and CBT (",
"      <a class=\"graphic graphic_figure graphicRef51677 \" href=\"UTD.htm?31/5/31838\">",
"       figure 1",
"      </a>",
"      ); this was the only group that differed significantly from placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10\">",
"       10",
"      </a>",
"      ]. In the long-term study, combination therapy and fluoxetine were superior to CBT at 6, 12, and 18 weeks, but by 30 weeks, the three treatments converged [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the research setting, initial treatment with placebo for 12 weeks was not associated with harm or diminished response to subsequent treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/40\">",
"       40",
"      </a>",
"      ]. This observation suggests that placebo treatment is an acceptable intervention in randomized controlled trials for adolescent depression. It does NOT suggest that it is acceptable to delay the onset of active treatment of adolescent depression in nonresearch settings.",
"     </li>",
"     <li>",
"      When treatment response was measured by the Clinical Global Impression Improvement score (CGI-I, (",
"      <a class=\"graphic graphic_table graphicRef70455 \" href=\"UTD.htm?22/48/23309\">",
"       table 1",
"      </a>",
"      )) at 12 weeks,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      alone was effective, but not as effective as the combination of fluoxetine and CBT [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10\">",
"       10",
"      </a>",
"      ]. The response rates were 71 percent for combination therapy, 61 percent for fluoxetine, 43 percent for CBT, and 35 percent for placebo (CBT monotherapy was not statistically different than placebo). By 24 weeks, the three treatments converged [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The mean highest dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      was lower in the combination group than in the fluoxetine monotherapy group (28.4 versus 33.3",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      and CBT appeared to be protective against harm-related adverse events (nonsuicidal self-harm, worsening of suicidal ideation without self-harm, suicide attempt, aggressive or violent ideation or action against another person or property) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=see_link\">",
"       \"Effect of antidepressants on suicide risk in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The response rate for CBT monotherapy in TADS at 12 weeks was lower than that described in other studies (43 versus approximately 60 percent). However, in the second phase of TADS, the response rate for CBT increased to 65 percent at week 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/11\">",
"     11",
"    </a>",
"    ]. This supports the hypothesis that the increased severity of illness in TADS patients compared to those in other studies delayed the onset of benefit for CBT relative to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/11\">",
"     11",
"    </a>",
"    ]. This is consistent with results of trials in adults in which the comparative of strength of CBT is greater during follow-up than acute treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial treatment of depression in adults\", section on 'Psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding rates of remission, speed of recovery, safety, function and quality of life, and predictors of outcome at 12 and 36 weeks were reported separately [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/42-47\">",
"     42-47",
"    </a>",
"    ]. Key findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission occurred in 23 percent of patients overall but was more frequent in patients treated with combination therapy (odds ratio 2.1 for combination therapy versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , 3.3 for combination therapy versus CBT, and 3.0 for combination therapy versus placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/42\">",
"       42",
"      </a>",
"      ]. At 36 weeks, the remission rates in all treatment groups were approximately 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recovery occurred earlier in patients treated with combination therapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      than in those treated with CBT or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/43\">",
"       43",
"      </a>",
"      ]. Between 65 and 72 percent of patients who achieved remission during acute treatment met criteria for recovery at 36 weeks; the recovery rate was similar across groups [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      was associated with an increased risk of suicide related events (9 percent versus approximately 5 percent in the combination and CBT groups, and 3 percent in the placebo group) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combination therapy was effective in improving functioning, global health, and quality of life;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      therapy improved functioning, but not other parameters [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Younger and less severely impaired adolescents responded better than older, more impaired adolescents or those with comorbid diagnoses [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combined results of the acute and long-term phases of the TADS, as well as the subgroup analyses, suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , CBT, and combination therapy are effective over a course of 36 weeks. Response occurs earlier in patients treated with fluoxetine, with or without CBT. However, CBT appears to protect against treatment-emergent suicidal events in patients taking fluoxetine.",
"   </p>",
"   <p>",
"    Considering the risks and benefits, combination therapy appears to be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    or CBT across 36 weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/11\">",
"     11",
"    </a>",
"    ]. Fluoxetine monotherapy is an alternative for patients with moderate to severe depression when CBT is not readily available, provided that the patient is monitored closely [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link&amp;anchor=H37#H37\">",
"     \"Psychopharmacological treatment for adolescent depression\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term observational follow-up was conducted in 196 patients treated in the TADS trial for up to five years after study entry [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/39\">",
"     39",
"    </a>",
"    ]. Nearly all of these patients eventually recovered (96 percent), and recovery was not significantly associated with any of the short-term treatments (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , CBT, combination, or pill placebo). Of the 189 patients who recovered, 47 percent subsequent suffered a recurrence. Recurrence was not associated with the initial treatment received, but recurrence was significantly higher among females compared with males (57 versus 33 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     ADAPT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Adolescent Depression Antidepressant and Psychotherapy Trial (ADAPT) compared SSRI and routine specialist care with and without CBT in 208 adolescents (aged 11 to 17 years) with moderate to severe major or probable major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/34\">",
"     34",
"    </a>",
"    ]. ADAPT included only patients with persistent depression and did not exclude patients with active suicidal intent, self harm, thought disorder, depressive psychosis, or conduct disorder.",
"   </p>",
"   <p>",
"    Combination therapy with SSRI and CBT was no more beneficial than monotherapy with SSRI [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/34\">",
"     34",
"    </a>",
"    ]. The treatment effect was similar in both groups after 12 weeks (with 40 and 43 percent of patients much or very much improved, respectively) and after 28 weeks (with 53 and 61 percent much or very much improved, respectively). Symptoms of suicidality and self-harm improved over time in both groups; treatment with CBT did not appear to be protective for suicidality.",
"   </p>",
"   <p>",
"    These results are consistent with those of a smaller trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/35\">",
"     35",
"    </a>",
"    ], but differ from those of the acute phase of the TADS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/10\">",
"     10",
"    </a>",
"    ]. The discrepant results may be related to the low attendance rates for CBT in ADAPT, differences in dose of or duration of therapy with SSRI, choice of outcome measure, or differing patient populations (patients in ADAPT were more severely impaired than those in TADS) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/38,46\">",
"     38,46",
"    </a>",
"    ]. Moreover, a significant methodological weakness in the ADAPT involved the implementation of the CBT treatment condition. Specifically, the CBT was not delivered using a systematic protocol specific for depression and the method of evaluating the integrity of the CBT provided did not involve assessment of variables generally deemed central to effective psychosocial management of depression. Nonetheless, the results are consistent with subgroup analysis of TADS, which found no greater response with combination therapy than SSRI monotherapy in more severely affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, ADAPT and TADS findings suggest that although combination therapy is preferred, monotherapy with SSRI may be a reasonable option for adolescents with moderate to severe depression, particularly if access to CBT is delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/11,38,43,46\">",
"     11,38,43,46",
"    </a>",
"    ]. If undertaken, such treatment should be accompanied by frequent clinical review and careful monitoring for benefit and adverse effects, particularly suicidal ideation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link&amp;anchor=H37#H37\">",
"     \"Psychopharmacological treatment for adolescent depression\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Electroconvulsive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroconvulsive therapy can be effective in the treatment of depression in adolescents. However it is only used as a last resort and with the caregivers' consent and adolescent's assent. In addition, state and local hospital guidelines must be followed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical response rate to monotherapy with psychosocial or pharmacologic interventions for MDD is approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/21,48-50\">",
"     21,48-50",
"    </a>",
"    ]; the rate of remission is between 35 and 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=see_link\">",
"     \"Psychosocial treatment for adolescent depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link\">",
"     \"Psychopharmacological treatment for adolescent depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the response and remission rates of monotherapy are so low, expert clinicians often recommend combined treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,36,37,51\">",
"     5,36,37,51",
"    </a>",
"    ]. Even though SSRI monotherapy has been associated with more rapid improvement, the TADS outcomes suggest that combined treatment is advantageous in multiple other domains: promoting remission, improving functionality, protecting against treatment-emergent suicidal events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHASES OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of depressive disorders should include an acute and continuation phase; some children also require maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment in the acute phase of therapy is improvement in symptoms and return to near-baseline mood. This usually takes from 6 to 12 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Safety concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first phase of treatment involves addressing potential safety concerns. Every adolescent identified as depressed must be evaluated for suicide risk and if risk is identified, safety must be assured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link\">",
"     \"Evaluation and management of suicidal behavior in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of the initial therapy in the acute phase depends upon the severity of depression, number of previous episodes, chronicity of depression, subtype of depression, age, contextual issues (eg, family conflict, academic problems, negative life events), comorbid diagnoses, suicidality, compliance with treatment, previous response to treatment, the patient's and family's motivation for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ], and their assessment of the balance of risks and benefits of therapy. Other factors to be considered include clinician availability, motivation, and expertise with a specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychotherapy may be a useful initial acute treatment for mild or uncomplicated depression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=see_link\">",
"       \"Psychosocial treatment for adolescent depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic intervention is indicated for adolescents with non-rapid cycling bipolar depression, psychotic depression, depression with severe symptoms that prevent effective psychotherapy, and depression that fails to respond to an adequate trial of psychotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"       5",
"      </a>",
"      ]. The initiation of pharmacologic therapy for adolescent depression and the possible association between antidepressants and suicidal thoughts or behaviors are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link&amp;anchor=H30#H30\">",
"       \"Psychopharmacological treatment for adolescent depression\", section on 'Initiation of pharmacotherapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=see_link\">",
"       \"Effect of antidepressants on suicide risk in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In light of the psychosocial context in which depression occurs, pharmacotherapy is not considered sufficient as the sole treatment. With few exceptions, the environmental and social problems associated with MDD remain after the patient's mood has been stabilized. Combination treatment increases the chance of improving depressive symptoms and family and peer relationships as well as increasing self-esteem, coping skills, and adaptive behaviors [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of adolescent depression may occur in a variety of settings: outpatient, partial hospitalization, day treatment, inpatient, or residential [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ]. The most appropriate setting depends upon the patient's clinical picture, the level of parental support, the motivation for treatment, and the ability to keep the patient safe. Treatment should be provided in the least restrictive setting that is safe and effective for a given patient. Decisions regarding movement of therapy from one setting to another are based upon ongoing assessment of the adolescent's ability to function in and benefit from a particular setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment planning should be collaborative with the adolescent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/6\">",
"     6",
"    </a>",
"    ]. His or her family should be well informed and involved in the planning process [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/6\">",
"     6",
"    </a>",
"    ]. The treatment plan should indicate the frequency of sessions based on the severity of symptoms, the age and developmental status of the patient, the degree of current exposure to negative life events, and other clinical factors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ]. Multiple sessions per week may be needed during the acute treatment phase. In addition the plan should recommend involvement of parents in treatment and other interventions directed at the adolescent's environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Continuation phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of continuation is to consolidate the treatment response and prevent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ]. There is limited empirical evidence to guide therapy during continuation treatment.",
"   </p>",
"   <p>",
"    Current practice standards indicate the psychosocial or pharmacologic treatments that were used to attain remission in the acute phase should be used for continuation therapy (unless contraindicated). During the continuation phase, patients typically are seen monthly or possibly biweekly depending upon their clinical status, functioning, support systems, stressors, motivation for treatment, and comorbid psychiatric or medical disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In light of the high rate of relapse and recurrence of depression in adolescents (40 to 60 percent), continuation therapy is recommended for all patients for at least six months after complete remission of depressive symptoms (ie, return to baseline mood) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients who had difficulty achieving remission, have a history of recurrent depression, or present with ongoing risk factors (eg, comorbidity, suicidality, stressors, family history) should receive continuation therapy for at least 12 months.",
"   </p>",
"   <p>",
"    Extrapolating from the adult literature on relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/55\">",
"     55",
"    </a>",
"    ], we recommend a minimum of nine months, and preferably 12 months of continued therapy following euthymia. However, if the depressive episode was subsyndromal or a mild depression (in context of no prior episodes of depression or major risk factors), an extensive continuation phase may not be warranted.",
"   </p>",
"   <p>",
"    The benefits of continuation therapy were demonstrated in a randomized trial in which 102 children and adolescents with MDD who responded to 12 weeks of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    were assigned to continue therapy with fluoxetine or placebo for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/54\">",
"     54",
"    </a>",
"    ]. Those assigned to fluoxetine had a longer time to relapse, defined by CDRS &ge; 40 (&gt;24 weeks versus 14 weeks), and a lower relapse rate (22 versus 48 percent when relapse was defined by CDRS &ge;40 and 42 versus 69 percent when relapse was defined by clinician determination of significant clinical deterioration).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Maintenance phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient has been asymptomatic for a period of approximately 6 to 12 months (continuation phase), the clinician determines whether maintenance treatment is indicated to prevent recurrence. The decision to recommend maintenance treatment is based upon factors associated with increased risk for recurrence, as well as severity of the present depressive episode (eg, suicidality, psychosis, functional impairment). Factors associated with risk for recurrence include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of prior depressive episodes",
"     </li>",
"     <li>",
"      Family history of recurrent MDD",
"     </li>",
"     <li>",
"      Family psychopathology",
"     </li>",
"     <li>",
"      Presence of comorbid disorders",
"     </li>",
"     <li>",
"      Environmental stressors",
"     </li>",
"     <li>",
"      Limited social supports",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients in whom maintenance therapy is warranted, the duration of the maintenance phase may vary from one year to indefinitely. Patients typically are seen monthly to every three months, depending upon clinical status. We recommend that adolescents with two or three episodes of MDD receive maintenance treatment for one to three years. We suggest longer maintenance therapy for those with more than one episode accompanied by psychosis, severe functional impairment, severe suicidality, and treatment-resistant depression. Unless contraindicated, treatments that attained remission in the acute episode should be used for maintenance therapy.",
"   </p>",
"   <p>",
"    Adolescents who achieved remission with medication should be offered psychotherapy to help them cope with the psychosocial sequelae of depression. Moreover, combination therapy may help prevent relapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    development or exacerbation of comorbid psychiatric disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the adolescent has had only a single, uncomplicated episode of depression, discontinuation (rather than maintenance) is indicated once the continuation phase is complete. The decision to discontinue treatment should be arrived at collaboratively with the adolescent and his or her family, with the family well informed and actively involved.",
"   </p>",
"   <p>",
"    Psychoeducation and discussion regarding recurrence of depression is an important element of termination or discontinuation of treatment. The adolescent patient and his or her family should be taught to recognize risk factors and early signs of recurrence and have a plan in place to prevent future depressive episodes. When the family is well educated, they can effectively monitor for signs of depression. The role of the adolescent's primary care practitioner in the monitoring depression cannot be overemphasized. The primary care provider is in a unique position to prevent future MDD episodes through early identification of potential recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INTEGRATED HEALTH CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression often is identified in the primary care setting. In the past, many primary care providers referred depressed teenagers to a mental health provider for additional intervention. However, primary care providers now manage the majority of depressed adolescents themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/6,56-64\">",
"     6,56-64",
"    </a>",
"    ]. Possible explanations for the shift of care from mental health providers to primary care providers include: a shortage of pediatric mental health providers; perceived stigma against mental disorders; and lack of adequate healthcare coverage for pediatric mental illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/60,63\">",
"     60,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many primary care providers who care for depressed adolescents feel",
"   </p>",
"   <p>",
"    inadequately trained, supported, or reimbursed for the management of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/61\">",
"     61",
"    </a>",
"    ]. This may result in inadequate treatment. Untreated depression is associated with suicide, which is a significant cause of morbidity and mortality for youth aged 15 to 24 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link&amp;anchor=H6#H6\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the potential life-threatening implications of underdiagnosed and undertreated adolescent depression, primary care providers and child psychiatrists must work together to surmount the barriers to the provision of appropriate care. This may include a brief consultation with a mental health provider about an individual patient, or identification of a mental health provider who is willing to see more difficult patients on relatively short notice.",
"   </p>",
"   <p>",
"    To facilitate effective diagnosis and treatment of mental health disorders in the primary care setting, models of integrated health care (IHC) between pediatric primary care clinicians and child psychiatrists have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. A full discussion on IHC is beyond the scope of this topic review. More information can be found in the references [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/56,71-79\">",
"     56,71-79",
"    </a>",
"    ] and the list of resources provided below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'IHC resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Briefly, IHC is a model of care that systematically integrates the physical and mental health of patients. Collaborative care, one model of IHC, has proven effective for the treatment of adult depression and anxiety in the primary care setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H40#H40\">",
"     \"Initial treatment of depression in adults\", section on 'Collaborative care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IHC is beginning to be used in the management and treatment of children and adolescents with emotional and behavioral problems, particularly adolescent depressive disorders and childhood attention deficit hyperactivity disorder. IHC is endorsed by the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics (AAP), which have implementation programs underway. Multiple programs, resources, and guidelines are available. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'IHC resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical practice guideline, Guidelines for Adolescent Depression in Primary Care (GLAD-PC,",
"    <a class=\"external\" href=\"file://www.thereachinstitute.org/guidelines-for-adolescent-depression-in-primary-care-glad-pc.html\">",
"     www.thereachinstitute.org/guidelines-for-adolescent-depression-in-primary-care-glad-pc.html",
"    </a>",
"    ), includes consultation and coordination of care with mental health specialists as one of its major tenets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/6,80\">",
"     6,80",
"    </a>",
"    ]. GLAD-PC provides a toolkit that includes rating scales to aid in the assessment and diagnosis of adolescent depression, information on the various treatment options, an",
"    <span class=\"nowrap\">",
"     algorithm/flowchart",
"    </span>",
"    for management of adolescent depression, and educational materials (",
"    <a class=\"external\" href=\"file://www.thereachinstitute.org/files/documents/GLAD-PCToolkit.pdf\">",
"     www.thereachinstitute.org/files/documents/GLAD-PCToolkit.pdf",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many patients with adolescent depression are successfully managed by primary care providers, referral to a mental health provider is sometimes necessary. Specific reasons to refer adolescent patients to mental health specialists are discussed below. In general, any time a clinician feels uncomfortable with managing pediatric depression, collaboration with",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral to a mental health specialist is recommended.",
"   </p>",
"   <p>",
"    Specific types of psychotherapy (eg, cognitive behavior therapy, interpersonal therapy for adolescents) can provide depressed adolescents with a means to better understand and manage their moods, a means to identify and manage psychosocial factors that contribute to the depression, and a place where they can restore a healthy sense of self and relationships. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=see_link\">",
"     \"Psychosocial treatment for adolescent depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific instances when referral to a mental health specialist is a priority include adolescents with a history of suicide attempt or current suicidal ideation, coexisting substance abuse, lack of response to the initial course of treatment, psychosis, bipolar disorder, or if the family is unable to monitor the adolescent's safety [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Referral to psychiatry, psychology, or other mental health provider also is warranted when depression is recurrent or chronic, complicated by comorbid conditions, marked functional impairment, or likely to be maintained by psychosocial factors (eg, a high level of family discord), and if the adolescent's presentation is unclear or guarded [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/80\">",
"     80",
"    </a>",
"    ]. In addition, referral to a psychiatrist or psychopharmacologist is indicated when the primary care provider believes the adolescent should be treated with antidepressants, but has little experience in prescribing psychopharmacologic medications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    has initiated medication but needs additional consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a referral to a mental health provider is initiated, we suggest that the primary care provider continue to follow up with the patient while he or she is waiting for the appointment, and throughout the treatment course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 60 percent of adolescents with MDD respond to initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"     5",
"    </a>",
"    ]. Predictors of nonresponse include severity of depression, hopelessness, comorbid psychiatric problems (particularly obsessive-compulsive disorder), suicidal ideation at entry into treatment, nonsuicidal self-injurious behavior, family conflict, and disappointing life events during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/15,21,46,82-86\">",
"     15,21,46,82-86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of resources for clinicians, patients, and families regarding the treatment of depression in children and adolescents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Academy of Child and Adolescent Psychiatry Web site provides information for health care providers and parents regarding children and antidepressants (",
"      <a class=\"external\" href=\"file://www.aacap.org/\">",
"       www.aacap.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The United States FDA Web site provides information regarding the use of antidepressants in children and adolescents (",
"      <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273\">",
"       www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Guidelines for Adolescent Depression in Primary Care (GLAD-PC) Toolkit, which includes rating scales, a management",
"      <span class=\"nowrap\">",
"       algorithm/flowchart,",
"      </span>",
"      treatment information, and educational materials (",
"      <a class=\"external\" href=\"file://www.thereachinstitute.org/files/documents/GLAD-PCToolkit.pdf\">",
"       www.thereachinstitute.org/files/documents/GLAD-PCToolkit.pdf",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/26/13738/abstract/6,80\">",
"       6,80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The American Psychiatric Association (",
"      <a class=\"external\" href=\"file://www.psych.org/\">",
"       www.psych.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      American Psychological Association (",
"      <a class=\"external\" href=\"file://www.apa.org/\">",
"       www.apa.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Alliance for the Mentally Ill (",
"      <a class=\"external\" href=\"file://www.nami.org/\">",
"       www.nami.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Institute of Mental Health (",
"      <a class=\"external\" href=\"file://www.nimh.nih.gov/health/topics/depression/index.shtml\">",
"       www.nimh.nih.gov/health/topics/depression/index.shtml",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Mental Health Association (",
"      <a class=\"external\" href=\"file://www.nmha.org/\">",
"       www.nmha.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     IHC resources",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Integrated Primary Care. AAP Children's Mental Health in Primary Care, E-Newsletter (",
"      <a class=\"external\" href=\"file://www2.aap.org/commpeds/dochs/mentalhealth/\">",
"       file://www2.aap.org/commpeds/dochs/mentalhealth/",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hogg Foundation for Mental Health Integrative Care Initiative. Connecting Body &amp; Mind: A Resource Guide to Integrated Health Care in Texas &amp; the US. This report describes integrated health care and identifies resources to assist with developing and implementing integrated care systems. The online version is updated regularly with new information (",
"      <a class=\"external\" href=\"file://www.hogg.utexas.edu/programs_ihc.html\">",
"       www.hogg.utexas.edu/programs_ihc.html",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A Resource Guide for Clinicians: Integrating Child and Adolescent Mental Health into Primary Care. Published by Texas Medical Association (",
"      <a class=\"external\" href=\"file://www.texmed.org/Template.aspx?id=3777\">",
"       www.texmed.org/Template.aspx?id=3777",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The Massachusetts Child Psychiatry Access Project (MCPAP,",
"      <a class=\"external\" href=\"file://www.mcpap.org/\">",
"       www.mcpap.org",
"      </a>",
"      ) provides primary care clinicians with timely access to child psychiatry consultation, including legislative-funded regional coordinators who identify appointment availability to psychiatrists and mental health practitioners. Approximately 95 percent of pediatric clinicians in Massachusetts have joined this program.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"       \"Patient information: Depression treatment options for adolescents (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depressed adolescents must be evaluated for suicide risk. Those with a history of suicidality or current suicidality require urgent referral to a mental health specialist. Other indications for urgent referral include comorbid substance abuse, lack of response to the initial course of treatment, psychosis, bipolar disorder, and inability of the family to monitor the adolescent's safety. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link\">",
"       \"Evaluation and management of suicidal behavior in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H23\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Education is an important component of treatment of depression. Education helps to empower the family and patient and invites them to be members of the treatment team. The patient and family should receive information about depression, the clinical course of depression, the risks of untreated depression, and the anticipated benefits and potential risks of the possible interventions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of depression in adolescents may involve psychosocial interventions, pharmacologic interventions, or a combination of the two. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Types of intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic therapy may be associated with adverse events, including an increased risk of suicidal thoughts or behaviors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=see_link\">",
"       \"Effect of antidepressants on suicide risk in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      and cognitive behavioral therapy as the initial treatment for adolescents with MDD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, decisions regarding the choice of therapy should involve the patient and his or her",
"      <span class=\"nowrap\">",
"       parents/caregivers.",
"      </span>",
"      After appropriate education, they, in conjunction with the treating clinician, must weigh the risks and benefits to determine their choice of therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of treatment in the acute phase is improvement in depressive symptoms and return to near-baseline mood; this usually takes 6 to 12 weeks. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Acute phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the psychosocial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pharmacologic treatments that induced remission of the acute MDD episode be continued for at least 6 and preferably 9 to 12 months after the patient has returned to near baseline mood (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Further maintenance treatment may be warranted based on the patient's risk profile for recurrence. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Continuation phase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Maintenance phase'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/1\">",
"      Harper, G, Marks, A, Nelson, WM. Adolescent Medicine: Teen depression: Overlooked and Undertreated. Patient Care 2002; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/2\">",
"      Flament MF, Cohen D, Choquet M, et al. Phenomenology, psychosocial correlates, and treatment seeking in major depression and dysthymia of adolescence. J Am Acad Child Adolesc Psychiatry 2001; 40:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/3\">",
"      Lewinsohn PM, Clarke GN, Seeley JR, Rohde P. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 1994; 33:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/4\">",
"      Keller MB, Lavori PW, Beardslee WR, et al. Depression in children and adolescents: new data on 'undertreatment' and a literature review on the efficacy of available treatments. J Affect Disord 1991; 21:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/5\">",
"      Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/6\">",
"      Zuckerbrot RA, Cheung AH, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial management. Pediatrics 2007; 120:e1299.",
"     </a>",
"    </li>",
"    <li>",
"     Birmaher, B, Brent, D. Depressive disorders. In: Pediatric Psychopharmacology: Principles and Practice, Martin, Scahill, et al, (Eds). Oxford University Press, Oxford 2003. p.466.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/8\">",
"      Brent DA, Birmaher B. Clinical practice. Adolescent depression. N Engl J Med 2002; 347:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/9\">",
"      Treatment for Adolescents With Depression Study Team. Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003; 42:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/10\">",
"      March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/11\">",
"      March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/12\">",
"      Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/13\">",
"      Emslie GJ, Rush AJ, Weinberg WA, et al. Recurrence of major depressive disorder in hospitalized children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/14\">",
"      Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996; 35:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/15\">",
"      McCauley E, Myers K, Mitchell J, et al. Depression in young people: initial presentation and clinical course. J Am Acad Child Adolesc Psychiatry 1993; 32:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/16\">",
"      Strober M, Lampert C, Schmidt S, Morrell W. The course of major depressive disorder in adolescents: I. Recovery and risk of manic switching in a follow-up of psychotic and nonpsychotic subtypes. J Am Acad Child Adolesc Psychiatry 1993; 32:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/17\">",
"      Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/18\">",
"      Kovacs M, Obrosky DS, Gatsonis C, Richards C. First-episode major depressive and dysthymic disorder in childhood: clinical and sociodemographic factors in recovery. J Am Acad Child Adolesc Psychiatry 1997; 36:777.",
"     </a>",
"    </li>",
"    <li>",
"     Birmaher, B, Brent, D. Pharmacotherapy for depression in children and adolescents. In: The Many Faces of Depression in Children and Adolescents, 1st ed, Shaffer, D, Waslick, BD (Eds), American Psychiatric Association, Washington, DC, 2002. p. 73.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/21\">",
"      Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 2000; 57:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/22\">",
"      Beardslee WR, Salt P, Versage EM, et al. Sustained change in parents receiving preventive interventions for families with depression. Am J Psychiatry 1997; 154:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/23\">",
"      Beardslee WR, Wright EJ, Salt P, et al. Examination of children's responses to two preventive intervention strategies over time. J Am Acad Child Adolesc Psychiatry 1997; 36:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/24\">",
"      Brent DA, Poling K, McKain B, Baugher M. A psychoeducational program for families of affectively ill children and adolescents. J Am Acad Child Adolesc Psychiatry 1993; 32:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/25\">",
"      Fristad, MA, Gavazzi, SM, Centollela, DM, Soldano, KW. Psychoeducation: A promising intervention strategy for families of children and adolescents with mood disorders. Contemp Fam Ther 1996; 18:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/26\">",
"      McClellan JM, Werry JS. Evidence-based treatments in child and adolescent psychiatry: an inventory. J Am Acad Child Adolesc Psychiatry 2003; 42:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/27\">",
"      Asarnow JR, Goldstein MJ, Tompson M, Guthrie D. One-year outcomes of depressive disorders in child psychiatric in-patients: evaluation of the prognostic power of a brief measure of expressed emotion. J Child Psychol Psychiatry 1993; 34:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/28\">",
"      Asarnow JR, Tompson M, Hamilton EB, et al. Family-expressed emotion, childhood-onset depression, and childhood-onset schizophrenia spectrum disorders: is expressed emotion a nonspecific correlate of child psychopathology or a specific risk factor for depression? J Abnorm Child Psychol 1994; 22:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/29\">",
"      Practice guideline for the assessment and treatment of patients with suicidal behaviors. Am J Psychiatry 2003; 160:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/30\">",
"      Rappaport N, Bostic JQ, Prince JB, Jellinek M. Treating pediatric depression in primary care: coping with the patients' blue mood and the FDA's black box. J Pediatr 2006; 148:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/31\">",
"      Merry SN, Hetrick SE, Cox GR, et al. Psychological and educational interventions for preventing depression in children and adolescents. Cochrane Database Syst Rev 2011; :CD003380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/32\">",
"      March J, Silva S, Vitiello B, TADS Team. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006; 45:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/33\">",
"      Clarke G, Debar L, Lynch F, et al. A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. J Am Acad Child Adolesc Psychiatry 2005; 44:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/34\">",
"      Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/35\">",
"      Melvin GA, Tonge BJ, King NJ, et al. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 2006; 45:1151.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Depression in children and young people. Clinical guideline 28. NICE, London 2005. Available at: www.nice.org.uk/pdf/CG028NICEguideline.pdf. Accessed on August 14, 2007.",
"    </li>",
"    <li>",
"     Royal Australian College of General Practitioners. Clinical guidance in the use of antidepressant medications in children and adolescents. Available at: www.racgp.org.au/guidelines/antidepressants. Accessed on August 14, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/38\">",
"      Hazell P. Depression in adolescents. BMJ 2007; 335:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/39\">",
"      Curry J, Silva S, Rohde P, et al. Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry 2011; 68:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/40\">",
"      Kennard BD, Silva SG, Mayes TL, et al. Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. Am J Psychiatry 2009; 166:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/41\">",
"      Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 1997; 171:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/42\">",
"      Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/43\">",
"      Kratochvil C, Emslie G, Silva S, et al. Acute time to response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/44\">",
"      Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006; 45:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/45\">",
"      Vitiello B, Rohde P, Silva S, et al. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/46\">",
"      Curry J, Rohde P, Simons A, et al. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/47\">",
"      Tao R, Emslie G, Mayes T, et al. Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder. J Am Acad Child Adolesc Psychiatry 2009; 48:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/48\">",
"      Asarnow JR, Jaycox LH, Tompson MC. Depression in youth: psychosocial interventions. J Clin Child Psychol 2001; 30:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/49\">",
"      Jayson D, Wood A, Kroll L, et al. Which depressed patients respond to cognitive-behavioral treatment? J Am Acad Child Adolesc Psychiatry 1998; 37:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/50\">",
"      Frank E, Karp JF, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol Bull 1993; 29:457.",
"     </a>",
"    </li>",
"    <li>",
"     March, J, Wells, K. Combining medication and psychotherapy. In: Pediatric Psychopharmacology: Principles and Practice, Leckman, JF, Martin, A, Scahill, I, Charney, DS (Eds). Oxford University Press, London 2002. p.426.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/52\">",
"      Jacobson NS, Dobson KS, Truax PA, et al. A component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol 1996; 64:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/53\">",
"      Spanier C, Frank E, McEachran AB, et al. The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: integrating psychological and biological factors. Psychol Med 1996; 26:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/54\">",
"      Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/55\">",
"      Linden M, Gothe H, Dittmann RW, Schaaf B. Early termination of antidepressant drug treatment. J Clin Psychopharmacol 2000; 20:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/56\">",
"      Stein RE, Zitner LE, Jensen PS. Interventions for adolescent depression in primary care. Pediatrics 2006; 118:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/57\">",
"      Costello EJ. Child psychiatric disorders and their correlates: a primary care pediatric sample. J Am Acad Child Adolesc Psychiatry 1989; 28:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/58\">",
"      Rushton J, Bruckman D, Kelleher K. Primary care referral of children with psychosocial problems. Arch Pediatr Adolesc Med 2002; 156:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/59\">",
"      Williams J, Klinepeter K, Palmes G, et al. Diagnosis and treatment of behavioral health disorders in pediatric practice. Pediatrics 2004; 114:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/60\">",
"      Kelleher KJ, McInerny TK, Gardner WP, et al. Increasing identification of psychosocial problems: 1979-1996. Pediatrics 2000; 105:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/61\">",
"      Olson AL, Kelleher KJ, Kemper KJ, et al. Primary care pediatricians' roles and perceived responsibilities in the identification and management of depression in children and adolescents. Ambul Pediatr 2001; 1:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/62\">",
"      Briggs-Gowan MJ, Owens PL, Schwab-Stone ME, et al. Persistence of psychiatric disorders in pediatric settings. J Am Acad Child Adolesc Psychiatry 2003; 42:1360.",
"     </a>",
"    </li>",
"    <li>",
"     Skaer, TL, Sclar, DA, Robison, LM. Antidepressant trends among children and adolescents diagnosed with depression: 1990-2001. In: National Institute of Mental Health New Clinical Drug Evaluation Unit Annual Meeting. Phoenix, Arizona 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/64\">",
"      Asarnow JR, Jaycox LH, Duan N, et al. Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: a randomized controlled trial. JAMA 2005; 293:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/65\">",
"      Brent DA, Perper JA, Moritz G, et al. Psychiatric risk factors for adolescent suicide: a case-control study. J Am Acad Child Adolesc Psychiatry 1993; 32:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/66\">",
"      Marttunen MJ, Aro HM, Henriksson MM, L&ouml;nnqvist JK. Mental disorders in adolescent suicide. DSM-III-R axes I and II diagnoses in suicides among 13- to 19-year-olds in Finland. Arch Gen Psychiatry 1991; 48:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/67\">",
"      Shaffer D, Gould MS, Fisher P, et al. Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry 1996; 53:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/68\">",
"      Weissman MM, Wolk S, Goldstein RB, et al. Depressed adolescents grown up. JAMA 1999; 281:1707.",
"     </a>",
"    </li>",
"    <li>",
"     Integrated Primary Care. American Academy of Pediatrics (AAP) Children's Mental Health in Primary Care, E-Newsletter. Available at: www.aap.org/mentalhealth. Accessed on February 9, 2009.",
"    </li>",
"    <li>",
"     Massachusetts Child Psychiatry Access Project. Available at www.mcpap.org. Accessed on February 11, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/71\">",
"      Cassidy LJ, Jellinek MS. Approaches to recognition and management of childhood psychiatric disorders in pediatric primary care. Pediatr Clin North Am 1998; 45:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/72\">",
"      Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA 2000; 283:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/73\">",
"      Briggs-Gowan MJ, Horwitz SM, Schwab-Stone ME, et al. Mental health in pediatric settings: distribution of disorders and factors related to service use. J Am Acad Child Adolesc Psychiatry 2000; 39:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/74\">",
"      Rushton JL, Clark SJ, Freed GL. Primary care role in the management of childhood depression: a comparison of pediatricians and family physicians. Pediatrics 2000; 105:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/75\">",
"      Richardson LP, Katzenellenbogen R. Childhood and adolescent depression: the role of primary care providers in diagnosis and treatment. Curr Probl Pediatr Adolesc Health Care 2005; 35:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/76\">",
"      Goodfriend M, Bryant T 3rd, Livingood W, Goldhagen J. A model for training pediatricians to expand mental health services in the community practice setting. Clin Pediatr (Phila) 2006; 45:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/77\">",
"      Zuckerbrot RA, Jensen PS. Improving recognition of adolescent depression in primary care. Arch Pediatr Adolesc Med 2006; 160:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/78\">",
"      Kates N. Improving quality of primary care reduces depression and improves quality of life in adolescents. Evid Based Ment Health 2005; 8:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/79\">",
"      Costello EJ, Edelbrock C, Costello AJ, et al. Psychopathology in pediatric primary care: the new hidden morbidity. Pediatrics 1988; 82:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/80\">",
"      Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics 2007; 120:e1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/81\">",
"      Hagman, J. Diagnosis and treatment of depression in adolescence. Adolescent Health Update 2001; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/82\">",
"      Wilkinson P, Dubicka B, Kelvin R, et al. Treated depression in adolescents: predictors of outcome at 28 weeks. Br J Psychiatry 2009; 194:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/83\">",
"      Goodyer IM, Herbert J, Secher SM, Pearson J. Short-term outcome of major depression: I. Comorbidity and severity at presentation as predictors of persistent disorder. J Am Acad Child Adolesc Psychiatry 1997; 36:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/84\">",
"      Asarnow JR, Emslie G, Clarke G, et al. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 2009; 48:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/85\">",
"      Brent DA, Kolko DJ, Birmaher B, et al. Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry 1998; 37:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/26/13738/abstract/86\">",
"      Rohde P, Seeley JR, Kaufman NK, et al. Predicting time to recovery among depressed adolescents treated in two psychosocial group interventions. J Consult Clin Psychol 2006; 74:80.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1231 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13738=[""].join("\n");
var outline_f13_26_13738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL COURSE AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TYPES OF INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Psychosocial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Combination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - TADS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - ADAPT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHASES OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Safety concerns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Continuation phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Maintenance phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Discontinuation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INTEGRATED HEALTH CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      IHC resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1231|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/5/31838\" title=\"figure 1\">",
"      TADS CDRSR results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1231|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/48/23309\" title=\"table 1\">",
"      Depression rating scales",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=related_link\">",
"      Effect of antidepressants on suicide risk in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=related_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=related_link\">",
"      Psychosocial treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_26_13739="International Neuroblastoma Risk Group staging system";
var content_f13_26_13739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F88604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F88604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International Neuroblastoma Risk Group staging system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10\">",
"     </colgroup>",
"     <colgroup width=\"90\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        L1",
"       </td>",
"       <td>",
"        Localized tumor not involving vital structures as defined by the list of image-defined risk factors and confined to one body compartment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        L2",
"       </td>",
"       <td>",
"        Locoregional tumor with presence of one or more image-defined risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        M",
"       </td>",
"       <td>",
"        Distant metastatic disease (except stage MS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        MS",
"       </td>",
"       <td>",
"        Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone marrow",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with multifocal primary tumors should be staged according to the greatest extent of disease as defined in the table.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Monclair T, et al: J Clin Oncol 27(2), 2009:298-303. Reprinted with permission. Copyright &copy; 2009 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13739=[""].join("\n");
var outline_f13_26_13739=null;
var title_f13_26_13740="Major triatomine species of Chagas";
var content_f13_26_13740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The major triatomine species that colonize the domestic and peridomestic environment and play an important role in the epidemiology of Chagas disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vector species",
"       </td>",
"       <td class=\"subtitle1\">",
"        Found in",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Triatoma infestans",
"        </em>",
"       </td>",
"       <td>",
"        Argentina*, Brazil&bull;, Chile&bull;, Paraguay*, southern Peru, Uruguay&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Rhodnius prolixus",
"        </em>",
"       </td>",
"       <td>",
"        Colombia, El Salvador, Guatemala&Delta;, Honduras, southern Mexico, Nicaragua, Venezuela",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Triatoma dimidiata",
"        </em>",
"       </td>",
"       <td>",
"        Belize, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, northern Peru, Venezuela",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Panstrongylus megistus",
"        </em>",
"       </td>",
"       <td>",
"        Argentina, Brazil, Paraguay, Uruguay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Triatoma brasiliensis",
"        </em>",
"       </td>",
"       <td>",
"        Northeastern Brazil",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <em>",
"      T. cruzi",
"     </em>",
"     transmission by",
"     <em>",
"      T. infestans",
"     </em>",
"     certified as interrupted in 6 provinces of Argentina and 1 department of Paraguay",
"     <sup>",
"      [1]",
"     </sup>",
"     .",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      <em>",
"       T. cruzi",
"      </em>",
"      transmission by",
"      <em>",
"       T. infestans",
"      </em>",
"      certified as interrupted throughout the country",
"      <sup>",
"       [1]",
"      </sup>",
"      .",
"      <br>",
"       &Delta;",
"       <em>",
"        T. cruzi",
"       </em>",
"       transmission by",
"       <em>",
"        R. prolixus",
"       </em>",
"       certified as interrupted throughout the country",
"       <sup>",
"        [1]",
"       </sup>",
"       .",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Pan American Health Organization. Chagas Disease (American Trypanosomiasis). 2010;",
"        <a href=\"file://www.paho.org/english/ad/dpc/cd/chagas.htm\">",
"         file://www.paho.org/english/ad/dpc/cd/chagas.htm",
"        </a>",
"        05/11/2010.",
"       </li>",
"      </ol>",
"      <br>",
"       Data from: WHO Expert Committee. Control of Chagas Disease. Brasilia, Brazil: World Health Organization, 2002:1-109.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13740=[""].join("\n");
var outline_f13_26_13740=null;
var title_f13_26_13741="Obstructive vs absorptive hydrocephalus in infants";
var content_f13_26_13741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of hydrocephalus in the infant and newborn: Classification of obstructive versus absorptive hydrocephalus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Communicating hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Permanent impaired absorption:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary congenital hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Malformed brain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Developmental/genetic association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Secondary prenatal hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Posthemorrhagic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Postinfectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Secondary postnatal hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Prematurity-related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Posthemorrhagic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Postinfectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Venous congestion: craniosynostosis, achondroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Venous thrombosis: superior vena cava obstruction after cardiac surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased secretion: Choroid plexus papilloma/carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Communicating hydrocephalus, with an obstructive component",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraventricular hemorrhage resulting in a clot at aqueduct or fibrosis of aqueduct (acute phase)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraventricular hemorrhage resulting in intracranial cysts (acute phase)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection resulting in intracranial cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis/encephalitis resulting in secondary obstruction*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chiari 2 malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dandy Walker malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Holoprosencephaly: lobar, semilobar, alobar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalocele",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lissencephaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydranencephaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Obstructive hydrocephalus, with a transient minor communicating component",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Same as group 2, subacute or late phase (at least several months from primary insult: infection, bleed)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large arachnoid cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chromosomal abnormalities, syndromic, genetic:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        X-linked hydrocephalus (mostly aqueductal stenosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Osteogenesis imperfecta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Craniofacial syndromic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Part of metabolic inherited disease:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hurler's disease (MPS T1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Achondroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Obstructive hydrocephalus (pure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial cysts with no evidence of bleed at diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triventricular hydrocephalus due to radiologically apparent aqueductal stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Membranous obstruction of aqueduct",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymmetrical hydrocephalus, due to atresia of the foramen of Monro",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstruction of fourth ventricle outlets",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In these disorders, the communicating component is initially prominent, but tends to decrease over time, so that the obstructive component predominates in the later phases.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Beni-Adani L, Biani N, Ben-Sirah L, Constantini S. The occurrence of obstructive vs absorptive hydrocephalus in newborns and infants: relevance to treatment choices. Childs Nerv Syst 2006; 22:1543; with kind permission from Springer Science + Business Media B.V.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13741=[""].join("\n");
var outline_f13_26_13741=null;
var title_f13_26_13742="Transpl survival CML by stage";
var content_f13_26_13742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Survival after allogeneic transplant in chronic myelogenous leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 342px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This graph shows the probability of survival versus years after allogeneic hematopoietic cell transplantation in patients with chronic myelogenous leukemia (CML) in chronic phase (red), accelerated phase (blue), and blast crisis (green). The difference in survival between patients in chronic phase and blast crisis was statistically significant (p &lt; 0.004).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Biggs, JC, et al. Blood 1992, 80:1352.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13742=[""].join("\n");
var outline_f13_26_13742=null;
var title_f13_26_13743="Pelvic congestion syndrome 11b";
var content_f13_26_13743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ovarian venogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 474px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHaAPEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxPVpPNvppsEF3LEfUmqbYHIyOp6Vr30GH3bcn61nyRL1GMg9fzrZo8mNSzuVxnvinqCOBipxA5xjj8eKb5bBmBHP/AOulyluoiMH8qcGPQGlSMgng+v8An86CmCOCT9KdgUkwIz359qil3E56d6lBwcY570rDIyMUWbEnFMoMSrZ559KQswPU5+vWp5Ey3AOKjaI9+frUWN1JPYs2cjLIj7iMdvauvtZt9qeecetcfAuM4/Kt+xk/ckZxxjGa0jojkrq7MrVyWnfJ+mKyhkHBrX1NT5jeh6YrMKjOfz4qJm2HtykZ6+tSRgbhnHXpmgDBxTlGWGP51CWpszQthjJXrjgZqldOzy5LKx5PHarqxt9mUjgkdz/9eqjr+96AHPStZLQ5KT967FjOMirTTvswOSehzUO3CcYOPxpM5JyevA5/Ci1kEpOUieC4IcBsj0NdRo8xcc8kVyUK5kwTiul0U4PXAqkZyudCSCOfSoCck845qYEMMZ7YproFAOe9UZoi5x060hwhPXmlY44NMc5AFJlIVHGe9Sxvz71UU5bGfpU6gj6Ui1csdutKOCeM1GhxUygHtzSCwu9fQ/nRRtPpRSCxgX8ULZOcVkyQxl+GPXpRq14A5XP4Csn7Sx5Jx+FVzWCMW9joLe2VlGGB71FcWOTkKD9Ko2t9ggHjPHFaCXJ2nDc+lO9yWmtyMWoUYA5Ax0qOS2+Y716+lWTO/PPP+fenwzMzgOAw9zQK5DHaZ5CjHXpSNagEfJXQW6RmPkCnNaxEjHSqsS2c0dNjcblyD09Kr3GnyIRtG4cda6w2efuYp0NixPzLkUWBTaOKNq6KDgmrVoWRCDxz/Wuqu9MR1xswfWs99FlXJjII9xSaHz33Oev1LDODjufSs1hgnt7V0F/Zyxghwf5ZrHZcHBH/ANaolE3pVEiuFyTTgmD2HepcKBnPFCIC/AwSR1+tSomk6mhsQQ77dCw4HtVK8tts2QK1Y2226gY55qtcD95kjirOaO5VYrHEMgZx0qmAN3H4c5/z2q1dBiCAOnbGKqlvl+Uknr60imSxhd6Bc5PXFa1i+xs5/Csm2OBgkkj/APVV6JyBkHrzQDWh1lrJ5igjrVh1O31rA0+58sgFuPrWyt1HtySB+NVczaIpMlsVGy8ZJ70slwjPgH8akAVhwaTKSIgMHPBqVfu80mOOM09F+UZqWaRHoOOKnXJ74NVwcGp1456ZqWVYmwfWio959TRSCx5lNK0srMe5qM8fjSnI/A0h9xTZtC1tBw+tWrWYqwViMetUjwD1NTR4bPtVJkVIX1NeKQMvHWrMYGR6ZrEjkMeeTjjtWzZSLIVB9atHNJWNy2HyDnPFTMrHnHenW0XyDHTHSrkVvnjvVoybKkKMSP8AGr0Cuo6mrdpZKPvfWpZ4tg4HFMVzPcknr1qN0dRmrKxsz8CpJoyqcg5pWA57Um3xEMo+tclcDEjYX3zt+ldfrbhImC9TzXKueWJB+lQ2awVyiQMgd84xUkCqZBtx75qRlJYnnr17/hT7NfmAK7QD3oY7dzds7BrmHcAFAHequqQrDIF3BiOtXNOd5GOG2oB0rM1AgzvzjB60dBJamdNLl/lx+A+lVyTjHOf85p8mW+6AST2/CmFBk8r0wRxnFSUrj0UsQnOKtxE9MHFVASMY6g/MR9amikJA4/I0mXGxdgO046Crkbnnnn3qjG5zwM9qtwhnb5MZOcZpkvcm8w5BJ+vFWYJTuzmqAYlhViI8DPrQBrwyBu4qc4K81nRSEYzWgh3DPH4UDuAXHJ4qUHA/rTQBg880YHPNS0UmOyfWimbh70UrBc83YLuIBHrUeOvt71LtJbrgd6bu+bGOvSqaLjKw3A55H6U9cheDQAQMvnrTiMqeePp/9akkOcxUGdvU98ba2dIGZAeSMdeazbdAzEjHXHStmzURkAHt0ArRHM3odNZ4IGc1tW6Kq5xisLTWYkZ/StzeQo9atGLRZUjPBqTajABuapCYg8frSi5AI707k2NO2sEfkHimahaKkZIPIFSWFySuKS7nWT5RjPSi5OtzgNbRssDmuckBDdR6V2/iK2UoSMbq4yWNkbkfpWbOmmyvtHmfMePU1e0+BXzjJbtWc5LYU8d8k1qaTdrby/MpbmkvMqWq0L9rA8J54FZOrMfNO3BzXWXAhmt1ZRtJ9K5bVrN433ZBBOQRTZEXcxR2Knn2+lLhWJBBPPPpUpjfcCGAP9KTyWIG9s5HpUuxokyNVBwuTuPFT28ZAycDPp1NSxxY4xj3/GpFUdzz60hpWFUY7cVIHJGD0PpUTNjGKbjPqaAsWIm5A/XNXIc9x15qmmSQBV2FfcZ9TTEW4euO/wBK0ozhO2elVLWMccVdxjtTFcUEcZFKSMZB5phORTgcClYaYzcf8iilzRRYdzzwkqzZ6/8A1qjKjOR61akt2A6Z+v8An/OahkVuVGe/OO9DQ4y7jc57cU8Hcw4784pgjK4ABye/erdnBk5Ye2O9CQVJLoS20WOeRntmtW2TAXI4piIFXOMVdtkHr0FWjFs19N4YE9BWi0oPB/GqdgpXoM571JO21j2quhD3LBuBjAzUAJMnpmq7OcZH8qfC5Zgxx15pBY24S0VqTu4xxWdBd4ny7Z56UzU7/wAm0AUVz8N2zSBiT1ouCRva0fNj3c4xXLStg5I6HFdQWE1pzycVzd4mHPHQ9qTHEzpsZ4FNVSOQMGpHT5unWn+XluRipNExwvpiFUk7abesX25btxTVh+fBIwDUt1FhVKj9KLBpfQpBM570FcEYAFWI0POQOelKyAL9aVhqREo2gE4+tMmBK57GnH72CT6dKlCZjAbsKAW5STIHPWpUPzct0FAU59e9SpGBk9O1CKbViSIZ7/8A1qvW/qB07VBCoYYzWjbRZbjBFNEMtQcKCakcnHAp0age1KR2piIQwx05p/vSdRxSD7v4UmNDs/5zRUNFLUZQudK3HKCs+40sg4IrtZoFVeOtZV3AwJLYwKtozUmcqbPHROPapooWHOMegraaAdgDURjwfu44pWK5isifLzknpVi2BVhyfShuCAF/OrFqhLDAz7VRLNmxIIAFSXsL53dqZaDDrgYFbSwiaLkU+hDOYnZo1zg+lR2ru5wc4zWzfWWOAM4qpBbOHGR8tKw73MvXX2xqo69KyYeo6A4rX8RhQQScVgrL25qS1qdLprEwkOwPHrWdfKPPIGaXS3xIBzzU1/EfMzjk+opiM0RZYnnA6UKhLAYyTVjy9oJxitHRLWOWfMhGB60WC4un6TE6iS5fbjoPWqd+sSy+XHkqvetnUwFyIXHsBXOSZDkOMnPORQ2CQ0ovXGMVBJgkAHcKsHJHTjpUQjJf27VJaE8oHqOaVojs6ng1m6r4ktNNDRxf6Tcjspwq/U/4VmeGvE8aX91NrTtskQBNi5AIPQDt1qeZXN1Qm43N7yxu6d6nji3dayrzxjpIYiC3uGI7gAD+dZz+Ntr/ALmxUr2Lvz/Km5IUcPUfQ7K3h546CtGNQgz3rzWTxvqWf3ENvGvupY/nmq7eJdeu2zFJJ9Io/wD6xpc6L+qT6s9X64I/Q01nVcKzqCfU/pXlBHiW9OcX5+uUH9Knt/DevyTJK8RDIwZTLKOo/GjmH9WjHeR6cw703ccYFI3r3phJHWqOUfmios+36UUAdTcW5TJPPvWZcQnGCPx9a7e+sTk4AxWFd2XOSB9K1aMIyOaEXJyOaZNGMehra+zfNjHWnjT94xilYq5zbQszZAPWrNpGVGD1rcfTMDgc1AbRo+dvFFgvcgiOwjPatC2u1jGDyKz3+UZxUDzleQOKLha5s3d3GIy2Oa5+61gKWWPFV7q8doyo61lsOSSalsaRYvrgXEZD4rHA2Pz0HFX2QsMryKhe0fOQM+tItWRdsXwwwK0rpWfkdaqafb7FBcYrRSeLcEI5FMkypmZRhup5q1bO0dq7qMN7VYuIUk5Q1YtY0WExyDI9aEguYQlleQZLE96bcE+YTnNbckECD5BwahNvDIp2xnIpWGmYxPHI49qiurVby3aLzJYdxHzREA1qCDB6GlEAXqOKRSdtUcDqHgq8QF7B1uB12n5WH9DWfomhtc65DYakk9t5gYD5cEkA9M9uK9XjXC4x09aeEU7SwGR0yOlRyI6VjJWaZl2Xw+0JYw0guZW/2pMfyAp0vhbRLbISxjPP8RLfzreWbahGRVS4cuxzzWlkc7rTe7KNvp1jbr+5tIE+ka1ZVVXhQAo7AUg544FLjJyOKLBzPuKxGelLvO3HOfrScDqaYTgnpzQSD5zmombqDxTyRjpio5AMDd0z0pDG7z6Cil3D3ooA9VvpZQPpWFd3LgnIrau5gxI7VmThGzkCtWcyMxbsbvmTmrkV0hPTAqGS3XdlPzqJ1ZR0zQWzTE0b9D+dKyIy9ARWIZHB6YpBcyDgE0hWL9zZoRnGKyb6zAQkd6t/bZAvQ4qKa7L8MlDGtDBNngnOfzpz2AZdwGO9bSRxy9Rirkdmg43ArSHzHNQ2Oeq/pV6KwUAl1/CteZI4RwKzLm7IyFFAXuZ9/IsPyqcGsxpmxnPfrUmoFi+TyD3qg0mDxyOc1JSRbjnkAJFaFtdBhiQDNZdqrytxnFakUUMafvPzNA2TtIMYX8qlWQqhyBk1WNzChxEuTVdrlncknGKLgkSuXLdMUJlmwwpytuHzU9YjwQTSGP2qAFBpeO1L5BGMnmo5Ac8du9MQySQ9BTA2f/r0MpzRwOT/ACoGOUe1LxnFIrkHPTmguS2QKAEI560jJx1zQeTyCaGIxgCgCNuhIqFt3IOakboSMVWlb5+vI7Uhjto/vGioPMPv+VFA7HptzJjOKz2md8j1q3cAsTgiq20qMnrWhzjUkI4YU+Zo1Tr1qCZSoODj61n3Epxhj260XGkWmlUdOTUe/PIxWYZtq/fz9ahNxkjacfjU3HY2vNBByARVa5nyvGOKzmnc4A60yUSEYBOSKCkhs+oPG+FNWbXUZGxgmsCeCXzOW4NX4beVEUgkUkNo6D7SzoN/OapXLpnO4AVTSSRFw5I9KpXTNv5JPtTYkgu5Q7cdKpKCW4/lUxyB04pADuHH4VJZqWKgQF+mKqXEheTOCRV+2wtptPU1RkUq/OfamShY+Tz1qUw8ZA5NRwH5uQavxIWXtmgZGqkAdwKtxuPQ1G0YX71KvbGcUhE8smBiqskhyMZp5PpSMQxxQFhgZSaY2SamCr260Mo28UxkCk+4NHJbrinHA45pjdeKQxc88U1yTS47EUjYHagBjYIHIzVSX1FWTgn0FQTAdRigEQbf9paKN/uKKBnpk6EA4qm0m04wPzrs9Q0y358uTaax59JjbpKCfrWrRyqRy91Mdhx1rHuZG3HJ5rrbzRTjAYEVj3OishzyalpmiaOfkORgtUUeWfkfLnOa05tNdCTkmmx2MnZcmlYq6GRovAA/GpTFnHUVNHbsp5Bx3qxs46HNOwrmfJApx9atGHKACnsh3qMVaaM7B6/SiwXMl4sZyKoXiKOSDmt+RPl+brWZeKpXHQ0mNO5jNgY4pV7HpzU0sW3BB/CkROMtUlFyRWMKle3emxyg/LIoYetWLV9q7QoIqceXncIlzTEyv9kAUSRn5TViIFeccVIrOw6AL6UMVHWgCF/zpjLuxyRikkbjimb+w796Q7DyCKaNxJ5poPqTTm4xg0DDcQf8aVW3Hk0zPpSL0zQIlYdSKhbhu1PVuo6e1MlHHXFAxN446UjMD1603HPqKCAOelADH4Xiq0n3TjOanY4PSq874WgaIMN60VHkeo/OikVY9q1e5YMRnisZL07iDisPVNXaSZsNWcuoOGBLGtOY5ow0OukuH/hP61H9qkHv9awoNT3EB6vCcPjGMU7hy2Lvnhv9ZGpFSxiAgfLjtVCJ9zgHpWrHCpTgUxPQFtYGHXpQ2nQsBtkAHpThDxwcVIsDdzQIr/2QpZSHU89KtSaMSoO4AGnRId/41andgAOwoFdmNcaYgGN5yKwb/T33HByBXTz5ZeDWdJAwY5P40mVFnMvbZGADwah+ysCc1vssYY9KrSbQ2BipsWmUYID29atrEFXJ6+lOXnFJKeDgUWAiZwucflVWWQ+wFPbOeahcdzyBUstDC3y5/rUe/HQikkYHAGKY556Uhj9/SpFYk81UZ+eO1SpIPUZpgWC+OT0pnmDrj8KiMm7sMVG0oAx1oAmMnOcUw3HJFQly2cnimd89PpSHYt+YGwR+FMbp05pqNnjn3qQ596AInOByKrS8g8Y5qeTqcnioWwfpQUV8/wCyKKfsopCLcshY5zUO4jmnAsQfSmEHtirIRPFKVHDYJ7VqWk7Ectg1jRpyC341biYqRgc5oQM6SxJlkHPHWujtlOAOQK5rRztKk9/Wuv01RIQQK0RjIsQ2uVDE1YWJfu44q0GGMelEciMxwM4pmVystmHf5AcjtUVzZOD6VsWPEjM2PapLqMMu488UWFfU5W4iCLnoK57UbsK5CnpW74hZsMsWfwrj5lO45z6VLNoIGuVY+hNQs+X4OeajlTbyAaZAGaQZHeoNLF5AxGcYpzKdhOakiA2gGnzgBMCn0Fcz5sEVTm4PFWJ2HzVVZs9e1SWiBuuOefaoWGTnJ+mKmflh/WmMCAMY+lIpEDZAH600tjv3pzZPWonHOc0mMVpMDj9KXzATUTEAckCgqOfemBOD6n608YAznJqqgI65I9acrYOMdelIC2jqD6H60rSbuhNUSTk8Z7mnjd14H0pgSyNUDZHI60/OcVHI+Bg8nFIYzn1FFN8xvaigLGjjaAEBpnl5YlhRLcOh4FOgkeTmQfSrRmPVST0rRsrUOoLCq8bKHwBwK1IHVcbeuKpEs0bWAqFNb+n7olUngd6w7NyxB4/GtyAEoKpGUjRScA4yRmnh+CBWaGIc1K0p2nB+tMmxr29zghcVannYR9sVz9s7eZnrU93dMRsxRcm2pBeBZHJIyTXPaja4YlR15rfj+YnrxWfqmAuRzSZcTl7iMqOtLbKAfmpLmRmfpxUkGMVBt0LkSAtn0pl6uBkU6J8GoLyVd2KGJGdMvBzVaT5RU80gPeqVwxzwfwqWaDZCCDzUTHnrUcjkE4IqEuWP3s0ikSs351CXO6jB9sU0LxxSGhc7iMnFDA9zQCFJxilL+2TQAEEcnnNNU4bgc+9PzkHPAqPjHJ/GgZMvTIxk0HPANRqRkfTtU0Q55zQAIpNLLH8vHNTHHQHrSODjjNAinsf0oqxiigLmjqFtt+4B+VV9hUDPcV1d5p24EnI+lUH0otjDH9a1szDmuYzLtIwefStGyBzxmrUWjAvuZj+Na9ppscYHc/zppCcitbb1wME5rp9OheROAcCm2VhG5BAGBXQ6dbqgwq1SRlKRj3dr5KZx1rPCszEdq7G8shKhBFYMunSLIyqDx047UWJjK5TiYR8tVS7u1E2F4/Grt5ZyR8txXO6sPKBz1NJlxLD6mwLKD+tUp7svnPSs0OxB4NIZNuQSc1JaQkrKz5HWpYGx6YqoqMxJ7VajTC4FJFE4cYNULnBY981Zl+T0qlI2eTgUMaK8pxj1NVZF496suT3NV3ZW71JZRkJJxk0qjaACealYAmmDGfepsUAGKNg6j0pCTnpS8joDQMicdMDn3poHennrkjFMAOR6UDQpPGBSEYHOaDwPl60wLke1IESREE1Ywcjn6VVjXpxmpgG3A8nFCBk4JHXHNI5PX8KAM4wfao5CwGAOO9MQuR6GioN59KKBnsDKH6gc+1V3gA6DitMWzn8KY0DKcYroZwplFIOB61ZhgAI3cVYjjKtgjmnhWJ6UCuWbZRkKGAFals4jIwciseFGJzg1pQZAwRTRMjYilWQc8Ulyiqm4MOlZ5d1Xg1Vv7orE3J6UyFEqarPGA3zcgdM1x2pSxSOzNjI96t39w8ruAeK4/V5mjdgCQahs6IRNJ5I1BPFZVxfxhyoXJHcVRind1wTTJFHXvUmqRcjuGkbg4FaUT8DHWs3TrcyuFXGTWhJBJbkb+KQMS5k2qc5JrPkmyOen0qzdScVRI3Z6fnQNCPJkDtUZAbPrUvlYzuOaaBjgA1LKItnHPB+lMPA4B/KrDbhwTTDHu5wf0pFERwQMdqYxxgA1PtwQO1MZMDpmlYCLO/OVAHvS+XkcHjinHOOlNLEd+f5UDGtGB2JxTQvQ4qTfx2pWIPoBQCEQZODUoA7dKijGTxgfhUoB7/nQDEI45PFQv7Z5NT9epzmoJB82DwBQwQ2imfJ70UDPpc6aVYiMZBqvNpTkDcuK6f7KVbKvUUsL4+8DXUeTzM5KayZScqeKh+zsqj5fzrp5bdxkkA1Xa3JHzJQUpmCkeH/+tVoD5R3q9JbAKODnvURjIWgfNcrE4Az171n6sB5JIFaTKw61m6nt8or3pMcdzj5dp3ZUkH3rl9etx5nyAgdq6m9UhzgGsXV4y8WRyRUM6InOwxbcmptp465zTlHzYIqZBkjrUlXNTw9YyyyFkRsDvitWa13MxmICqOAab4evDAjKM89qL1JslnyAeTVdCepzd0gMzAdM1DtCk9xj0q1cAl2JxnNVyP0qWWgxxUarknv6VYjGSdw4o2qvSpZRAEBPpSOoAAFSleajdWznrQNEZXJ6UhTI56+lSAnOaTPOBSGR7Bt6VBIuTgDH9avMF2+/tUfBHAoGZzqwb5qco74P+cVO67v6UwLhgOSO1IaHIPl7n+tS7O/NEQz8oHTpUwAHU9qYFZ0KkfoagkU9PXrVubB+lQSDjPpSYIr7JPQUVJk+1FBR9NDV0zS/2mrZzXKgnPy5/OnbnDZPAFdR5fIdSb1MYLCnrdwkctzXJGVs7gfamieRcYY0XFyHZiaNx2Ioa1imB2nBrlo7uZV61KmqyxnJzRcXIzUurJ17cVhanCSvNasOvoQBIvGe9TSzWd+uAwUkdKHqNNo881GEht3Wsm4h3IVIrvNQ0j7207lrnbjTypI6VFjaMrnDzQmNzxTlAyBjJNb15p/J45rNMRjcEHBqbGqY61JjAKde1LdXc7fKzkj0qSNTtJqlcEhuaYEbgtyRzTdmCTxipUUMM5yakVQF/pUjK5jwPamsNoOQT06VbOCOn51GVHfikykyArjv0qJnBIA4qyyjvUDAZOBxSKRC4yMgU3YT1FTZHTpSKeBg/WgaGFAOgpjDANWCODzUMi0gIHA9cUm3PQU5/wAaEJPOcj6UDHxKy9OCKR8kU+Mknp70rnqTQBAxI9M1GxGckVMQMfMOaryqQTyAKTGhu1fT9aKZk+v6UUDPc0cFRnrSsAMVASFBIGTSbicYrpPPJ2UEdcVUkYq+Ac4qyCChFV5EJJoAmikynJqwkW8ZGar28TFgPWtyOALGD29qEhN2MeSAIctkZ5qFAwIKnGK1LiIu2euKpuNp70BcelzIq4Yk1Uu5EbORzVhQTzVeaHc2TmgaMeWPcTkc1l3ttlsgYro5YgBkdTWbcRHJIqWWmYJUgEGqdwMjgVuXMR2kgVjXke0k4zmkzRMrxk78HFTccZqBQT904INWFGRjHFSMZj0NNC5zn8akKgUnFJgQMuc9KhkGByKtEYPb86ifkmgtFbAIprL+FTlR3waT8PakMYCMZNNYZOe3epQoI4FNcDFAyq64PHpSxR4NS8YHFO2kdqQxgXAPOaQ9csKl7dBzTDgdOPWgCEtkYqvKuRjGSatPtx7VXkAI4PWgaINr+lFGw/3qKB3PbBcr0KU6ORTn5cCnmzcDoeaQWzK3Ga6DzyQIpHSo3h3EFc1PGrDAIq1EmWGP5UCuNsLVnkUdq3HtwItvSptLtgEDEcmrdzCW+7n8qoybuznpocAgHmqUsLEgcfSt+e3bHTB/nVIwndjH40ikypbwALkiqt0m0jHStcRZBC8VSuo8e9DBMw505PNVXjUL1yavXQIfIAxVafAHHX61LNUY96CDxWJdfdxW/fLkdayLiI8nPFSzRGakfOe1TRIaeqc8d+tTKhIoKuQMvr1qFhV+SLC5H5VWkTjpSY0ymRnrmmslWGTjntUZGOnPNSNFdunvTWwOTxVhhj/GomHPIzSKRDnGD3pjZJ96mcHHPSkKjHWgoYqnuOaChHfJpw7e1OGOTjvSGR7Sfb2psgzUhB30xxgimCIcdevFV5SeSKtsOOKqzKAAcY9qQyDPtRT8t6CigD6L8hjggUrWrMR0xVZLxiBwc1dgm4zj611Hl6oYtqc4IH5VbtrBWPTvUtuwkYDHBrXtolxQS2NtrQ4AXgCr6WWR81TW4CjJ/SnmdR1pAijNpueQKpy6XgZUitnzwRVeZgAT3NAMw5rFo1zWRdW5JJxXTswIww61RurYEFgDQCOMvbdlycHms24jODmu0ltRIoBAxWRqulEJuXpSaNYyOVa1ec7UUke1PTT7ZVcTo7vjjjvWhayyWU2Bg56itiHbKqysgYnt6Uim7HnlxaNFIfkKL2zTAoXkCuv8QWcbxmYtg9AM9K5YxjJOaRpF3Ivlx7ntUJUZIFWimQMVHIo246UikUJ4wMkVWYDrV6dTzz0qow9allIgde+aYR0zVnaMdaayk96kor4GDjpSFeOOtSldvXil25xzn6UxlYjB6Gl6NVh04qNh7dKQyPBwe9McDFSDJOe1Ru2aBohIwcVBN0qaRsDIqrMxOcnNJlJDN3vRUeBRSHY+gYwqMCAc9KtBwGFQxqAASBmpAQpFdZ5bNK3dVUHGK0YZyBjNY9u/mHC1pQYLYoIZr20x2bSeaR36c1XhzjApshIU4B4oYiYTYOSR9KHuATwazXdieBik7gZ5oAvpKrP05p88gMeM5rJWUrIRjgUfaG5z0zQFieRgBwKr3pDWbEjmoZbsBcGoHmEkZ9KQ0czNA8tzsTO4nAraitZrC2CsQS3r2pLZFS+D4GaluFnnLsxPB496Ro30OV1mGQNuebcD2rJCcHIzWxr8JjcEnlu3pWUFJXmpZtEYyLjp0qCVFANWy2Bg9KqXZ44pFoz5TwT61XJ/KrDAnJzxVdl/KkykNIOMAUBSTz+VShSACTxUhQEetIdymU5HBox271Oe+elM69qQyIjrmo2APFWGGQSOn0qKSgaICuCMY/OoJPbirWR1B5NQSDAPpSKRVbnvVKcnd0q+3H071UuCGB4pMoqbn/u0U7avvRSKPfVkkwo5x61aRicF+Kr+XyBjgdBVoQhwOOldZ5bLtiVD8HrWmjc/KM571l2kDbgBwBWxbDovr60GbLEAJYCrbR4TtzUVuhV8YrQaDK8DnFISMK5jKMOnNQrGQeSSTW1LZs7gso245qCS0J5A4FFx2sZUsIGR3qlOrlsJ261rXaeWffFZVxcFQRxmmCKFypX75qaFt0RPaqUsxZ/nyfapY5BtAGfekXYgmm2T8dv1q3eXDLYeYziNT0Hes2c/6QC3TrRdRG8IWNiV7Cgdjn9TuGuJc84HQ1V3BU+9mp9YtTavtLqT6Cs9W3KRwKhm6HSyYUngAc5Nef8Ai/4gWtiHt9LMd1cjIMgOUQ/+zde1QfEKy8ValvjtRC+nA8RW7kOwx/FnGfoK8mnhmt5WjuIpIpB1R1KkfgawnNnpYbDQkuaTue+LrGniyhnnvbdVkRXyZAOoqnc+LdChGW1GFsdo/m/lXm+i+BNS1ayhvI57ZLeZdylnJbr6Ae1bUPwxfcPtGpLjv5cRP8zQpSeyB0aMXrI3Ln4haJGh8p55T6LGR/OsyX4l2gQiCxnYn++wFWbf4aaYuPOu7qTHYbVH8q0oPAOgRkE20kuP70rUe8K+HW1zkp/iRdMD5OnwofUsT/QVmzePNbl4XyEPQbI+f1Jr02Pwxo0GDHpttx3ZN386vR2VtCAYraFAP7qAUcr7h7aitonKfDzUdQ1K3vTqfmM6MhRmTbwwOQOO2P1rp5V55HWrJxz6VC656VSVkc85qcuZKxCoycEVFOgOcdPepT8pAzUUp45FAkVpgBxWfcnGQBVqVt31qjOAMEk5pMtEWT6UU3n1NFAz6UaHHOams0+b5qfHGc5bk0+PPmdM11HktlhUA/xFWICVfIz+NJGpCgkUKfn6c0EmxABIAc4NacSjABrFsy2eBjFa0T/KM9aTKg7PUnZeO1VbuVYYiTjpTppiqHZ1rGuppJNysM5pJdxzknsZN7d+ZMVB+tQNEr5wealntlVt3OaikIXgcVRJiaiwhcgsM1UhvNpIVs5NQa8+J2CmsmCZjnNSbpaG5cXAUZOCaiudUSKIJBHtbuay2nBYAtzWnaaTHdQCUzj/AGgaLhZdTHupvtCOX5cd6zAcE8V1EtlbLFIsbhpcdq5qRdsu09jUs0jqMdflzxj0rN1LTrLUItl/bQzp2DqDj6elajDK8c1XdTjOOKlmkW46ooaVYW+mWS2lkGS3QnapOcZOev4mreCc4FJjFPRhjHSkNtt3Y38RThTH56/lQhx8ppiHNg8Ypr4Io75pGJ54BpDK8uMdKjbJ6cCpG3dPeoJMigYjjnr2qvIMA7uamJLH/CoZQfXpSKRTkXnioWtd7cg9KvxxZYZqYRnmkVexk/YR70Vr+UKKLDue/mPjkjNS28PIwDnParawAsGxV+0gH5e1dJ5JUkjMaYqvER5meprVuoycjaBUFtb/ALzJXrSEPtSwbGM5q+A54HAojtwkmRyKtBRihsuMWyp5bc5qrNEeTgVqlR0qlfMI0zikncUo2Me7jULWDfAhzitK/udxIB6dqy5WMmeTTEjj/ELMJKxYps8DpXRa/FkE1yygiTuRUnVDVFhjk571saFJNK/lRgHd1zWKOtW7CV4ZQyEqc0IHsdNNpnkoWklCZ4IHWsDXILOFwLV2kYj5ifWuy0+G3ubAXVw5L9Ntc54htoVJeFcZNDIg9TnAw28iq75xx0q0eMVDKuRUmyKjDnk8UA4p5Unnv0oIOMDkUiiMsFPJxTx65pWiDLnnNBG0Adu9ADW6ZHWoyT34qbAOagl4B44oGRO3vVdz+NTSdM9DUQGe/WkwRH0wMc09YGk5bpVqGAHlhU/l8kDp7UIdyoIR90Cp0tyBV2C0bnsKsGEKOOvSiwrlD7Mf7tFaWxvf8qKLFnu5h2nA61etkITJ603zo8jIGanjkRuARWzuebFXZWnU7wetTQxcZxU2xWqRVxipcjSNK7GBcUYNSNTKk0aSGtWRqrkttFajnrWRef6w5bmriYTkYc8ZMhBxiqkqFckDOO1akqDdzk1Tl2gMT0qiUczq0QdX7Vx8ymOQgCu5vyC2NvFcpqcQWXI49qhnRTKCqT1p6vgYPGKauQfpTpMnJpGljf8AD97gGNssD0BNWtfVVgG9huY5CjtXMwPJE+5Mgj0qeWWSY7pWJNO+hPLrcoz/ACdKg3Z47GrUyiq5BwKktDScDikB6ZFOCtj2oU9sGkMVPvY/OmuoPXoakVT9M07bu6mmBTbAJAz+dRyBTg5NWpgOdtVn6ZoAqsCWqW1g3kZ5OenrSpGzsOtaMEaRLxyaVguJ5SqAAOamtYDJJjHSnIu+TjNbdtAIrYOfvNTsJsoOqqQqioGUE55rUMIYEnnHSovIX6CgSZU2n+9RWl9n9qKZdz1N5Cx5zUkMjIai2HdntU25QMnArQ4DTtJS/BOavJyKwbOcmTjpWvHKGFRNXNqM7blh1yKhIwalR80j89KzV0dMkpK6Kz9Kyb9CHz1Fa7g81m3h+XnmtUzhluZE2QMis655GScCtKUYHNUJlyCfXtVCRlXADZ71zGpoGd67Ke3PlMQOa5TUIgrt1FSzamzGs4hLcrGTjJqxqFo1tM0bHirNrot7uWdV2oTkE963bvTY51jDA+ZjkmpNHKxyUY5681bity2OCK1f7MEL4IyRU5gVUAxz9aLBzGG9qNpJxxVV4VzwBW1cBQCKypjzxQNMrNCBwRUDgLjBqySWyO9VnHODSKGbyW9jSk4PHShB8wGOKWU/LwBQBWkPPTrREocnjimuRk98VasVBU8AmgYCIJjAqeNMjPSnxxcZIyamhhJYcd+mKCS1pdoJZRnoOa1potx2qMAVZ0y28u0L4+Y0pjYk4BAz1qkjNy1M9wVARcE00xKSPl571deDJyR+IqOZBEhbpQNMk8pfUUVS+1J60UF6nr7WY2/KcVQurNz0reOMVC+M9KEzCcEjJtoTGKtJNtOMYq0Qu3GBVWePaCQM+lUmZNE0UpLj0q4jZHNY0U7RP83Aq7DdIwHPNKUbmlOfKy3IvFULyNdhPerfm5HTiq9yu9aS0Co03dHPXUZB61GYwVGOTVm7UmTpgUQxbgfSquZlfyt6EMPxrnNQsN90qDJLNXXqgSNiewrOsbcT6lvblV+aixSdiez03zruFP8AljABkVPqekM6iRAowegqR7lbW3bd9+ZuPYUXGqwpZhXYmQdBSsFzltQhxMQc5FZlwmAcZzWvqE7XT+Zt2j0FZ82MYIoLiZNwDsOaypAN2BnNa15gKcdDWTKSrcZqWbIifIJHSq8o56ZzU555qGQ+nWkyisSwOOlIxPpT2XPPemucjAFAyu5+YjitfSIGcnPTFUoIRI43CuksbcRQqx4Y9KZMmQtEM/KKvadZiSVfenR25kYAdK6DRbNRISBwKZm3ZEht9saIBgd6huEA+UYwK1rlQZMAe1VjACSTyBVGVzKMTD6Vm6oxxtAxXQGPG446Vz+oKWkJzSLizL3N6L+VFT+Uff8AKipudJ7kBjtSFQauTRbc4HFVT8p6VnGVyqtHk0YiRZ7cUyZQByKmSQDioJjyTVRvcxmoqGhm3wVVNZn2sI461p3pHlkkZNc/csQ/zcDqK2RyWOksrlJlA71bOCDmuUtrgouckVp2d6rjEhxQ0CdiWeAGYnGc07yNi9ODVoFWHyjNRyA4xk5pWAo3hVLdsdcVX0pCkEkuOXO0VavUBhb1qvplw0kscO3Cpkn3oAi1HabkoSP3a8fWufkyZizGtDUcyXUjcjnmqDKScDj+tBSGyn5cdqp3ABUjJFXZsgbduT3NVZyNvvSZcTCu2Cvgc1nyruPFaV0hYtg4qjJGV6j8almqKjcHABqCRDnnNXeCemKHj+Xk8n2pFGbjHORQVBABqeWFgc7SRToYt7quD1pjLmmWgdcitwoNgAHAqTT7MRQqdpqy0ODgDvTRlKVwsVBYYGK6XTYgrAD86xrdNrADjIro9PAym3rTM5O4TJhsEZ5qnKDuKjpWtcrg8mqLJls0EFGQERPxjiudvFYnOOAe1dfNHmP2NYl9bYYgd6LlxZl+W392itLyDRSOjmR7AyhhzVG5i2nitCmOgcYNccZcrPcr0VViZargZqGTvWjLBgEjmqkkeD0rojNM8evh5QVjOkjVutZt7Yea3y9TWzcEICTWZJdEEqnXNbLU4HozLNlIikMMDuarOAjjaeRWtLKZUIPU1myoVfkYNCEamn3D8An860ymY896wrYcgk1u25xEM8imwRXkAMZBNU8i2YugGW4q7OwAPHBqhcEEYxSAzLlQX7k1F5YOSRVogc8GkUKw6c0DKM+NhA4zWfcIMDA/WtS8jPYZBqhLH8p44pFIybiIEnFZ9xEyjA5raaI4PNVpoBxmk0apmMsZAJIp3lkgZHFXpIhnuKaUxjPSkVcpPCRjirek2Pm3QJzgGpUi3Hp1rpdFsPKtC7gl26UEylZDGTDAAfKOlDJuYAjj0q+sOzGTye1Tw24bJK8+vrVGNynDDlxxgVu6agP3appESwGMe1bNhb7R14oDcLmM9xwKpPHxwOa2ZY91U2QbtvShDasUJo/kXjAAqmYBI4B5ycc1syx5yO2KrwwHzlB5G70oCxT+wxehorU+zj3ooNbM62ilorgPpxtQzwhhkdanoPSmnYipFSVmYlzDkHNY91FsboOvXFdRcAY6CqFxGhXlFP4V1RldHgV6CUtDm3woqjIC8hz+FdUbeErzDH0/uikW2g/54Rf98Cr5jD2Xmc9bqwxk10FspEA+lPjgiB4iTr/dFXkjQD7i/lScgVLzMmYDoeKoyxDJPauieKMkZRfyqKWKPH+rTr6CjmD2XmcpKMZAoQbFPeukeCLaf3Sf98imCCLb/qk/75FHMHsvM5WUk4yOoqm8ROc9K7T7NAcZhi6f3BTPstv/AM8Iv++BRzFKl5nEvGBz0A7VUmUO3Nd7Ja2+B+4i/wC+BVeSztv+feH/AL4FHMUqXmcG0QDH0qMQZ5Nd8tna5/49of8AvgUjWdrn/j2h/wC/YpcxfsvM5HSrI3FwoAyAa7O3tBtC4+VRVzSLW3UttgiH0QVqLFGOiKPwo5jN0vM5S6gxIQvAqaOEBK6CSGIk5jQ/8BFIIo/+eaf98inzE+y8zJs7fc+5u1aUKgHAq1HGgBwi/lUsUabvuL+VS5GkKOq1IJUwoqsU9RWrMowOBUGxf7o/KpjI3rUFzFEoOoFMSIeZn3zWiEXH3V/KhUXd91fyquYy9grrUzfJNFa/lp/cX8qKOdm/sV3P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left ovarian venogram shows occlusion of the left ovarian vein following coil embolization (arrows). The patient's symptoms improved significantly after embolization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_26_13743=[""].join("\n");
var outline_f13_26_13743=null;
